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ABSTRACT 
 
AN SSX4 KNOCK-IN CELL LINE MODEL AND in silico ANALYSIS OF GENE 
EXPRESSION DATA AS TWO APPROACHES FOR INVESTIGATING 
MECHANISMS OF CANCER/TESTIS GENE EXPRESSION 
 
Duygu Akbaş Avcı 
M.Sc. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Ali O. Güre 
August 2009, 104 pages 
 
Cancer/testis (CT) genes mapping to the X chromosome (CT-X) are normally expressed in 
male germ cells but not in adult somatic tissues, with rare exception of oogonia and 
trophoblast cells; whereas they are aberrantly expressed in various types of cancer. CT-X 
genes are coordinately expressed and their expression is associated with poor prognosis in 
various types of cancer. The mechanisms responsible for the reactivation of CT-X genes 
during tumorigenesis are of great interest because of their prognostic and therapeutic value. In 
this study, we aimed to develop two approaches by which the mechanisms underlying the 
regulation of CT-X gene expression in cancer could be identified. Current evidence implicates 
promoter-specific demethylation as the key event inducing CT-X gene expression in cancer 
but the mechanisms of this epigenetic deregulation remain to be explored. We presume that 
coordinately expressed CT-X genes are regulated by common mechanisms. We, thus, decided 
that the study of a given CT-X gene could elucidate mechanisms pertinent to all.   
 
Our first approach was to generate a a model whereby variations of the expression of an 
individual CT-X gene, namely SSX4, upon various manipulations could be easily monitored. 
For this pupose, we used the SSX4 targeting vector to generate an SSX4 knock-in (KI) lung 
cancer cell line (SK-LC-17) with a GFP reporter gene expressed from SSX4 promoter. SK-
LC-17 is known to express SSX4 as well as other CT-X genes and its SSX4 promoter has 
been characterized in detail. We, thus, obtained one clone with homogenous GFP expression 
verified by sequencing for correct integration of SSX4 KI targeting vector. In the long-term, 
this cell line model will be used to identify transcriptional regulators of CT-X gene expression 
that function either in a direct manner as epigenetic controllers or indirectly as effectors 
upstream to epigenetic mechanisms. 
 
Based on the fact that CT-X gene expression occurs coordinately in all tumor types, the 
second series of experiments described herein aimed to develop an approach whereby genes, 
which are differentially expressed between CT-X expressing (CT-X positive) and non-
expressing (CT-X negative) tissues or cells could be identified. Towards this aim a meta-
analysis of publicly available microarray datasets from different types of tumors and cancer 
cell lines was developed. Using this approach, the CT-X positive group was observed to 
contain gene expression signatures indicative of higher proliferative and metastatic capacity 
when compared to the CT-X negative group. Additional studies based on class prediction 
analysis in a lung cancer cell line dataset were performed to compensate for bias due to tissue 
specific differences between datasets obtained from the meta-analysis. Lastly, we selected a 
set of genes that behaved commonly in both meta-analysis and class prediction analysis to be 
validated in cancer cell lines with known CT-X expression profiles. 
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ÖZET 
 
KANSER-TESTİS GEN İFADESİ MEKANİZMALARININ ARAŞTIRILMASI İÇİN 
İKİ YAKLAŞIM: SSX4 MODEL HÜCRE HATTININ OLUŞTURULMASI VE GEN 
İFADE VERİLERİNİN in silico ANALİZİ 
 
Duygu Akbaş Avcı 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Yrd. Doç. Dr. Ali O. Güre 
Ağustos 2009, 104 sayfa 
 
X kromozomu üzerinde bulunan kanser-testis (CT-X) genleri normalde erkek eşey 
hücrelerinde ifade edilirken, oogonia ve trophoblast hücreleri dışında yetişkin vücut 
hücrelerinde ifade edilmezler; oysa ki birçok kanser türünde beklenmedik şekilde ifadeleri 
vardır. CT-X genleri eşgüdümlü olarak ifade edilir ve birçok kanserin kötü gidişatıyla 
ilişkilendirilmişlerdir. Tümör oluşumu sürecinde CT-X genlerinin yeniden etkinleşmesinden 
sorumlu mekanizmalar, prognoz ve terapiye yönelik değerlerinden dolayı önem 
taşımaktadırlar. Bu çalışmada, CT-X gen ifadesinin kontrolünde görevli mekanizmaları 
tanımlamak amacıyla iki yaklaşım geliştirmeyi hedefledik. Mevcut bulgular CT-X gen 
ifadesini tetikleyen kilit olay olarak promotora bağlı demetilasyonu işaret etmektedir; ancak 
bu epigenetik bozulmanın mekanizmaları açıklanmayı beklemektedir. CT-X genlerinin 
eşgüdümlü ifadelerinin ortak mekanizmalar tarafından düzenlendiğini öngördük. Bu nedenle 
bir CT-X genindeki mekanizmaların açığa çıkarılmasının tüm diğer CT-X genleriyle ilintili 
olacağına karar verdik.     
 
İlk yaklaşımımız değişik dış etkenlerce oluşturulan, herhangi bir CT-X gen (bu çalışmada 
SSX4 geni) ifadesindeki değişimlerin izlenmesini sağlayan bir model oluşturmaktı. Bu amaçla 
bir SSX4 “knock-in (KI)”  akciğer kanseri hücre hattı (SK-LC-17) oluşturmak için, SSX4 
genini hedefleyen ve SSX4 promotorundan GFP (yeşil floresan protein) belirteç genini ifade 
eden bir vektör kullandık. SK-LC-17 akciğer kanseri hücre hattının SSX4 ve diğer CT-X 
genlerini ifade ettiği bilinmektedir ve bu hücredeki SSX4 promotor bölgesi ayrıntılı olarak 
tanımlanmıştır. Bu yüzden homojen olarak GFP ifade eden ve SSX4 KI vektörünün doğru 
olarak yerleştiğinin sekanslanarak doğrulandığı bir tektip hücre (klon) elde ettik. Uzun 
vadede, bu hücre hattı modeli CT-X gen ifadesinin – doğrudan epigenetik denetleyiciler 
olarak ya da dolaylı yoldan epigenetik mekanizmaları etkileyerek işleyen – transkripsiyona 
bağlı düzenleyicilerini bulmak için kullanılacak. 
 
Bu çalışmada tanımladığımız ikinci deney serisi ile, CT-X gen ifadesinin tüm tümör tiplerinde 
eşgüdümlü olduğu gözönüne alınarak, CT-X ifadesi olan (CT-X pozitif) ve olmayan (CT-X 
negatif) doku ya da hücrelerde ayırt edici ifadeye sahip genleri bulmayı sağlayacak bir 
yaklaşım geliştirmeyi hedefledik. Bu amaca yönelik, değişik tümör ve kanser hücre hatlarına 
ait, ulaşılabilen veri gruplarını kullanarak bir “meta-analiz” yöntemi geliştirdik. 
Geliştirdiğimiz bu yaklaşımı kullanarak, CT-X pozitif grupların negatiflerle 
karşılaştırıldığında, yüksek bölünme ve metastaz kapasitesini işaret eden gen ifade imzalarını 
içerdiğini gözlemledik. Yaptığımız ek çalışmalarda, meta-analizde elde edilen veri grupları 
arasından dokuya özgü değişimlerin etkilerini gözardı etmek için, seçilen bir akciğer kanseri 
hücre hattı veri grubunda sınıf-tahmini (class-prediction) analizi yaptık. Son olarak, CT-X 
ifade profilleri bilinen hücre hatlarında onaylanmak üzere, hem meta-analizde hem de sınıf-
tahmini analizinde ortak davranan bir gen seti belirledik. 
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v/v     volume/volume 
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1 INTRODUCTION 
 
1.1 Cancer/Testis Genes 
Cancer/testis (CT) genes are normally expressed in male germ cells but not in adult somatic 
tissues, with rare exception of ovary and trophoblast; whereas they are aberrantly expressed in 
various tumor types. They often encode tumor antigens that are immunogenic in cancer 
patients, as a result, they have the potential to be used as biomarkers and targets for 
immunotherapy. The first CT gene, termed melanoma antigen-1 or MAGE-1 (later renamed 
MAGEA1), was first isolated by genomic DNA expression cloning using melanoma-reactive 
cytotoxic T cells derived from a melanoma patient (van der Bruggen, Traversari et al. 1991). 
A range of other tumor antigen genes, including BAGE and GAGE1 were discovered using 
cytotoxic T cells isolated from the same patient in which MAGEA1 was discovered (Boel, 
Wildmann et al. 1995; De Backer, Arden et al. 1999). Since identification of tumor antigens 
utilizing T cell clones is a relatively difficult process, an easier approach, cDNA expression 
cloning using serum IgG antibody from cancer patients, called SEREX (serological analysis 
of recombinant cDNA expression libraries), was subsequently developed by Sahin et. al. 
(Sahin, Tureci et al. 1995). SSX2 and NY-ESO-1 were the first CT genes identified by 
SEREX (Sahin, Tureci et al. 1995; Chen, Scanlan et al. 1997). SEREX led to the 
identification of many additional CT genes. In addition to immunological approaches, many 
CT genes were found based on their specific mRNA expression profile utilizing high-
throughput transcript techniques and analyses (like representational difference analysis 
(RDA), differential display, cDNA oligonucleotide array analysis, in silico expression 
analysis) in comparing transcriptomes of tumor versus normal or testis versus other tissues. 
(Gure, Stockert et al. 2000). 
 
In recent years, the number of CT genes have rapidly increased.The Cancer/Testis gene 
database (CTdatabase) (http://www.cta.Incc.br) was newly created to gather and uniformly 
present the available information on CT genes (Almeida, Sakabe et al. 2009). The database 
provides basic gene, protein and expression information in normal and tumor tissues as well 
as immunogenicity in cancer patients. The CTdatabase now lists >130 RefSeq nucleotide 
identifiers as CT genes that belong to 83 gene families.  
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1.1.1 Genomic organization of CT genes 
CT genes are divided between those that are encoded on the X-chromosome (CT-X genes) 
and those that are not (non-X CT genes). Most of CT-X genes are grouped in families that are 
embedded in tandem or inverted repeats (Warburton, Giordano et al. 2004). An analysis of the 
human X chromosome revealed that approximately 10% of the genes on the X-chromosome 
are CT genes (Ross, Grafham et al. 2005). The presence of CT-X genes as multi-gene families 
in large  highly homologous inverted repeats suggests that CT-X genes mainly arose via 
segmental duplications. 
 
The non-X CT genes, on the other hand, are distributed throughout the genome and do not 
generally form gene families or reside within genomic repeats (Simpson, Caballero et al. 
2005). 
1.1.2 Conservation 
Comparison of human and chimpanzee genome showed that all human CT gene families are 
well conserved between the two species. The divergence rates were analyzed for human and 
chimpanzee CT gene orthologues and it was found that CT-X genes were evolving faster and 
undergoing stronger diversifying selection than non-X CT genes (Stevenson, Iseli et al. 2007). 
 
On the other hand, CT genes are poorly conserved between human and mouse, with few 
exceptions (Stevenson, Iseli et al. 2007). All the MAGE genes identified until now are 
characterized by the presence of a  large central region termed the MAGE homology domain 
(MHD). MAGE genes are classified into two subgroups, I and II, partly based on their 
expression profile. The type I MAGE genes have restricted expression pattern of CT genes 
wherase the type II MAGE genes are also expressed in normal tissues; in fact some of its 
members are not CT genes (Xiao and Chen 2004). Type I MAGE genes including MAGEA, 
MAGEB and MAGEC subfamilies are not conserved between human and mouse whereas the 
type II MAGE genes (mainly MAGED subfamily, necdin) have well-conserved mouse 
orthologues (Chomez, De Backer et al. 2001). Alignment of the MHD sequences between 
MAGE genes also revealed that type I and type II genes are phlogenetically distinct branches 
of the MAGE family. MAGE proteins from Drosophila and Aspergillus are most closely 
related to the type II MAGE proteins (Barker and Salehi 2002). 
 
The mouse homologues of human SSX family are found as two subfamilies, Ssxa and Ssxb 
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(Chen, Alpen et al. 2003). In mouse, Ssxa has only one member whereas Ssxb contains at 
least 12 closely related members. In this regard, the Ssxb subfamily is more similar to the 
human SSX family. However, Ssxa and Ssxb sequences are about equally distant from the 
human SSX genes and there is no evidence that Ssxb is the evolutionarily ancestor of human 
SSX (Chen, Alpen et al. 2003). In contrast, all human and mouse SSX proteins share 
conserved KRAB (Kruppel-associated box) domain at the NH2 terminus and SSX-RD 
domain (SSX repression domain)  at the COOH terminus, respectively. This implicates the 
functional importance of these protein domains (Chen, Alpen et al. 2003). 
1.1.3 Expression 
In the testis, CT-X genes are generally expressed in speramatogonia, which are proliferating 
germ cells whereas non-X CT genes are expressed during later stages of germ-cell 
differentiation, such as in spermatocytes and spermatids. 
 
A recent study reported an in silico expression analysis of 153 CT genes in normal and cancer 
expression libraries. Based on the combined expression profiles from these libraries and RT-
PCR analysis on a panel of 22 normal tissues, it was suggested that CT genes could be 
classified into 3 groups: (i) testis-restricted (expression in testis and placenta only), 
testis/brain-restricted (expression in testis, placenta and brain-regions only) and testis-
selective (expression in other normal tissues as well) (Hofmann, Caballero et al. 2008). Of 
153 genes, 7 CT genes were not identified in any library at all (2 CT-X and 5 non-X CT) and 
additional 8 CT-X genes were not present in any testis-annotated library. Testis-restricted and 
testis/brain-restricted CT genes are always expressed at lower intensities in placenta and brain 
than in testis, respetively. As shown in Table 1.1, most of the CT-X genes are testis-restricted 
or testis/brain-restricted compared to the non-X CT genes (Hofmann, Caballero et al. 2008).  
 
Table 1.1: CT-X and non-X CT genes that show testis-restricted, testis/brain-restricted and testis-selective 
expression (Hofmann, Caballero et al. 2008) 
  CT-X Non-X CT 
Testis-restricted  35 4 
Testis-brain restricted 12 2 
Testis-selective 26 59 
 
 
The expression frequency of CT genes is variable in different tumor types. Melanoma, non-
small cell lung cancer, hepatocellular carcinoma and bladder cancer have been identified as 
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high CT-gene expressors, with breast and prostate cancer being moderate and 
leukemia/lymphoma, renal and colon cancer low expressors (Hofmann, Caballero et al. 2008).   
 
Expression analysis of CT-X genes in breast, melanoma and lung tumpors showed that CT-X 
genes are frequently co-expressed (Sahin, Tureci et al. 1998; Scanlan, Gure et al. 2002; 
Tajima, Obata et al. 2003; Gure, Chua et al. 2005). Besides co-expression of CT-X genes, it 
was shown that coordinately expressed CT-X genes are associated with poor prognosis in 
multiple myeloma, and non-small cell lung cancer. CT-X gene expression in these tumors is 
also significantly correlated with later stages of disease (Gure, Chua et al. 2005; Condomines, 
Hose et al. 2007). In addition, expressional analysis of individual CT-X genes showed that 
they are more frequently expressed in metastatic tumors than in primary tumors, indicative of 
a worse prognosis (Scanlan, Gure et al. 2002; Velazquez, Jungbluth et al. 2007).  
1.1.4 Regulation of expression 
Current evidence indicates that CT-X genes are activated by promoter-specific demethylation. 
So far, CT-X genes studied are induced by DNA methyltransferase (DNMT) inhibitor, 5-aza-
2’-deoxycytidine (5-azaDC) treatment and, their promoter proximal regions are methylated in 
normal cells and tumor cells, which do not express CT-X genes (Weber, Salgaller et al. 1994; 
De Smet, Lurquin et al. 1999; Gure, Wei et al. 2002; Lim, Kim et al. 2005; Wischnewski, 
Pantel et al. 2006). On the other hand, it is interesting that SSX, MAGE and LAGE promoter-
reporter constructs are active in both normal cells (fibroblasts) and cancer cell lines (AOG 
unpublished data) (Scanlan, Gure et al. 2002). This suggests that transcription factors required 
for the transcriptional activation of CT-X genes are present in both normal and tumor cells. 
Therefore, the mechanisms that normally lead to DNA methylation of CT-X promoters in 
normal cells are deregulated and the transcription factors are able to drive CT-X gene 
expression in cancer cells. 
 
Genome-wide hypomethylation was firstly proposed as a mechanism to induce CT-X gene 
expression (De Smet, Lurquin et al. 1999). Hypomethylation of repeat sequences (LINE, 
SINE elements, etc.) cause genomic instability in cancer cells. Although there is an 
association between hypomethylation of L1 repeats and CT-X genes (Gure AO, unpublished 
data), genome-wide hypomethylation alone is not sufficient for the activation of CT-X genes 
as DNA is globally demethylated in colon cancer (Goelz, Vogelstein et al. 1985) , which is a 
low CT-expressor.  
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There are two studies investigating the role of DNMTs in epigenetic regulation of CT-X 
genes. Depletion of DNMT1, but not of DNMT3a and DNMT3b, in MZ2-MEL melanoma 
cells induced the activation of the MAGEA1 transgene, which was methylated in vitro and 
integrated into the genome (Loriot, De Plaen et al. 2006). In Hct116 colon cancer cells, the 
genetic knockout of both DNMT1 and DNMT3b could robustly induce MAGEA1, NY-ESO-
1 and XAGE1 expression; whereas individual DNMT1 or DNMT3b knockout had a modest 
or negligible effect (James, Link et al. 2006).  
 
Along with the DNA methylation, it was found that histone acetylation plays a secondary role 
as histone deacetyltransferase (HDAC) inhibitor,  trichostatin A, by itself or in combination 
with 5DC  could induce CT-X genes, including MAGE and SSX family members (Gure, Wei 
et al. 2002; Wischnewski, Pantel et al. 2006). It was shown that induction of GAGE gene 
expression in HEK293 cells by promoter-specific DNA demethylation is dependent on RNA 
transcription, following histone acetylation (D'Alessio, Weaver et al. 2007).  
 
Moreover, it was suggested that BORIS (brother of the regulator of imprinted sites, a 
homologue of the abundant transcription factor CTCF) could induce CT-X gene expression. 
Unlike CTCF, BORIS is not expressed in normal cells whereas it is expressed in male germ 
cells. During spermatogenesis, its expression coincides with a marked decrease in CTCF 
expression (Hong, Kang et al. 2005). Both CTCF and BORIS were shown to bind MAGEA1 
and NY-ESO-1 promoters. Ectopic expression of BORIS in normal fibroblasts induce 
demethylation of MAGEA1 and NY-ESO-1 promoters by displacing CTCF at these loci 
(Hong, Kang et al. 2005; Vatolin, Abdullaev et al. 2005). 
 
Another insight for the regulation of CT-X genes comes from their organization into inverted 
repeats (IRs) on the X-chromosome (Warburton, Giordano et al. 2004). These inverted repeats 
containing CT-X genes could form different DNA structures, which may play a role in 
regulating CT-X gene expression. One of the large invereted repeats, MAGE/CSAG-IR, was 
proposed to extrude into a double cruciform DNA structure (Losch, Bredenbeck et al. 2007). 
Then, it was shown that in melanoma cell lines, MAGE and CSAG genes encoded in the 
MAGE/CSAG-IR are expressed coordinately and independent from the MAGEAs encoded 
outside the IR (Bredenbeck, Hollstein et al. 2008). It seems that the chromatin structre might 
be responsible for coordinate expression of CT-X genes in cancer, however, the difference in 
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this structure should be investigated for normal and cancer cells to understand CT-X gene 
activation.  
1.1.5 Function 
1.1.5.1 The function of CT-X genes 
Most of CT-X genes do not have characterized biological functions in both the germ line and 
tumors. However, there is emerging data for MAGE genes mostly in terms of  tumorigenesis 
(Simpson, Caballero et al. 2005). However, how they function in proliferating germ cells 
(spermatogonia) has remained to be elusive.  
 
Using yeast two-hybrid screen, the transcriptional regulator SKI-interacting protein (SKIP) 
was identified as a binding partner for MAGEA1 (Laduron, Deplus et al. 2004). SKIP is a 
transcriptional regulator that connects DNA-binding proteins to coactivators or corepressors. 
MAGEA1 was found to inhibit the activitiy of SKIP-interacting transactivator, namely the 
intracellular part of Notch1, by binding to SKIP and recruiting histone deacetylase 1. This 
shows that MAGEA1 can act as trancriptional repressor (Laduron, Deplus et al. 2004). The 
function of MAGEA1 in the germ line has not been elucidated, but it is possible that pathways 
acting through SKIP are involved. It is highly probable that MAGEA1 represses the 
expression of genes required for differentiation in spermatogonia (Simpson, Caballero et al. 
2005). MAGEA4 was similary identified in a yeast two-hybrid screen with the oncoprotein 
gankyrin; MAGE-A4 binds to gankyrin and suppresses its oncogenic activity (Nagao, 
Higashitsuji et al. 2003). Recently, MAGE-A3/6 was identified as a novel target of fibroblast 
growth factor 2-IIIb (FGFR2-IIIb) signaling in thyroid cancer cells, such that FGF7/FGFR2-
IIIb activation resulted in H3 methylation and deacetylation of the MAGE-A3/6 promoter, to 
down-regulate gene expression (Kondo, Zhu et al. 2007). 
 
Recent data indicate that expression of CT genes in cancer cells contributes directly to the 
malignant phenotype and response to therapy (Simpson, Caballero et al. 2005). It was found 
that cell lines, which express at least one of the three MAGE genes (MAGEA1, MAGEA2, 
and MAGEA3), were more resistant to TNF cytotoxicity than cell lines that expressed none of 
the MAGE genes (Park, Kong et al. 2002). Overexpression of MAGEA2 and MAGEA6 genes 
leads to acquisition of resistance to the chemotherapeutic drugs paclitaxel and doxorubicin in 
human cell lines (Glynn, Gammell et al. 2004). Besides MAGE gene family, expression of 
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GAGE family members, GAGE7C or GAGE7B, contributes directly to tumorigenesis by the 
inhibiton of apoptosis. Following their transfection into HeLa cells, GAGE7C or GAGEFB 
conferred resistance to apoptosis induced by either interferon-γ or by FAS (Cilensek, Yehiely 
et al. 2002). 
1.1.5.2 The functions of non-X CT genes 
Non-X CT gene products mostly have specific functions in spermatocytes during meiosis and 
in spermatids. The non-X CT genes SCP1 and SPO11 are components of the synaptonemal 
complex protein involved in chromosome reduction in meiosis (Keeney, Giroux et al. 1997; 
Pousette, Leijonhufvud et al. 1997). Their aberrant expression in cancer cells might cause 
abnormal chromosome segregation and aneuploidy (Simpson, Caballero et al. 2005). Another 
non-X CT gene, PLU-1, is a transcriptional co-repressor that interacts with the transcription 
factors BF-1 and PAX9 to regulate gene expression in the germ line (Tan, Shaw et al. 2003). 
It is most higly expressed in pre-meiotic spermatogonia, where it is proposed to repress the 
expression of genes required for the maintenace of germ cells in the testis, driving the germ 
cell differentiation (Madsen, Tarsounas et al. 2003). BRDT/CT-9 was found to mediate 
chromatin compaction folowing acetylation of histones and it is thougt to function in the 
elongating spermatids (Pivot-Pajot, Caron et al. 2003). And lastly, TPX1 and ADAM2 (a 
disintegrin and metalloproteinase domain 2) are expressed on the cell surface where TPX1 
attaches  spermatogenic cells to the surrounding Sertoli cells in the testis (Busso, Cohen et al. 
2005) while the metalloproteinase ADAM2 participates in sperm–egg membrane binding 
(Evans 2001).  
1.1.6 Immunogenicity of CT antigens 
NY-ESO-1 is considered to be the most immunogenic CT-X antigen known to date as 
compared to other CT-X gene products, namely MAGEA1, MAGEA3 and SSX2 (Scanlan, 
Gure et al. 2002). Spontaneous immunity to NY-ESO-1 is common although immunological 
responses to NY-ESO-1 vary by individual, cancer type and grade of differentiation 
(Nicholaou, Ebert et al. 2006). Patients with advanced prostate cancer, neuroblastoma or 
melanoma are more likely to have detectable anti-NY-ESO-1 antibodies, with antibody 
responses are observed in up to 50% of patients whose tumors express NY-ESO-1. 
Simultaneous antibody and T-cell responses are commonly observed for NY-ESO-1 
(Nicholaou, Ebert et al. 2006). More recent studies indicate that responses may be unmasked 
after depletion of regulatory T lymphocytes in vitro, suggesting that active suppression of 
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anti-NY-ESO-1 cellular immunity also occurs commonly (Nicholaou, Ebert et al. 2006). 
 
Given the restricted expression pattern of CT-X genes and immunogenic properties of protein 
products of these genes, they present potential for use as therapeutic cancer vaccines. 
Vaccinations, with antigens specifically expressed by the tumor, are aimed at generating a 
specific anti-tumor response by triggering the immune system (Zendman, Ruiter et al. 2003). 
Initial clinical trials with NY-ESO-1 and MAGEA3 were disappointing. Following 
vaccination with NY-ESO-1 peptide, three of the five patients eventually developed disease 
progression (Jager, Gnjatic et al. 2000) In addition, injection of the MAGE-3.A1 peptide 
induced tumor regression in a significant number of the patients, even though no massive 
CTL (cytotoxic T lymphocyte) response was produced (Marchand, van Baren et al. 1999). 
Therefore, tumors escape from the attack by the immune system or a sustained immune 
response can not be developed by NY-ESO-1 and MAGEA3 peptides. 
 
1.2 SSX gene family  
Synovial sarcoma X-translocation (SSX) genes were first identified as fusion counterparts to 
SYT in in t(X;18)(p11.2;q11.2) chromosomal translocation that is present in 70% of synovial 
sarcomas (Clark, Rocques et al. 1994). The first member of the SSX gene family (HOM-
MEL-40) identified by SEREX was SSX2 (Sahin, Tureci et al. 1995; Tureci, Sahin et al. 
1996). By genome homology searches all 9 members of the SSX family together with 10 
pseudogenes were subsequently identified (Gure, Tureci et al. 1997). SSX mapped to X 
chromosome within Xp11.2 (Clark, Rocques et al. 1994). SSX family members have high 
homology ranging from 89 to 95% at the nucleotide level and 77 to 91% at the amino acid 
level (Gure, Tureci et al. 1997). There are 2 SSX2 and 2 SSX4 genes oriented tail to tail and 
head to head, respectively. Normal testis expresses SSX1, 2, 3, 4, 5 and 7 but not 6, 8 and 9. 
Among tumor tissues, SSX1, 2 and 4 expression is found at substantial frequencies, whereas 
SSX3, 5 and 6 are rarely expressed and SSX7, 8 and 9 expression have not been detected 
(Gure, Wei et al. 2002). SSX proteins have two domains; one is Kruppel-associated box 
(KRAB) repression domain at the N terminus, the other is a repression domain (SSX-RD) at 
the C terminus (Lim, Soulez et al. 1998). They appear to be transcriptional regulators, whose 
actions are mediated primarily through association with or recruitment of Polycomb group 
repressors by the SSX-RD domain (Ladanyi 2001). 
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1.3 Epigenetic regulation of gene expression 
Epigenetics is defined as heritable changes in gene expression that are not coded in the DNA 
sequence itself. Current literature demonstrates clearly the importance of epigenetic gene 
regulation in development, differentiation and proliferation. Epigenetic deregulation can result 
in human diseases such as cancer and neurodevelopmental disorders. In mammals, epigenetic 
processes mainly include DNA methylation, histone modifications, and noncoding 
RNA-mediated processes. They can not be thougt individually, they interact with each other 
and constitute a network to regulate gene expression. These epigenetic mechanisms, the 
crosstalk between them and how they are altered in cancer are summarized below. 
1.3.1 DNA methylation 
In mammals, methylation occurs almost exclusively at cytosines in the context of CpG 
dinucleotides (CpGs). Four DNA methyltransferases (DNMTs) sharing a conserved DNMT 
domain have been identified in mammals. DNMT1 maintains DNA methylation during 
replication by methylating the hemi-methylated sites (Bestor, Laudano et al. 1988). DNMT3a 
and DNMT3b are responsible for de novo methylation, as they are able to target unmethylated 
CpG sites (Okano, Xie et al. 1998). DNMT2 has only weak DNA methyltransferase activity 
in vitro and has recently been shown to efficiently methylate tRNA (Liang, Chan et al. 2002). 
 
DNA methylation represses gene transcription either by directly preventing the binding of 
transcription factors to their promoters or through indirectly recruiting methyl-CpG binding 
proteins (MBDs). DNA methylation is essential for mammalian development, as DNMT3a-/- 
died at about 4 weeks after birth and DNMT3b-/- exhibited many developmental defects in 
mice (Okano, Xie et al. 1998). Mammalian DNA methylation has been implicated in a wide 
range of cellular functions, including tissue-specific gene expression, cell differentiation, cell 
fate determination, genomic imprinting, and X chromosome inactivation (Li and Zhao 2008). 
 
The first genome-wide analysis of DNA methylation in the human genome showed that gene-
rich domains including coding sequences contain high levels of DNA methylation. In colon 
cancer cells, gene-poor regions showed DNA hypomethylation supporting the hypothesis that 
global hypomethylation contributes to chromosomal instability and tumor progression 
(Weber, Davies et al. 2005). The bisulfite sequencing analysis of three human chromosomes 
confirmed that sequences outside of promoters have a high degree of DNA methylation 
(Eckhardt, Lewin et al. 2006). Thus in mammals DNA outside regulatory regions (intergenic 
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DNA, coding DNA and repeat elements) seems to be methylated (Weber and Schubeler 
2007).  
 
Genome-wide DNA methylation maps of human somatic (fibroblast) and germline cells 
showed that most CpG promoters having a high CpG content (HCPs) are unmethylated in 
both cell types, but a subset of CpG promoters having an intermediate CpG content (ICPs) are 
methylated only in primary cells wheras they are unmethylated in germ cells. These HCPs 
carry H3K4me2 which may protect them from DNA methylation. However, they are inactive 
and how activation of these accessible promoters is prevented is not known. The ICPs are 
mostly tissue-specific transcription factors , thereby they are repressed by DNA methylation 
in order to prevent alternative differentiation pathways. CT-X genes fall into HCP class and 
the mechanisms that are responsible for their methylation might be different than those that 
cause methylation of ICPs (Weber, Hellmann et al. 2007).  How is DNA methylation targeted 
to the promoters including the promoters of CT-X genes? There are proposed models which 
are shown in Figure 1.1. There could be some protecting factors that prevents DNA 
methylation at promoters and loss of these factors may cause DNA methylation.Transcription 
of promoters could prevent DNA methylation but not always. For example; most HCPs do not 
have methylated CpG islands even though they are inactive (Weber, Hellmann et al. 2007). 
Some transcription factors such as Myc could interact with DNMTs and recruit them to the 
promoters (Brenner, Deplus et al. 2005). HMTs by direct interaction with DNMTs or the 
histone mark itself could recruit DNMTs to gene promoters which will discussed in the next 
section. 
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Figure 1.1: Models for targeting DNA methylation to the promoters in mammalian cells (Weber and 
Schubeler 2007). (a)  The selective loss of an as-yet-unidentified protecting factor, X could target DNMTs to 
gene promoters . (b) Absence of transcription could initiate DNA methylation on some promoters. (c) Some 
transcription factors (TFs) have been proposed to interact with DNMTs and recruit them to their target sites. (d) 
HMTs DNMTs could be targeted by histone methylation through an interaction with the histone 
methyltransferase (HMT) or the histone mark itself. Box denotes first exon; circles denote methylated (black) or 
unmethylated (white) CpGs. 
 
 
 
The DNA methylaton pattern in the human genome has functional importance in terms of 
gene expression and genome integrity. It was proposed that DNA methylation in the coding 
DNA inhibits cryptic transcriptional initiation outside gene promoters (Weber and Schubeler 
2007). DNA methylation in gene-poor regions (repeat elements) serves to maintain genome 
integrity. In mammals, most repeats are found to be methylated (Rollins, Haghighi et al. 
2006) and DNA methylation mediates their silencing (Walsh, Chaillet et al. 1998; Bourc'his 
and Bestor 2004; De La Fuente, Baumann et al. 2006). In cancer, genome-wide 
hypomethylation of repeat sequences lead to genome instability. Deletion of Dnmt1 and 
Dnmt3b induces chromosomal abnormalities in cancer cell lines (Karpf and Matsui 2005; 
Chen, Hevi et al. 2007). In addition, there is a strong association between LINE expression 
caused by DNA hypomethylation and  overexpression of the c-MET oncogene in chronic 
myeloid leukemia. Then, it was found that transcription from the antisense promoter of  a 
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LINE element within intron 2 of c-MET gene is driving its elevated expression (Roman-
Gomez, Jimenez-Velasco et al. 2005). Besides genome-wide hypomethylation, there is gene-
specific hypomethylation occurring in cancer cells, exemplified by CT-X genes. Which 
mechanisms are responsible for this pattern in cancer cells have not been known in detail. 
Despite the main roles of DNMTs in DNA methylation, current evidence does not implicate a 
reduction in their expression that contributes to cancer-related both gene-specific and 
genome-wide hypomethylation (Wilson, Power et al. 2007). One study showed an association 
between hypomethylation of BAGE loci (non-X CT gene) with hypomethylation of nearby 
juxtacentromic repeats and it was proposed that DNA hypomethylation may proceed into 
repeat sequences due to the mechanisms that cause hypomethylation of individual genes 
(Grunau, Sanchez et al. 2005). RNAs may be involved in DNA hypomethylation. One study 
reported that expression of an antisense RNA to the Sphk1 gene promotes region-specific 
hypomethylation (Imamura, Yamamoto et al. 2004). 
1.3.2 Histone modifications 
The nucleosome is the basic structural unit of chromatin, that consists of four core histones-
H2A, H2B, H3 and H4- around which 146 bp DNA is wrapped. Histone proteins are subject 
to over 100 known post-translational modifications, including acetylation, methylation, ADP-
ribosylation, ubiquitination, and phosphorylation. These modifications occur on the side 
chains of specific residues in the histone tails and cores and functionally impact transcription, 
replication, recombination, and repair (Mendenhall and Bernstein 2008).  
 
All histone acetylations are associated with gene transcription whereas deacetylations are 
associated with gene repression. Active genes are characterized by high levels of H3K4me1, 
H3K4me2, H3K4me3, H3K9me1, and H2A.Z (a histone variant) surrounding transcription 
start sites (TSSs) and elevated levels of H2BK5me1, H3K36me3, H3K27me1, and 
H4K20me1 downstream of TSS and throughout the entire transcribed regions. In contrast, 
inactive genes are characterized by low or negligible levels of H3K4 methylation at promoter 
regions, high levels of H3K27me3 and H3K79me3 in promoter and gene-body regions; low 
or negligible levels of H3K36me3, H3K27me1, K3K9me1, and H4K20me1 in gene-body 
regions; and uniformly distributed and low levels of H2A.Z (Barski, Cuddapah et al. 2007). 
 
Almost each of the histone modifications are exerted by different enzymes. In general, histone 
acetyltransferases (HATs) and deacetylases (HDACs) carry out (de-)acetylation; histone 
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methyltransferases (HMTs) - specifically lysine and arginine methyltransferases- and lysine 
demethylases carry out (de-)methylation; and serine/threonine kinases carry out 
phosphorylation. No arginine demethylases have been identified to date (Kouzarides 2007). 
 
There are a number of indications that repressive histone modifications work hand-in-hand 
with DNA methylation to repress transcription (Fuks 2005). On the one hand, it is proposed 
that DNA methylation  influences histone modification pattern. DNMTs and MBDs recruit 
repressor complexes containing HDACs (Bird 2002). On the other hand, it is proposed that 
histone modification is prerequisite for DNA methylation. In mammals, DNMTs interact with 
Suv39h H3K9 methyltransferases, and loss of H3K9 methylation in Suv39h-knockout 
embryonic stem cells showed impaired DNA methylation at major centromeric satellites 
(Lehnertz, Ueda et al. 2003). Moreover, DNA methylation comes after  H3K9 methylation of 
p16ink4a tumor suppressor gene (Bachman, Park et al. 2003). However,  how does crosstalk 
between DNA methylation and H3K9 methylation occur? There could be adaptor proteins 
such as HP1 that binds to methylated lysines or a direct interaction can occur between DNMT 
and H3K9 HMT (Fuks 2005).  
 
The Polycomb group protein, EZH2 is an HMT that mediates H3K27 methylation 
(H2K27me3) and forms the Polycomb repressive complexes 2 and 3 (PRC2/3) with EED and 
SUZ12. PRC2/3 play a role Hox gene silencing, X-inactivaton and cancer metastasis. It was 
shown that EZH2 direct DNA methylation through direct binding with DNMTs (Vire, 
Brenner et al. 2006).  
 
Lastly, H4K20me3  methylation by the Suv4–20h histone methyltransferases is a hallmark of 
pericentric heterochromatin (Schotta, Lachner et al. 2004; Martens, O'Sullivan et al. 2005). In 
cancer cells, a loss of H4K20me3 was observed (Fraga, Ballestar et al. 2005). Whether this 
loss involves the Suv4–20h enzymes remains to be proven. In the same cancer cells, the loss 
of H4K20me3 appeared to occur in the vicinity of pericentromeric repeats that show 
decreased DNA methylation  (Fraga, Ballestar et al. 2005). A model was proposed how DNA 
methylation might be connected to H4K20me3 (Fuks 2005) (Figure 1.2). 
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Figure 1.2: Model of how DNA methylation might be linked to H4K20me3 (Fuks 2005). Based on the data 
generated by Fraga et al., it was suggested that in normal cells, DNMT might interact with Suv4–20h. This 
interaction might be direct or through the HP1 protein and this would lead to H4K20me3 and methylation of  
DNA repeat sequences. Which comes first is not known. In cancer cells, the interaction of Suv4–20h, HP1 and 
DNMT would be disrupted by mutation, translocation, an inappropriate expression level, or defective post-
translational modification of one of the partners. This would result in the observed DNA hypomethylation and 
decrease in H4K20 trimethylation. 
 
1.3.3 Noncoding RNA mediated epigenetic gene regulation 
Noncoding RNAs (ncRNAs) play a significant role in the control of epigenetic regulation, 
chromosomal dynamics, and long-range interactions. ncRNAs are either small or long.  
1.3.3.1 Long noncoding RNAs 
Long ncRNAs are generally longer than ~200 nucleotides and their expression is strictly 
regulated (Mercer, Dinger et al. 2009). Long ncRNAs can mediate epigenetic changes by 
recruiting chromatin remodelling complexes to specific genomic loci. One of the ncRNAs 
expressed from human homeobox (Hox) loci, silences transcription across 40 kb of the 
HOXD locus in trans by inducing a repressive chromatin state by recruitment of the 
Polycomb repressive complex PRC2 (Rinn, Kertesz et al. 2007). One of the long ncRNAs is 
Xist RNA, which play an essential role in X-chromosome inactivation. Xist RNA is expressed 
exclusively from the X chromosome to be inactivated. It is <17 kb (depending on species) and 
it is capped, spliced, and polyadenylated. After Xist RNA coating, the inactive X-
chromosome is associated with repressive histone modifications such as H3K9me2 and 
H3K27 me3. Xist RNA has been shown to recruit EZH2 HMT that trimethylates H3K27 
(Heard, Chaumeil et al. 2004). Long ncRNAs are also implicated in genomic imprinting. At 
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the Kcnq2 and Igf2 imprinted clusters, expression of ncRNAs from the unmethylated paternal 
alleles is required for silencing in cis. In Kcnq2 imprinted cluster, Kcnq1ot1 long ncRNA is 
expressed from the paternal allele. In this cluster, all paternally repressed genes were 
associated with repressive histone modifications such as H3K9me2 and H3K27me3, 
particularly in the trophectoderm-derived placenta. Then, it was demonstrated that EZH2 was 
required for imprinted gene repression in vivo. Kcnq1ot1 long ncRNA possibly recruits EZH2 
to the repressed paternal allele and recruited EZH2 trimethylates H3K27 repressing gene 
expression on the paternal allele (Terranova, Yokobayashi et al. 2008).    
1.3.3.2 Small noncoding RNAs 
Small RNAs are characterized by their limited size (~20 -30 nucleotides) and their association 
with Argonaute (Ago) family proteins that have a role in all small RNA pathways. Ago 
proteins bind various <32 nt small RNAs which guide the Argonaute complexes to their 
regulatory targets. The Ago family proteins can be grouped into two classes: the Ago 
subfamily and the Piwi subfamily.At least three classes of small RNAs are encoded in human 
genome, based on their biogenesis mechanism and the type of Ago protein that they are 
associated with: microRNAs (miRNAs), endogenous small interfering RNAs (endosiRNAs or 
esiRNAs) and Piwi-interacting RNAs (piRNAs). Although these are the three main small 
RNAs known to date, numerous other small RNAs are still being discovered in the light of the 
recent developments (Kim, Han et al. 2009).  
 
RNAi mediates heterochromatin formation in fission yeast. siRNAs generated from the 
heterochromatin regions were suggested to recruit H3K9 HMT to these loci. Because RNAi is 
central to heterochromatin formation, this study has challenged the intuitive belief that silent 
chromatin is not transcribed (and therefore, that RNA is not available or required to initiate 
silencing). RNAi-mediated chromatin effects have also been uncovered in organisms as 
diverse as Tetrahymena, Drosophila, and mammals, but the detailed mechanisms  have yet to 
be revealed (Hall, Shankaranarayana et al. 2002; Volpe, Kidner et al. 2002; Bernstein and 
Allis 2005).  
 
RNAi-like mechanisms are now known to play a critical role in mediating heterochromatic 
gene silencing and can prevent the mobilization of transposable elements (Bernstein and Allis 
2005). RNAi-deficient C. elegans show high rates of transposition (Tabara, Sarkissian et al. 
1999). In Drosophila, I elements (similar to mammalian LINE elements) can be silenced by 
previous introduction of transgenes expressing a small region of the transposon (Jensen, 
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Gassama et al. 1999; Bernstein and Allis 2005). In the mouse embryo, knock-down of Dicer 
results in an increase in the levels of retrotransposon transcripts (IAP and MuERVL) 
(Svoboda 2004). These results indicate that RNAi mechanism is important for maintainance 
of  genomic stability and it may be a conserved mechanism across species (Bernstein and 
Allis 2005). 
 
1.4 Combined analysis of microarray datasets: meta-analysis 
With the implementation and wide-spread use of high-throughput microarray technology, 
there occurred a massive increase in publicly available datasets that can be used for 
subsequent analysis. However, direct comparison among heterogenous datasets was not 
possible due to the complicated experimental variables that are intrinsic to array experiments. 
For the elimination of these handicaps meta-analysis of microarray datasets appears to be a 
good and practical solution. Meta-analysis is a powerful tool for analyzing microarray 
experiments by combining data from multiple studies (Hong and Breitling 2008).Various 
papers have been published comparing data across labs generated by diffferent platforms 
(both Agilent and Affymetrix platforms) to determine whether they are comparable or not. 
Among different platforms, the Affymetrix platform provides by far the most consistent data 
across labs (Irizarry, Warren et al. 2005). 
 
In recent years several meta-analysis methods have been proposed using different approaches. 
First, Fisher’s inverse chi-square test computes a combined statistic form the P-values 
obtained from the analysis of the individual datasets. This method is easy to use and does not 
require additional analysis. However, by working with the P-values it is impossible to 
estimate the average magnitude of differential expression and one can obtain inconsistent fold 
changes (Hong and Breitling 2008). Secondly, Choi et al. used a t-like statistic (defined as an 
effect size) as the summary statistic for each gene from each individual datasets. They then 
proposed a hierarchical modeling approach to assess both intra- and inter-study variation in 
the summary statistic across multiple datasets and reports  The approach has been 
implemented into a Bioconductor package GeneMeta facilitating its application (Choi, Yu et 
al. 2003). Lastly, the non-parametric rank product (RP) method has been introduced in 
another Bioconductor package (RankProd) (Hong, Breitling et al. 2006). It was initially 
proposed to identify differentially expressed genes between two conditions and based on 
calculating the rank products from replicate experiments (Breitling, Armengaud et al. 2004). 
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Then, it was developed to be used as a meta-analysis algorithm (Hong, Breitling et al. 2006). 
It is derived from biological reasoning about the fold-change criterion and identifies genes 
that are consistently found among the most up-regulated and down-regulated genes in a 
number of experiments (Hong and Breitling 2008) The rank product method offers several 
advantages over linear models or t-tests. It has increased power in low sample number and/or 
large noise settings. In addition, it has the ability to overcome the heterogeneity among 
multiple datasets and has been shown to be more consistent and reliable as compared to t-test 
based methods (Breitling and Herzyk 2005) Both the t-test based and RP method utilize 
permutation tests to assess the statistical significance, reporting the false discovery rate (FDR) 
of the identification based on combined statistics (Hong and Breitling 2008)  
 
There are key points to be considered in conducting a meta-analysis. A recent review on the 
meta-anlysis presented a checklist for conducting meta-analysis of microarray datasets by 
dissecting the process to seven distinct issues (Ramasamy, Mondry et al. 2008). The first five 
issues were related to data acquisition and curation: identifying suitable microarray studies, 
extracting the data from studies, preparing the individual datasets, annotating the individual 
datasets, resolving the many-to-many relationship between probes and genes. Choosing the 
appropraite meta-analysis technique was presented as the sixth issue (Ramasamy, Mondry et 
al. 2008). The seventh issue of analyzing, presenting, and interpreting data was discussed 
briefly using an illustrative meta-analysis. Specifically, during the extraction of the data from 
the studies, in order to eliminate bias due to specific algorithms used in the original studies, it 
was recommended to obtain the feature-level extraction output (FLEO) files, such as CEL and 
GPR files, and converting them to gene expression data matrices (GEDMs) in a consistent 
manner. In addition when annotating the individual datasets, one can map probe-level 
identifiers such as I.M.A.G.E Clone ID, Affymetrix ID, or GenBank accession numbers to a 
gene-level identifier such as UniGene, RefSeq, or Entrez Gene ID (Ramasamy, Mondry et al. 
2008).   
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2 OBJECTIVES AND RATIONALE 
 
Cancer/testis (CT) genes are expressed at different frequencies in a wide range of cancer 
types. Previously, it was shown that coordinate expression of CT-X genes in non-small cell 
lung cancer (NSCLC) associates with poor prognosis (Gure, Chua et al. 2005). The 
mechanisms responsible for the reactivation of CT-X genes during tumorigenesis are of great 
interest because of their prognostic and therapeutic value. In this study, we aimed to develop 
two approaches by which the mechanisms underlying the regulation of CT-X gene expression 
in cancer could be identified. Current data suggests that CT-X gene expression is regulated by 
promoter specific methylation but the mechanisms of this regulation are not known. Our 
rationale is based on the hypothesis that coordinately expressed CT-X genes might be 
regulated by common mechanisms.  
 
Our first approach was to generate a model by which the expression of an individual CT-X 
gene could be easily monitored. Such a model could then be used to test the effect of various 
manipulations on CT-X gene expression. For this approach we chose SSX4 since SSX4 
promoter has been characterized in detail in this laboratory (Gure AO, unpublished data). We 
aimed to generate an SSX4 knock-in (KI) lung cancer cell line (SK-LC-17) with a GFP 
reporter gene expressed from SSX4 promoter. Such a cell would be visible by cytometry and 
manipulation of the genes’ regulation would be easy to observe. We chose to generate this 
cell line using the SK-LC-17 lung cancer cell line since it is known to express SSX4 readily 
and its SSX4 promoter is known to be completely demethylated (Gure AO, unpublished data). 
A subsequent goal would be to transfect the knock-in cell line with a cDNA library prepared 
from a CT-X negative cell line and select the clones with repressed GFP expression by flow 
cytometry. We thus, would expect to obtain the clones with methylated SSX4, since SSX4 
expression is repressed by promoter-specific methylation, and isolate the cDNA causing this 
modification. In this way, transcriptional repressors of CT-X gene expression that function 
either in a direct manner as epigenetic controllers or indirectly as effectors upstream to 
epigenetic mechanisms can be identified.  
 
Our second approach was to utilize a meta-analysis of publicly available microarray data 
towards identifying genes whose expression (or the lack thereof) correlate with CT-X gene 
expression. We thus, wanted to simultaneously analyze datasets from tumor tissues 
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originating from various tissues. Since most public datasets are from a given tissue type, and 
we hypothesized that if all samples within a given dataset could be classified into CT-X 
positive and negative subgroups, that the comparison of these subgroups as a meta-analysis 
would reveal the CT-X-specific mechanisms instead of tissue specific differences. However, 
CT-X expression control might have tissue specific components as well, so we chose to 
include analyses that were limited to a given dataset, namely class prediction analyses.    
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
3.1.1 Reagents 
All laboratory chemicals were analytical grade from Carlo Erba (Milano, Italy), Merck 
(Schucdarf, Germany), Riedel-de Haën (Germany) and AppliChem (Darmstadt, Germany). 
Agar and yeast extract were supplied from BD Biosciences (USA). Tryptone was from Conda 
Laboratories (Spain). TRI Reagent (for RNA isolation) was purchased from Molecular 
Research Center, Inc (USA). Phenol:Chloroform:Isoamyl Alcohol 25:24:1 was purchased 
from Sigma-Aldrich (Belgium). 
3.1.2 Kits 
Qiagen Plasmid Mini-prep kit (for small-scale plasmid DNA isolation), Maxi-prep kit (for 
large-scale plasmid DNA isolation) and QiaQuick Gel Extraction kit (for recovery and 
extraction of DNA from agarose gel) were from Qiagen (Maryland, USA). PureLink Genomic 
DNA Mini kit (for small scale genomic DNA isolation) was obtained from Invitrogen 
(Germany). 
3.1.3 Bacterial strains 
The bacterial strain used in this work was: E. coli DH5α. 
3.1.4 Enzymes 
Restriction endonucleases were purchased from New England Biolabs (UK). T4 DNA Ligase 
was purchased from Fermentas (Germany). 
3.1.5 PCR, Real-time PCR and cDNA synthesis reagents 
For cDNA sythesis, DyNAmo cDNA Synthesis Kit was used (Finnzymes, Finland). 
DyNAzyme II Hot Start DNA Polymerase for the amplification of fragments up to 1 kb was 
purchased from Finnzymes (Finland). Elongase Enzyme Mix for the amplification of 
fragments up to 30 kb and the greater amplification of smaller fragments was purchased from 
Invitrogen (Germany). SYBR Green Master Mix and TaqMan Gene Expression Master Mix 
used in real-time PCR were obtained from Finnzymes (Finland) and Applied Biosystems 
(USA) respectively. 
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3.1.6 DNA Molecular Size Markers 
GeneRuler DNA Ladder Mix (0.1-10 kbp) and GeneRuler 50 bp DNA ladder (50-1000 bp) 
were purchased from Fermentas (Germany). 
3.1.7 Primers 
The primers used in conventional PCR and quantitative real-time PCR analyses were 
synthesized by Iontek (Istanbul, Turkey). Pre-designed and synthesized FAM dye-labeled 
TaqMan MGB probes and unlabeled PCR primers for SSX4, NY-ESO-1, MAGEA3, GAGE 
and GAPDH used in real-time PCR were purchased from Applied Biosystems (USA).  
3.1.8 Electrophoresis, photography and spectrophotometer  
Horizontal electrophoresis apparatuses were from E-C Apparatus Corporation (USA). The 
power supply Power-PAC300 and Power-PAC200 was from BioRad Laboratories (USA). 
The Molecular Analyst software used in agarose gel profile visualizing was from Vilber 
Lourmat (France). Beckman Spectrophotometer Du640 was purchased from Beckman 
Instruments Inc. (USA) and Nanodrop ND-1000 Full-spectrum UV/Vis Spectrophotometer 
was purchased from Thermo Fisher Scientific (USA). 
3.1.9 Tissue culture reagents 
Dulbecco’s modified Eagle’s medium (DMEM), RPMI-1640 medium and Fetal Bovine 
Serum (FBS) were obtained from Biochrom (Germany). L-glutamine, non-essential amino 
acid, and penicillin/streptomycin mixture were from PAA (Austria). Trypsin was purchased 
from Sigma-Aldrich (USA). Hygromycin was purchased from BD Biosciences (USA). 
3.1.10 Transfection reagents 
Lipofectamine 2000 transfection reagent was obtained from Invitrogen (Germany). Opti-
MEM I Reduced Serum Medium that was used to dilute Lipofectamine 2000 transfection 
reagent and DNA before combining them was obtained from Gibco (Invitrogen). 
 
3.2 SOLUTIONS AND MEDIA 
3.2.1 General solutions 
50X Tris-acetic acid-EDTA (TAE): 121g Tris-base was first dissolved in 350 ml ddH2O. 
18.6g EDTA and 28.6 ml glacial acetic acid were then added and the solution was brought to 
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500ml with ddH20. Working solution (1X TAE) was prepared by diluting of 50X TAE to 1X 
with ddH20. 
 
Ethidium bromide: 10 mg/ml in water (stock solution), 30 ng/ml (working solution) 
 
6X Gel loading dye solution: 10mM Tris-HCl (pH 7.6), 60mM EDTA (0.5M, pH8.0), 60% 
glycerol, 0.03% bromophenol blue or 0.03% xylene cyanol were mixed. Two different gel 
loading dyes were prepared; one with only bromophenol blue, the other with only xylene 
cyanol. Bromophenol blue co-migrates around ~300 bp DNA and it was used when analyzing 
larger DNA fragments. Xylene cyanol co-migrates around ~4000 bp and it was used when 
analyzing smaller DNA fragments. 
 
3M Potassium-Acetate (KAc), pH 5.2: 29.4 g KAc was added to ∼50 ml ddH2O. pH was 
adjusted to 5.2 by the addition of glacial acetic acid (30-35 ml). The solution was brought to 
100 ml with ddH20. 
3.2.2 Microbiological media, solutions and media 
Luria-Bertani medium (LB): Per liter; 10 g bacto-tryptone, 5 g bacto- yeast extract, and 10 
g NaCl were dissolved in ddH20 and autoclaved. LB agar plates contained additionally 15 g/L 
bacto agar. 
 
Glycerol stock solution: Bacterial cultures were strored at -80°C in LB with a final 
concentration of 25% glycerol. 
 
Carbenicillin: Stock solution was prepared as a 100 mg/ml solution byin ddH20. It was 
sterilized by filtration and stored at -20°C. Working solution was100 μg/ml. 
 
Transformation Buffer (TB): For TB, solutions of 0.5 M PIPES, 0.5 M CaCl2, 1 M KCl, 1 
M MnCl2 and 1 M KOH were first prepared. TB contained 10 mM PIPES, 15 mM CaCl2, 250 
mM KCl and 55 mM MnCl2. All components except MnCl2 were added and pH was adjusted 
to 6.7 with 1 M KOH. The solution is was filter sterilized near fire and stored at 4oC.  
3.2.3 Cell culture solutions 
Growth medium: 10% FBS, 1% penicillin/streptomycin, 1% L-glutamine (if the medium is 
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L-glutamine free), 1% non-essential amino acids were added to DMEM/RM1640 medium. 
Growth medium was stored at 4oC. 
 
Freezing medium: 10% DMSO and 10% FBS were added to the growth medium to obtain a 
freezing medium with 10% DMSO and 20% FBS. The freezing medium was freshly prepared 
and kept on ice before use.  
 
10X Phosphate-buffered saline (PBS): 40 g NaCl, 1 g KCl, 8.9 g Na2HPO4 and 1.2 g 
KH2PO4 were dissolved in ddH20. The solution was brought to 500 ml with ddH20. Working 
solution (1X PBS) was prepared by diluting 10X PBS to 1X in water (pH should be between 
7.2 and 7.4) and autoclaved. 
 
Hygromycin: Stock solution was 50 mg/ml solution in PBS and it was stored at 4°C. 50 
μg/ml was used for stable cell line selection and maintenance. 
 
3.3 METHODS 
3.3.1 General Methods 
3.3.1.1 Preparation of transformation-competent E.coli DH5α cells 
50 ml LB was inoculated with a single colony from a freshly grown plate of E. coli DH5α 
strain and incubated overnight at 37oC, shaking at 200 rpm. With this fresh 50 ml of overnight 
culture, 200 ml LB in 1L flask was inoculated until an optical density 0.2 at 600 nm (OD600) 
was reached. The culture was incubated at 20oC, shaking at 200 rpm. The culture should be in 
log phase growth that is the proper stage for making competent cells. Once the culture had an 
OD600 value between 0.5 and 0.6 (it will take 5-7 hours), it was poured into sterile tubes and 
incubated on ice for 10 minutes. The cells must be kept on ice throughout the rest of the 
procedure. The cells were harvested by centrifugation at 2500xg for 10 minutes at 4oC and the 
supernatant was discarded. The pellet was resuspended in 64 ml Transformation Buffer (TB) 
by gently pipetting up and down. Resuspended cells were left on ice for 10 minutes and 
centrifuged at 2500xg for 10 minutes. After the supernatant was removed away, the pellet was 
gently resuspended in 16 ml of ice-cold TB containing 7% DMSO and incubated on ice for 10 
minutes. The competent bacteral cells were quickly aliquoted into cold 1.5 ml microcentrifuge 
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tubes (150 μl per tube) and snap-frozen with liquid nitrogen. Frozen competent cells were 
stored at -80oC.  
3.3.1.2 E.coli DH5α transformation 
150 μl competent E. coli DH5α cells were thawed on ice and polypropylene screw capped 
tubes were placed on ice as well. After thawing, 10 ng plasmid DNA or ligation mixture was 
added to competent cells. DNA-bacteria mixture was incubated on ice for 30 minutes after 
mixing gently without vortex. Then, the mixture was transferred to 42oC water bath for 45 
seconds (heat-shock) and immediately placed on ice for 2-3 minutes. 850 μl of pre-warmed 
LB was added onto cells, which were then cultured for 1 hour at 37oC with shaking at 200 
rpm. After 1-hour incubation, samples were centrifuged at 13000 rpm for 20 seconds, and the 
supernatant was removed away but leaving approximately 100 μl LB. The pellet was 
resuspended in the remaining LB. The bacteria cells were plated out on LB-agars with 
selection agents such as ampicillin. The plates were incubated overnight at 37oC without 
shaking to allow the growth of the transformants. 
3.3.1.3 Long term storage of bacterial strains 
To keep bacterial cells including plasmid in it or as empty for future experiments and to have 
a stock of strain in a laboratory is necessary. The most frequently used method is “Glycerol-
Stock” method. A single colony picked from either an agar plate or a loop-full of bacterial 
stock was inoculated into 5 ml LB (with a selective agent if necessary) in 15 ml screw capped 
tubes. Tubes were incubated overnight at 37 oC, shaking at 200 rpm. For glycerol stock, 500 
μl of bacteria cell culture was added into 500 μl of sterile 50% (v/v) glycerol in LB. This mix 
was snap-frozen with liquid nitrogen and stored at -80 oC. 
3.3.1.4 Plasmid DNA purification  
3.3.1.4.1 Small-scale plasmid DNA purification (mini-prep) 
The plasmid that is prepared in small-scale was used for sequencing or cloning procedures. 
1.5 ml of bacterial cell culture grown overnight was used for isolation of plasmid DNA with 
Qiagen plasmid mini-prep kit according to the manufacturer’s instructions. Plasmid DNA was 
eluted in a total volume of 50 μl ddH2O.The quality of miniprep was checked by loading 250 
ng of final yields on agarose gel and visualizing under U.V. 
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3.3.1.4.2 Large-scale plasmid DNA purification (midi-prep) 
The plasmid that is prepared in large-scale was used for sequencing or mammalian cell 
transfection procedures. 100 ml of bacterial cell culture grown overnight was used for 
isolation of plasmid DNA with Qiagen plasmid midi-prep kit according to the manufacturer’s 
instructions. Plasmid DNA was eluted in a total volume of 100 μl ddH2O. The quality of 
midiprep was checked by loading 250 ng of final yields on agarose gel and visualizing under 
U.V. 
3.3.1.5 Phenol/chloroform DNA extraction and ethanol precipitation 
This method was preferred to remove proteins from a DNA sample (plasmid DNA or 
genomic DNA). The procedure given here was for isolation of plasmid DNA from large-scale 
restriction enzyme reactions. If the sample volume is small (<250 μl), the sample was diluted 
to 350-500 μl. Before use, phenol:chloroform:isoamylalcohol 25:24:1 (v/v) was shaked 
vigorously. An equal volume of phenol: chloroform: isoamylalcohol was added to the sample. 
After the sample was mixed by vortex for 1 minute, it was centrifuged at 13000 rpm for 10 
minutes at room temperature (RT) in a bench-top centrifuge to separate the aqueous phase, 
which contains DNA from the organic phase that contains proteins. The aqueous phase was 
removed to a new tube. To remove traces of phenol, an equal volume of chloroform was 
added to the tube and the sample was mixed by vortex for 1 minute before being centrifuged 
at 13000 rpm for 2 minutes at RT. In order to precipitate DNA, 0.1 volume of KAc pH 5.2 
was first added and then 100% ethanol (EtOH) was added until 70% EtOH was reached in 
DNA solution. The DNA solution was incubated at -80oC for 2 hours or overnight at -20oC. 
After incubation, the precipitated DNA was recovered by centrifugation at 13000 rpm for 10 
minutes at 4oC. The supernatant was discarded and the pellet was washed with 70% EtOH. 
EtOH was removed away after centrifugation at 13000 rpm for 5 minutes at 4oC. The DNA 
pellet was air-dried for 15 minutes and resuspended in sterile ddH2O and stored at -20oC. 
3.3.1.6 Genomic DNA purification from cultured cells 
Cultured cells that were grown in 10 mm tissue culture dishes to 80-90% confluency were 
washed with 1X PBS, trypsinized, and centrifuged at 1000 rpm for 5 minutes at 4oC. The 
pellet was resuspended in 5 ml 1X PBS and centrifuged at 1000 rpm for 5 minutes at 4oC. 
Then, it was stored at -80oC until used for genomic DNA isolation. Genomic DNA was 
isolated by use of  “PureLink genomic DNA mini kit” following manufacturer’s instructions. 
Genomic DNA was eluted in a total volume of 100 μl. The quality of genomic DNA was 
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checked by loading 250 ng of final yields on agarose gel and visualizing under U.V. 
3.3.1.7 Total RNA Extraction from cultured cells 
Exponentially growing monolayer cultures were washed with PBS, trypsinized, and 
centrifuged at 1000 rpm for 5 minutes at 4oC. The pellet was resuspended in 5 ml 1X PBS and 
centrifuged at 1000 rpm for 5 minutes at 4oC. Then, it was stored at -80oC until used for RNA 
isolation The total RNA isolation from cell line pellets was performed using TRI reagent 
(Trizol). Per 5-10 x 106 cells, 1 ml Trizol was added to the pellet. The pellet was dissolved in 
Trizol by pipetting up and down until a homogenous solution was obtained. The mixture was 
tranferred to a 1.5 ml eppendorf tube and incubated for 5 minutes at RT. Per 1 ml Trizol, 200 
μl chloroform was added to the tube. After shaking vigorously for 15 seconds, the mixture 
was centrifuged at 13.000 rpm for 15 minutes at 4oC. The aqueous phase that contains RNA 
was transferred to a new tube and 500 μl isopropanol was added to it. After mixing by 
inverting gently, the mixture was incubated for 10 minutes at RT and then centrifuged at 
13.000 rpm for 10 minutes at 4oC. The supernatant was discarded and the RNA pellet was 
washed with 1 ml of %75 EtOH (the pellet should move in this step). After centrifugation at 
13.000 rpm for 5 minutes at 4oC, the supernatant was removed away and the pellet was air-
dried for 3-5 minutes. The RNA pellet was dissolved in 250 RNase-free ddH2O and RNA was 
incubated for 15 minutes at 55 oC to increase its solubility. The concentration of the isolated 
RNA and OD 260/280 ratio (between 1.8-2.1) were measured with the NanoDrop ND-1000 
spectrophotometer. Isolated RNAs were snap-frozen with liquid nitrogen and stored at -80oC. 
3.3.1.8 Quantification and qualification of nucleic acids 
Concentration and purity of the double stranded (ds) nucleic acids (plasmid and genomic 
DNA) and total RNA were determined by using the RNA and ds DNA options on Nanodrop 
ND-1000 Full-spectrum UV/Vis Spectrophotometer (Thermo Fisher Scientific, Wilmington, 
DE, USA). OD 260/280 ratio indicated the purity of nucleic acids and should be generally 
between 1.8-2.1 for them. 
3.3.1.9 Restriction enzyme digestion of DNA 
For cloning, 5-10 μg plasmid DNA was digested in a 50 μl reaction volume that was 
incubated overnight. Restriction enzyme reaction mixtures of PCR products were incubated 
for 4-6 hours. Diagnostic restriction enzyme digestions in order to verify the correctly ligated 
construct were carried out in a 20 μl reaction volume that was incubated for 2-4 hours and 
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0.5-1 μg plasmid DNA was used. Reactions were carried out with the appropriate reaction 
buffer and conditions according to the manufacturer’s recommendations. Digestion of DNA 
with two different restriction enzymes was also performed in the appropriate common 
reaction buffer and conditions recommended by the manufacturer. 
3.3.1.10 DNA extraction from agarose gel 
DNA extraction from agarose gel was performed using QiaQuick Gel Extraction kit (Qiagen) 
according to the manufacturer’s instructions. Recovered DNA was used for either DNA 
ligation or DNA sequencing in this study.  
3.3.1.11 DNA ligation 
T4 DNA ligase was used for DNA insert ligation into vector DNA. Ligation was performed in 
10 μl or 20 μl reaction volumes depending on the concentration of vector (backbone) and 
insert DNA. Usually, 100 ng of vector DNA was used. According to the molar ratio of 
vector:insert DNA, the amount of insert DNA was calculated using the formula below: 
 
 
 
Reactions were carried out with 10X or 2X T4 DNA ligase buffer and were incubated at RT 
or 16oC overnight. 
3.3.1.12 Agarose gel electrophoresis of DNA 
DNA fragments were fractionated by horizontal electrophoresis by using 
standard buffers and solutions. DNA fragments less than 1 kb were generally separated on 
1.5% or 2.0 % agarose gel, those greater than 1 kb (up to 11 kb) were separated on 1 % 
agarose gels. Agarose gels were prepared by completely dissolving agarose in 1x TAE 
electrophoresis buffer to required percentage in microwave and ethidium bromide was added 
to final concentration of 30 μg/ml. The DNA samples were mixed with 6X DNA loading 
buffer and loaded onto gels. The gel was run in 1x TAE at different voltage and time 
depending on the size of the fragments at room temperature. Nucleic acids were visualized 
under U.V. and GeneRuler DNA molecular size markers (Fermentas) were used to estimate 
the fragment sizes.  DNA Ladder Mix (0.1-10 kbp) was loaded for products sizes of over 1kb 
and 50 bp DNA ladder (50-1000 bp) for product sizes of below 1kb. 
ng of vector x kb size of insert                               insert x  molar ratio of             = ng of insert DNA  
kb size of vector                                           vector 
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3.3.2 Computational Analyses 
The sequences of genes that were chosen for validation of class-prediction analysis in 
GSE4824 lung cancer cell lines dataset were obtained from NCBI (National Center for 
Biotechnology Information). The exon-intron information of these genes were derived using 
Ensembl Genome Browser (http://www.ensembl.org). Restriction endonuclease maps of the 
plasmid DNAs were analyzed using the online NEBcutter2 
(http://tools.neb.com/NEBcutter2/) tool. Primers were designed using Primer3 online primer 
design tool tool (http://frodo.wi.mit.edu/) (Rozen and Skaletsky 2000). The results of the 
DNA sequencing of engineered constructs were visualized using Chromas-v1.45 available for 
download at http://www.technelysium.com.au/chromas14x.html. The alignments of nucleic 
acid were performed by using the NCBI BLAST (nucleotide blast and blast2Sequences) 
algorithm available at the web page (http://www.ncbi.nlm.nih.gov/BLAST) and ClustalW 
algorithm provided by EMBL-EBI at http://www.ebi.ac.uk/Tools/clustalw2/index.html 
(Thompson, Gibson et al. 1997).  
3.3.3 Vector construction  
SSX4 knock-in (KI) vector was generated and sequence-verified by Dr. Ali O. Güre in 
Cornell University, USA. Additional restriction enzyme digestions of the KI vector were 
performed in Bilkent University. In addition, enhanced green flurescent protein (EGFP) of the 
KI vector was sequenced with the primers given Table 3.1. The steps in the generation of 
SSX4 KI vector were as follows: 
1- EGFP was amplified using XbaI-HindIII containing PCR primers from pHygEGFP 
plasmid and cloned into the XbaI-HindIII digested SSX4 A3-B pGL3 luciferase 
reporter vector including containing the corresponding SSX4 5’ genomic sequence 
(see Figure 4.1 for A3 and B primer locations). 
2- 3’ SSX4 homology sequence was amplified with BamHI-SalI containing PCR primers 
and was cloned downstream of EGFP.  
3- Since BamHI and BglII generated compatible cohesive ends, hygromycin resistance 
gene (PGK/HYG) with its own 5’regulatory region and PolyA signal obtained by 
BglII digestion was cloned into BamHI digested construct between GFP and SSX4 3’ 
homology sequence. 
4- ß-Actin promoter driven diphteria toxin (β-actin/DTA) was cloned into NotI-KpnI 
digested construct, upstream of SSX4 5’ homology sequence. 
The final SSX4 KI vector (12 kb in length) in the linear form is shown in Figure 3.1. 
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Figure 3.1: SSX4 KI vector. The components of SSX4 KI construct were indicated below the boxes. Yellow 
boxes showed first, forth and fifth exons of SSX4. 
   
 
Table 3.1: The sequencing primers that were used to sequence EGFP 
Primer ID 5'-3' sequence 
P16 (Fwd) GTCCTGAGGCTGGAAAGACTCA 
M4 (Rev) ATTCATCGATCGCAGATCCTTATCG 
P50 (Fwd) CAGGCTGTTTCTCTCGCAGGTG 
M45 (Rev) TAATAGCGAAGAGGCCCGCAC 
*Fwd: Forward Rev:Reverse 
 
 
The construct lacking ß-Actin promoter driven diphteria toxin (DTA) was used as a control to 
observe if GFP was expressed from the SSX4 promoter, following transient transfection into 
SK-LC-17 lung cancer cells. This plasmid is referred to as “Step 6”. Another control plasmid 
was generated in order to test correct amplification of primers used in nested PCR by cloning 
EGFP obtained by XbaI-HindIII digestion from SSX4 KI plasmid into XbaI-HindIII digested 
SSX4 A1-B pGL3 luciferase reporter vector. The reaction setup for this cloning experiment is 
given in Table 3.2. First, SSX4 KI and SSX4 A1-B pGL3 vectors were double digested to 
obtain a 0.75 kb insert (EGFP) and a 5.6 kb vector DNA, respectively. The reaction was 
incubated at 37oC overnight and digestion products were purified on an agarose gel. After 
DNA extraction from the gel, ligation reaction was set using 3:1 molar ratio of insert/vector 
and incubated at 16 oC overnight. As a control, only vector DNA was used for ligation 
reaction. The ligated DNA was transformed into competent E.coli DH5α cells  
 
Table 3.2: The reaction setup for cloning EGFP into SSX4 A1-B pGL3 luciferase vector 
XbaI&HindIII digestion Ligation of insert into vector 
4 μg plasmid DNA 100 ng vector 
1 μl XbaI 40.2 ng insert 
1 μl HindIII 1 μl 10X LigationBuffer    
5 μl NEB Buffer 2 1 μl T4 DNA Ligase 
5 μl 10X BSA completed to 10 μl with  ddH2O. 
completed to 50 μl with ddH2O.   
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3.3.4 Testing for Correctly Integrated Vector by Nested PCR 
 
Two pairs of primers were used in two successive runs of PCR in a nested PCR reaction; the 
second pair amplifies a secondary target within the initial amplification product. Nested PCR 
was performed to screen SSX4 KI clones. Forward primers were 640 to 500 bp upstream from 
SSX4 5’ homology sequences and thus corresponded to genomic DNA of the cell, whereas 
reverse primers aligned to the EGFP sequence that would be expected to be part of the 
construct. The sequences of primers that were used in the first (1st) and the second (2nd) runs 
of nested PCR are listed in Table 3.3.  
 
Table 3.3: Primers used in nested PCR to test for correct vector insertion* 
Primer ID 5'-3' sequence Tm (oC) 
Amplicon 
length (bp) 
P4 (Fwd) AGAATGAGATGGGAGGATTGACCAAG 
M4 (Rev) GTGCAGATGAACTTCAGGGTCAGC 
63oC 1848 
A2.1 (Fwd) ATATTTCTCGAGCACTATTCACAATAGCAAAGAC 
M26 (Rev) GGTGAGACTGCTCCCAGTGC 
63oC 1580 
P4 (Fwd) AGAATGAGATGGGAGGATTGACCAAG 
M7 (Rev) AAGCACTGCACGCCGTAGGTC 
65oC 1914 
A2.1 (Fwd) ATATTTCTCGAGCACTATTCACAATAGCAAAGAC 
M4 (Rev) GTGCAGATGAACTTCAGGGTCAGC 
65oC 1702 
*P4&M4 and A2.1&M26; P4&M7 and P4&M7 and A2.1&M4 primer pairs were used in two successive runs of 
nested PCR. 
 
 
The reaction setup for nested PCR and PCR conditions optimized for primer pairs were given 
in Table 3.4 and Table 3.5, respectively. 
 
Table 3.4: The reaction setup for nested PCR 
Reagents 1st round of PCR reaction 2nd round of PCR reaction 
5X Buffer B 5  μl 5  μl 
10 mM dNTP mix 0.5  μl 0.5  μl 
10 μM forward primer 0.5  μl 0.5  μl 
10 μM reverse primer 0.5  μl 0.5  μl 
Elongase enzyme mix 0.5  μl 0.5  μl 
DNA 
100 ng genomic DNA  
/12 pg plasmid DNA 
2 μl of 5:125 diluted 1st PCR 
product 
ddH2O completed to 25  μl  completed to 25  μl  
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Table 3.5: PCR conditions for primer pairs used in nested PCR 
Initial denaturation 94oC 30 seconds 
40 cycles 94oC 30 seconds 
  63oC-65oC 30 seconds 
  68oC 30 seconds 
Final extension 68oC 10 minutes 
 
3.3.5 Tissue culture  
3.3.5.1 Cell lines  
Lung cancer cell line SK-LC-17 was cultured in RPMI-1640. 15 HCC derived cell lines 
(Huh7, FOCUS, Mahlavu, Hep40, Hep3B, Hep3B-TR HepG2, PLC/PRF/5, SK-Hep1, 
Snu182, Snu387, Snu398, Snu423, Snu449 and Snu475) were used in this study. Snu182, 
Snu387, Snu398, Snu423, Snu449 and Snu475 and Hep40 were cultured in RPMI-1640 and 
the rest were cultured in DMEM. 14 colon cancer cell lines SW620, SW480, SW837, SW48, 
Hct8, Hct15, Hct116, Colo205, KM12, LoVo, Co115, HT29, WiDr, LS513 were cultured in 
RPMI-1640. 7 breast cancer cell lines MCF-7, MDA-MB-231, MDA-MB-157, CAMA1, SK-
BR-3, BT20 and BT-474 were cultivated in DMEM. Melanoma cell lines SK-MEL-28 and 
SK-MEL-30 were cultured in RPMI-1640.  
3.3.5.2 Growth conditions of cell lines 
Dulbecco’s modified Eagle’s medium (DMEM) or RPMI 1640 supplemented with 10% FCS, 
1% penicillin/streptomycin mixture, 1% NEAA, 1% L-glutaime (if the medium is L-
glutamine free) was used to culture the cell lines used in this study. The cells were incubated 
in a humidified incubator at 37oC supplied with 5% CO2. SSX4 KI transfected stable clones 
were cultured in parental cell line’s culture medium + 50 μg/ml hygromycin. The cells were 
passaged before reaching confluence. The growth medium was aspirated and the cells were 
washed once with autoclaved sterile 1X PBS. Trypsin was added to the flask to remove the 
monolayer cells from the surface (0.3 ml per 25-cm2 flask, 1 ml per 25-cm2 flask) and 
incubated at 37oC for 2-10 minutes depending on the cell line. After adding fresh medium 
onto cells to neutralize trypsin, cell suspension was transferred to a 15 ml sterile falcon tube 
and centrifuged at 900 rpm for 3 minutes. Supernatant was discarded and the pellet was 
resuspended with growth medium to be transferred to either fresh petri dishes or fresh flasks 
at required dilutions (from 1:2 to 1:10). All media and solutions used for culture were kept at 
4°C (except stock solutions) and warmed to 37°C before use. 
 32
3.3.5.3 Thawing cyropreserved cell lines 
One vial of the frozen cell line from the liquid nitrogen tank was taken and immediately put 
into ice. The vial was immersed in 37oC water bath until the external part of the cell solution 
was thawed (takes approximately 1-2 minutes). The cell solution was quickly poured into a 15 
ml sterile falcon tube containing 5 ml warm culture medium. The cells were centrifuged at 
900 rpm for 3 minutes at RT. Supernatant was discarded and the pellet was resuspended in 5 
ml culture medium to be plated into 25-cm2 flask. After overnight incubation in a humidified 
incubator at 37oC supplied with 5% CO2, culture mediums were refreshed. 
3.3.5.4 Cyropreservation of cell lines 
Exponentially growing cells were harvested by trypsinization and neutralized with growth 
medium. The cells were precipitated at 900 rpm for 3 minutes. The pellet was suspended in a 
cold freezing medium containing 10%DMSO and 20%FCS. 1ml of cell suspension was 
placed into 1ml screw capped cryotubes. The tubes were first frozen at -20oC for 1hour and 
then left at -80°C overnight. The next day, the tubes were transferred into the liquid nitrogen 
storage tank. 
3.3.5.5 Transfection of SK-LC-17 lung cancer cells 
Transfections were performed using Lipofectamine 2000 transfection according to the 
instructions of the supplier (Invitrogen). For transient transfection with Step 6 construct or the 
pHygEGFP plasmid, 6-well plates were used. Exponentially growing SK-LC-17 cells were 
plated in 6 well-plates at a concentration of 6.5 x 105 cells/well, a day before transfection. The 
cells were incubated overnight and reached 90-95% confluency. Transfection was performed 
in cell culture medium with a 1:2, DNA (μg) to Lipofectamine 2000 (μl) ratio. Briefly for one 
well, 4 µg of plasmid and 8 µl of Lipofectamine 2000 were diluted in 100 µl OptiMem I 
Reduced-Serum medium or cell culture medium lacking FBS. The solutions were mixed 
gently and the one containing Lipofectamine 2000 was incubated for 5 minutes at RT. The 
diluted DNA was combined with diluted Lipofectamine 2000 (total volume > 200 µl) and 
after a brief vortex, the mixture was left to RT for the formation of transfection complex for 
30-45 minutes. During incubation, the growth medium of cells was changed with OptiMem I 
Reduced-Serum medium lacking antibiotics. Then, transfection complex was pipetted 
dropwise onto the cells and the plate was mixed gently by rocking it back and forth. The 
medium was replaced with fresh growth medium after 5 hours. After 48-72 hours incubation, 
cells were harvested and used for subsequent experiments.  
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Stable transfection of SK-LC-17 cells with SSX4 KI construct was performed in 150 mm 
petri dishes with 7.5 x 106 cells plated one day before transfection. 56 µg of NotI linearized 
SSX4 KI plasmid and 112 µl of Lipofectamine 2000 were diluted in 3.5 ml OptiMem I 
Reduced-Serum medium or cell culture medium lacking FBS. 48 hours following 
transfection, cells were trypsinized and re-plated at lower density into 75 cm2 flasks. Cells 
were cultivated in the presence of 50 μg/ml hygromycin for 1-week. After 1-week, cells were 
harvested and diluted to 0.5 cell/100 μl of cell suspension before they were seeded in 96-well 
plates in the presence of hygromycin (100 μl per well).  
3.3.5.6 Flow cytometry analysis 
Flow cytometry analysis was performed in a BD FACSCalibur system. Transiently 
transfected SK-LC-17 cells with pHygEGFP plasmid and Step6 construct, as well as stable 
SSX4 KI clones and parental SK-LC-17 cells were harvested by trypsinization and 
resuspended in 1X PBS. Resuspended cells were kept on ice and in the dark until analysis in 
flow cytometry. Upon adjustment of instrument settings, 20.000 cells were counted for the 
analysis.  
3.3.6 cDNA synthesis 
cDNA was synthesized by using DyNAmoTM cDNA Synthesis Kit according to the 
manufacturer’s instructions. Briefly; for 1X reaction 1μg of total RNA, 1μl of random 
hexamers and required amount of RNase-free ddH2O were mixed in a total 8μl volume. 
Prepared mixes were incubated at 65°C for 5 minutes and chilled on ice. Consequently, 10μl 
of 2X RT reaction buffer and 2μl of M-MuLV RNase H+ reverse transcriptase (including 
RNase inhibitor) were added to complete the reaction volume to 20µl. Then, the reaction 
mixes were incubated in a ABS thermal cycler 9700 programmed as follows: 25oC for 10 
minutes, 37°C for 60 minutes, 85oC for 5 minutes and 4oC hold. Each cDNA sample was 
diluted at a ratio of 1:2 with ddH2O and stored at -20oC to be used as a PCR template for 
further experiments.  
3.3.7 Primer design for expression analysis by real-time quantitative RT-PCR 
Primer pairs used in the validation of microarray analysis results of lung cancer cell lines were 
designed using Primer3. They targeted exon-exon junctions or different exons in order to 
prevent amplification of possible contaminating genomic DNA (Primer 3 reference). The 
primer pair was designed such that it would only be able to produce a longer amplicon from 
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genomic DNA or would not be able to amplify the corresponding genomic DNA region in a 
given PCR condition (critical parameter was extension time). The primer pair used for 
amplification of the housekeeping gene, GAPDH was described before (Sayan, Sayan et al. 
2001). Primers used for expression analysis have been designed strictly considering these 
criteria, and are listed in Table 3.6. 
 
Table 3.6:Sequences of the primers used for validation analysis* 
Gene 
symbol 
5'-3' Sequence (upper: forward; 
lower:reverse) 
Tm 
(oC) 
Amplicon 
length 
(bp) 
ACACTTGGGAGCCCTGTATG SCD  GCAGCCGAGCTTTGTAAGAG 60
oC 152 
AACCAATGCCAACCATGACT RAD21 CCTCTTCCTCTTGGCTTTTG 60
oC 152 
CACAGCCCCAGGTACAAACT HSPH1 TGGGCTTTTTAGCTTCTGGA 60
oC 144 
CTGTCTGGGACTGGGAACTT HSP90B1 TGGAGCAGATGTGGGTACAA 60
oC 197 
ATACGGCAACTGCCTCCTAA LAPTM4B CGGTAGCAGTTCCAAACACA 60
oC 146 
CGCCATGGCAATTACAAAAT NFYC GCTCGGCAGGAGTTACAGAC 60
oC 119 
GAAGGAGGAAGGCAAGATCC SSRP1 CTTCTCATCCCGGTCACTGT 60
oC 178 
CCGGAGACCTAGATGTCATTG TWIST CACGCCCTGTTTCTTTGAAT 60
oC 148 
TCAGGTTTGCCAAAGGAATC LIMK2 ATGAGGCAGTTGTGCGAGTT 60
oC 91 
GGCTGAGAACGGGAAGCTTGTCAT GAPDH CAGCCTTCTCCATGGTGGTGAAGA 60
oC 151 
*GAPDH was used for normalization of qPCR data. 
 
 
3.3.8 Real-time quantitative PCR (qPCR) 
3.3.8.1 Taqman probe-based qPCR of lung, colon, breast and hepatocellular carcinoma 
(HCC) cell lines 
Taqman probe-based qPCR was performed using Taqman Gene Expression Assays (Applied 
Biosystems) for four CT-X genes; NY-ESO-1, MAGEA3, SSX4 and GAGE. Each assay 
contained a pre-designed FAM-dye labeled Taqman MGB probe and two unlabeled 
oligonucleotides. Taqman MGB probes were sequence-specific dual-labeled probes with a 
fluorophore (e.g. FAM) at 5’ end, a non-fluorescent quencher (NFQ) and minor groove binder 
(MGB) at 3’end. Sequences of probes used in qPCR are given in Table 3.7. Each probe had a 
unique assay ID except GAPDH since it was purchased as an endogenous control that can be 
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used for singleplex PCR reactions. “_m” in assay ID indicates an assay whose probe spannes 
an exon junction and will not detect genomic DNA. The probes for CTAG1A; CTAG1B, 
multiple GAGE genes and MAGEA3 were designed to be complementary to the 1st-2nd  
exon junction whereas SSX4 and SSX4B probes were designed to span the 3rd-4th exon 
junction. The probe for GAPDH was located in 3rd exon. GAPDH was used for normalization 
of qPCR data. Neither probe sequence nor primer sequences were provided by Applied 
Biosystems. Only context sequence was provided as the nucleotide sequence surrounding the 
probe. Multiple GAGE genes represented GAGE7, GAGE12I, GAGE2A, GAGE8, GAGE4, 
GAGE5, GAGE1, GAGE13,  
GAGE12H, LOC729408, GAGE12D, GAGE12J, GAGE6, GAGE12E, GAGE12C, 
GAGE12G. 
 
Table 3.7: The probes used in qPCR. 
Assay ID /Product 
ID Gene symbol Context sequence 
Tm 
(oC) 
Amplicon 
length (bp) 
Hs00265824_m1 CTAG1B, CTAG1A GCTTGAGTTCTACCTCGCCATGCCT 60
oC 103 
Hs00275620_m1 Multiple GAGE genes  ACTGAGATTCATCTGTGTGAAATAT 60
oC 69 
Hs00366532_m1 MAGEA3 GGTGAGGAGGCAAGGTTCTGAGGGG 60oC 145 
Hs02341531_m1 SSX4, SSX4B AACCACAGGAATCAGGTTGAACGTC 60
oC 101 
4333764F GAPDH -  60oC 122 
 
 
qPCR was performed on a Stratagene MX3005P Real-time PCR System (USA). The PCR 
reaction was set according to the manufacturer’s recommendations. Briefly for 1X reaction; 
10 µl of 2X Taqman Gene Expression Master Mix, 1 µl of 20X Taqman Gene Expression 
Assay (probe-primer mix), and 2 µl of 1:1 diluted cDNA template were mixed in a total 
volume of 20 µl. 12 μl mineral oil was added to cover top of the mixture to prevent 
evaporation. After an initial 2 minutes of incubation at 50oC [uracil-DNA-glycosylase (UDG) 
activation] and 10 minutes of initial denaturation at 95°C, 2-step thermal cycling was 
performed at 94°C for 15 seconds, 60°C for 1 minute for a total of 40 cycles. If the master 
mix contains dNTP mix with dUTP, UDG treatment can prevent the reamplification of 
carryover-PCR products by digesting any dU-containing DNA(Longo, Berninger et al. 1990). 
Ten-minute incubation at the 95°C substantially reduces UDG activity. Because UDG is not 
completely deactivated during the 95°C incubation, it is important to keep the annealing 
temperatures greater than 55°C and to refrigerate PCR products at 2 to 8°C in order to prevent 
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amplicon degradation.  
 
The master mix also contained ROX passive reference dye which was used to normalize 
fluorescent fluctuations due to well-to-well changes in concentration or volume. ROX does 
not take part in the PCR reaction and its fluorescence remains constant during the PCR 
reaction. Since the emission wavelenghts of FAM (517 nm) and ROX (607 nm) are different, 
they could be used together in the same reaction. Stratagene MX3005P sofware performed 
normalization by dividing the fluorescence intensity of FAM by the fluorescence intensity of 
ROX and obtained a ratio defined as the Rn (normalized reporter) for a given reaction tube.  
3.3.8.2 qPCR of lung cancer cell lines using SYBR Green I 
qPCR using SYBR Green I was performed for validation analysis in lung cancer cell lines 
using Stratagene MX3005P Real-time PCR System (USA). 1X reaction contained 10 µl of 2X 
SYBR Green PCR Master Mix, 0.4 µl 25 µM forward and reverse primers, and 2 µl of 1:1 
diluted template cDNA were mixed in a total volume of 20 µl. After an initial 2 minutes of 
incubation at 50oC (UDG activation) and 15 minutes of denaturation at 95°C, thermal cycling 
was performed at 94°C for 30 seconds, 60-62°C for 30sec (optimized for each primer pair), 
72°C for 30 seconds for a total of 50 cycles and a final extension step at 72°C for 10 minutes. 
In order to validate the production of a single target-specific PCR product, the amplification 
was followed by a melt curve protocol with an initial step at 55°C for 30 seconds and 80 
repeats of 0.5°C increments with 15 seconds dwell time, from 55°C to 95°C. 
3.3.8.3 Calculation of relative expression using ∆∆Ct formula 
In cell lines and tissues, the relative expression ratio (R) of transcripts (target gene) was 
measured based on a modified ∆∆Ct formula (Pfaffl 2001) and normalized to GAPDH 
(reference gene). In R= (Etarget) ∆Ct target (control-sample) / (Eref) ∆Ct ref (control-sample) formula, Etarget and 
Eref  reflect PCR efficiencies of the primers for target genes and reference genes, respectively. 
We assumed the PCR efficiencies of the primers used in Taqman probe-based qPCR as 2.0.   
In cell lines, GAPDH was the reference gene. ∆Ct values were obtained by subtracting Ct 
values of individual genes (sample) from the average Ct value of all cell lines for that gene 
(control). All reactions were performed in duplicates. A no-template control of nuclease-free 
water was included in each run. Relative expression tables were established by representing 
∆∆Ct values in log2 base, and in all subsequent analyses these values were used. 
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3.3.9 Bioinformatic analyses 
3.3.9.1 Data retrieval for meta-analysis 
Tumor and cell line microarray datasets were obtained from the Gene Expression Omnibus 
(GEO) (http://www.ncbi.nlm.nih.gov/geo/ ) and Array Express 
(http://www.ebi.ac.uk/microarray-as/ae/ ) repositories, and in one case from 
http://data.cgt.duke.edu/oncogene.php. Inclusion criteria were as follows:  
1. Only datasets from solid tumors and tumor cell lines without any drug treatment were 
used. 
2. Datasets were analyzed only if they were available as raw data within CEL files. 
3. Datasets were restricted to either the Affymetrix HG-U133A or HG-U133Plus2 
platforms. 
4. Datasets were used if they showed differential CT-X gene expression in the cluster 
analysis; as in a dataset, some tumor samples express CT-X genes coordinately 
whereas other tumor samples do not express CT-X genes (section 3.3.9.5). 
Table 3.8 shows datasets that met these inclusion criteria. Although other tumor datasets 
(colon, prostate etc.) that fitted into the first three criteria (1-3) were obtained, in the cluster 
analysis, they did not show differential CT-X gene expression pattern and therefore they were 
not included in meta-analysis. Samples corresponding to normal tissues were excluded from 
these datasets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38
Table 3.8: Tumor and cell line microarray datasets used in meta-analysis 
GSE 
number/Array 
Express ID 
Tumor type / Cancer cell lines Sample size 
Array 
platform Reference 
E-GEOD-
GSE7390# Node-negative breast tumors 198 HG-U133A 
(Desmedt, Piette et al. 
2007) 
GSE6008* Ovarian tumors 99 HG-U133A (Hendrix, Wu et al. 2006) 
GSE10072* Lung adenocarcinoma tumors 58 HG-U133A (Landi, Dracheva et al. 2008) 
E-TABM-36# Hepatocellular carcinoma tumors 57 HG-U133A (Chiang, Villanueva et al. 2008) 
GSE4824* Lung cancer cell lines 70 HG-U133A (Zhou, Peyton et al. 2006) 
GSE5720* NCI-60 Cancer cell panel 60 HG-U133A (Shankavaram, Reinhold et al. 2007) 
GSE9843* Hepatocellular carcinoma 91 HG-U133Plus2 
(Chiang, Villanueva et 
al. 2008) 
GSE3141$ Primary lung tumors 111 HG-U133Plus2 (Bild, Yao et al. 2006) 
GSE9891* Ovarian tumors 385 HG-U133Plus2 
GEO Datasets, Bowtell 
D, 2008 
GSE5460* Breast tumors 127 HG-U133Plus2 
GEO Datasets, 
Richardson AL, 2007 
Dataset sources: #Array Express, *GEO, $http://data.cgt.duke.edu/oncogene.php.  
 
 
3.3.9.2 Normalization of raw data within CEL files 
After raw data were downloaded for each dataset, they were preprocessed individually using 
GeneSpring GX 9.0.6 software (Agilent Technologies). Data were normalized with the GC-
RMA algorithm. This algorithm performed three tasks in the following order: background 
correction, quantile normalization and probe summarization. Baseline transformation was not 
performed subsequent to probeset summarization. After GC-RMA normalization, expression 
values of probesets were obtained in log2 scale.  
3.3.9.3 Quality control on samples of individual datasets 
Quality control (QC) analysis was performed for each dataset using GeneSpring GX 9.0.6 
software. The following analyses were carried out during QC analysis: 
- Principal Component Analysis (PCA) calculated the PCA scores for each sample and 
depicted them in a 3D scatter plot. This analysis was useful when viewing of 
separations between groups of replicates. For the datasets used in this study, although 
some samples were grouped separately, most samples were clustered together in a 3D 
PCA plot.  
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- The correlation analysis calculated the correlation coefficients using Pearson 
correlation coefficient for each pair of arrays and displayed them as a correlation table. 
Correlation coefficients ranged around 0.7-1.0 which were acceptable.  
- 3’/5’ ratios for actin and GAPDH probesets were calculated for each array, reflecting 
RNA sample quality.The hybridization quality was analyzed by hybridization controls 
for each array. All the samples in terms of 3’/5’ ratios and the hybridization quality 
were included in further analyses according to the QC results. 
3.3.9.4 Hierarchical clustering analysis of tumor and cell line datasets 
Seven CT-X gene families were selected to be used in cluster analysis and grouping of 
datasets according to their expression values. The selected CT-X genes and their 
corresponding probeset IDs on Affymetrix HG-U133A and HG-U133Plus2 arrays are shown 
in Tables 3.9 and 3.10, respectively. Since there is considerable homology among members 
of a given CT gene family, these probesets were analyzed to see whether they were specific 
for the target transcripts using “Probe Match” tool that was available in NetAffx Analysis 
Center on the web page of Affymetrix (http://www.affymetrix.com/analysis/index.affx). Two 
probesets (215885_at for SSX2 and 215932_at for MAGEC2) present on both HG-U133A 
and HG-U133Plus2 were found not to be unique and were excluded from further analysis. 
 
Table 3.9: Probesets used on Affymetrix HG-U133A array 
CT-X Gene 
Families Probe Set ID Gene Symbol 
NY-ESO-1  210546_x_at NY-ESO-1 
NY-ESO-1  211674_x_at NY-ESO-1 
NY-ESO-1  217339_x_at NY-ESO-1 
GAGE  208283_at GAGE1 
GAGE  207086_x_at GAGE1, GAGE12, GAGE13, GAGE2, GAGE4, GAGE5, GAGE6, GAGE7,GAGE8 
GAGE  207739_s_at GAGE1, GAGE12, GAGE13, GAGE2, GAGE4, GAGE5, GAGE6, GAGE7,GAGE8 
GAGE  208155_x_at GAGE1, GAGE12, GAGE4, GAGE5, GAGE6, GAGE7 
GAGE  206640_x_at GAGE12, GAGE13, GAGE2, GAGE4, GAGE5, GAGE6, GAGE7 
GAGE  208235_x_at GAGE12, GAGE7 
MAGEA  207325_x_at MAGEA1 
MAGEA  210295_at MAGEA10 
MAGEA  210503_at MAGEA11 
MAGEA  210467_x_at MAGEA12 
MAGEA  214603_at MAGEA2  
MAGEA  209942_x_at MAGEA3 
MAGEA  214254_at MAGEA4 
MAGEA  214642_x_at MAGEA5 
MAGEA  214612_x_at MAGEA6 
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MAGEA  210274_at MAGEA8 
MAGEA  210437_at MAGEA9 
MAGEB  207534_at MAGEB1 
MAGEB  206218_at MAGEB2 
MAGEB  207579_at MAGEB3 
MAGEB  207580_at MAGEB4 
MAGEB  207581_s_at MAGEB4 
MAGEC  206609_at MAGEC1 
MAGEC  220062_s_at MAGEC2 
MAGEC  216592_at MAGEC3 
SPANX  220922_s_at SPANXA1,SPANXA2, SPANXB1, SPANXB2, SPANXC, SPANXE,SPANXF1 
SPANX  220921_at SPANXB1, SPANXB2, SPANXF1 
SPANX  220217_x_at SPANXC 
SSX  206626_x_at SSX1 
SSX  206627_s_at SSX1 
SSX  215881_x_at SSX10, SSX2, SSX3, SSX5, SSX7, SSX9 
SSX  207493_x_at SSX2 
SSX  210497_x_at SSX2  
SSX  216471_x_at SSX2  
SSX  207666_x_at SSX3 
SSX  211670_x_at SSX3 
SSX  211731_x_at SSX3 
SSX  208586_s_at SSX4  
SSX  210394_x_at SSX4 
SSX  211425_x_at SSX4 
SSX  208528_x_at SSX5 
 
 
Table 3.10: Probesets used on Affymetrix HG-U133Plus2 array. 
CT-X Gene 
Families Probe Set ID Gene Symbol 
NY-ESO-1  210546_x_at NY-ESO-1 
NY-ESO-1  211674_x_at NY-ESO-1 
NY-ESO-1  217339_x_at NY-ESO-1 
GAGE  208283_at GAGE1 
GAGE  207086_x_at GAGE1, GAGE12, GAGE13, , GAGE2, GAGE4, GAGE5, GAGE6, GAGE7,GAGE8 
GAGE  207739_s_at GAGE1, GAGE12, GAGE13, GAGE2, GAGE4, GAGE5, GAGE6, GAGE7,GAGE8 
GAGE  208155_x_at GAGE1, GAGE12, GAGE4, GAGE5, GAGE6, GAGE7 
GAGE  206640_x_at GAGE12, GAGE13, GAGE2, GAGE4, GAGE5, GAGE6, GAGE7 
GAGE  208235_x_at GAGE12, GAGE7 
MAGEA  207325_x_at MAGEA1 
MAGEA  210295_at MAGEA10 
MAGEA  210503_at MAGEA11 
MAGEA  210467_x_at MAGEA12 
MAGEA  214603_at MAGEA2  
MAGEA  1553830_s_at MAGEA2  
MAGEA  209942_x_at MAGEA3 
MAGEA  214254_at MAGEA4 
MAGEA  214642_x_at MAGEA5 
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MAGEA  1553585_a_at MAGEA5 
MAGEA  214612_x_at MAGEA6 
MAGEA  210274_at MAGEA8 
MAGEA  210437_at MAGEA9 
MAGEB  207534_at MAGEB1 
MAGEB  1552913_at MAGEB18 
MAGEB  206218_at MAGEB2 
MAGEB  207579_at MAGEB3 
MAGEB  207580_at MAGEB4 
MAGEB  207581_s_at MAGEB4 
MAGEB  1552858_at MAGEB6 
MAGEC  206609_at MAGEC1 
MAGEC  220062_s_at MAGEC2 
MAGEC  216592_at MAGEC3 
SPANX  220922_s_at SPANXA1,SPANXA2, SPANXB1, SPANXB2, SPANXC, SPANXE,SPANXF1  
SPANX  224032_x_at SPANXA1, SPANXA2, SPANXC, SPANXE 
SPANX  220921_at SPANXB1, SPANXB2, SPANXF1 
SPANX  220217_x_at SPANXC 
SSX  206626_x_at SSX1 
SSX  206627_s_at SSX1 
SSX  215881_x_at SSX10, SSX2, SSX3, SSX5, SSX7, SSX9 
SSX  207493_x_at SSX2 
SSX  210497_x_at SSX2  
SSX  216471_x_at SSX2  
SSX  207666_x_at SSX3 
SSX  211670_x_at SSX3 
SSX  211731_x_at SSX3 
SSX  208586_s_at SSX4  
SSX  210394_x_at SSX4 
SSX  211425_x_at SSX4 
SSX  208528_x_at SSX5 
 
 
 
Following normalization, only probeset IDs corresponding to the selected CT-X genes (Table 
9 and Table 3.10) were imported to GeneSpring GX 9.0.6 software as a .txt file to acquire 
their normalized expression values from individual datasets that were used for cluster 
analysis. Hierarchical cluster analysis was performed using average linkage method with 
Euclidean distance matrix measure. As a second method of analysis we carried out class 
prediction analysis for the GSE4824 dataset (lung cancer cell lines) using BRB Array Tools 
(http://linus.nci.nih.gov/BRBArrayTools).  
3.3.9.5 CT-X grouping of tumor and cell line datasets 
To group samples into CT-X expressors and non-expressors normalized data for individual 
datasets were first exported from GeneSpring into R and the“grouping” algorithm defined in 
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Appendix A was utilized. The manipulations performed by this script are listed below. 
Briefly, the script ranks probests for each sample from the highest to the lowest and uses this 
information to determine a cut-off value above which CT-X gene expression is considered 
positive. Two separate grouping analyses were performed, one for tumor samples and one for 
cell lines. Each grouping analysis was performed seperately for HG-U133A and HG-
U133Plus2 based data. The grouping script carried out the following commands: 
1. The expression value for each CT-X gene family (e.g. SSX, MAGE, GAGE etc.) was 
defined:  
a. For each sample, the “CT-X gene value” corresponding to the average value of 
several probesets of the same CT-X gene was determined (for those genes for 
which several probesets existed; e.g. 208586_s_at, 210394_x_at and 
211425_x_at are three probesets each hybridizing with SSX4). 
b. Then the “CT-X gene family value”, corresponding to the average value of 
individual CT-X genes within the same family was detemined. 
2. Normalized data of individual datasets were combined into a single expression matrix 
and the average rank value corresponding to the expression value of 3.5 was 
determined for each matrix. This corresponded to the 10,856th probeset (rank) for the 
combined cell line expression matrix, and to 10,001st rank for combined tumor 
expression matrix (Table 4.3), among 22,283 probests ranked from the highest to the 
lowest expression value (for HG-U133A). For the combined tumor expression matrix 
formed using HG-U133Plus2 platform, this corresponded to the 28, 581st rank among 
54,675 probesets. 
3. To determine if a given sample could be considered positive for a given CT-X gene 
expression, its “CT-X gene family value” had to be higher than that of the average 
rank calculated in step 2 within each sample data. 
4. For each of the seven CT-X gene families, each sample was assigned a number based 
on whether it was positive (1) or negative (0) for a given CT-X family value. 
5. The script then calculated the sum of all values (0 or 1) for each sample for each CT-X 
gene family and grouped the samples into 3 categories: Samples with expression for at 
least 2 CT-X gene families (CT-X positive group, “1”), those with expression of only 
one CT-X gene family (CT-intermediate group: “-1”), and without CT-X expression 
(CT-X negative “0”).   
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3.3.9.6 Meta-analysis  
All the scripts written in R that performed data pre-processing, and meta-analysis are listed in 
Appendix A. 
3.3.9.6.1 Data pre-processing 
1. Using GeneSpring, each sample within all datasets that were categorized as CT-X 
positive “1” and - negative “0” were selected and intermediate “-1” samples were 
discarded.   
2. Then, for each sample, those probesets with normalized expression values below the 
cut-off rank, as defined by the grouping script explained in section 3.3.9.5, were 
filtered out. 
3. Among the remaining probesets only those that were common to all samples were then 
combined in an expression data matrix using the R based “pre-processing script”. 
Thus, 19,421 probesets for tumor samples, and 18, 411 probests for the cell line data 
remained.  
3.3.9.6.2 Meta-analysis using Bioconductor RankProd package 
The resulting combined-filtered expression data matrices were used by the RankProd package 
(Hong, Breitling et al. 2006) in the R environment to identify genes differentially expressed 
between CT-X positive and CT-X negative groups. 
The RankProd algorithm applies a series of calculations: 
1. Once two experimental conditions (the two experimental groups: A & B) are defined 
(in our case the CT-X negative and CT-X positive groups), for a given dataset, and a 
fold change value (FC) is calculated for each probeset that corresponds to the ratio of 
its value in a sample in A (#a1), compared to that of a sample in B (#b1). The 
algorithm then calculates a second FC value for #a1 by measuring the ratio of its value 
to that of another sample in B (#b2).  The algorithm thus calculates all FC values for 
every possible pairwise comparison for a given probeset in each dataset.  
2. After a FC is found for all probesets, it is ranked within each comparison such that the 
probeset with the greatest fold change is assigned a rank: 1/n, where n equals the total 
number of probesets. 
3. Then all rank values obtained for one probeset are multiplied, generating the rank 
product (RP). The rank products of a probeset are combined from different datasets by 
taking their geometric mean.  
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4. To evaluate the significance of RP values, random permutations of expression values 
are performed for each array and then RP values are calculated as described above. 
This determines how unlikely it is to observe the same RP for a probeset by chance, 
thus converting from the RP value to an E-value, similar to that of BLAST. For 100 
random permutations, the average expected value E (RP) ≈ x(RP)/100 is calculated 
which refers to how many simulated RP values smaller than or equal to a real RP 
value are found.  
5. Then, for each gene g, the percentage of false positives (PFP) which corresponds to a 
false discovery rate is calculated if this gene would have a significant fold change 
(p<0.05).  
A total of 100 permutations were performed to obtain significant genes at 5% FDR rate. 
RankProd generated up-regulated and down-regulated gene lists and also two respective plots 
showing estimated FDR (PFP) versus the number of identified genes. To obtain biologically 
relevant genes, probesets with less than 1.2 fold change were excluded from further analysis. 
3.3.9.6.3 Validation of the rank-product method using HG-U133Plus2 tumor datasets 
HG-U133Plus2 contains all probesets (with a few exceptions) contained within HG-133A. 
Normalized data of individual datasets were first combined into a single expression matrix. 
To validate the initial RankProd data, we therefore, filtered in those probesets used for the 
initial meta-analysis with HG-U133A based data (corresponding to ~19,415 probesets) from 
HG-U133Plus2 tumor datasets by an R based script. We thus generated a second data matrix. 
Using these probesets that were thus identical between the two platforms, a second meta-
analysis was performed by RankProd. 
3.3.9.7 Class prediction analysis of GSE4824 lung cancer cell line dataset  
The raw data was normalized by GC-RMA algorithm using BRB Array Tools. The class 
prediction analysis of BRB Array Tools creates a multivariate predictor in order to determine 
to which of the two classes (in our case; CT-X positive and negative) a given sample belongs 
(BRB Array Tools User’s Manual). Different predictors (nearest centroid, compound 
covariate, support vector machine etc.) were utilized simultaneously to obtain an output 
probeset list that disciminates CT-X positive and negative lung cancer cell lines at 0.001 
significance. 
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3.3.9.8 Finding common probesets between different analyses by CROPPER 
CROPPER is a free web-based software that can perform cross-platform/cross-species 
combinations of genomic data derived from heterogenous sources 
(http://katiska.uku.fi/~jmpaanan/cropper/). In this study, it was used to find common 
probesets from the same platform between different analyses. 
3.3.9.9 DAVID functional annotation clustering 
DAVID (the database for annotation, visualization, and intergrated discovery) bioinformatic 
resources was used in order to analyze probeset lists derived from both meta-analysis and 
class prediction analysis (http://david.abcc.ncifcrf.gov/). Among four useful DAVID’s major 
analytic modules, functional annotation clustering was employed in this study. First, the 
probeset list was submitted to DAVID and HG-U133A platform was set as the background 
for subsequent analysis. GOTERM_BP_ALL from gene ontology and  BBID, BIOCARTA, 
KEGG_PATHWAY from pathways were selected for DAVID functional annotation 
clustering. Enrichment score 1.3 is equivalent to non-log scale 0.05 (Huang da, Sherman et al. 
2009). 
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4 RESULTS 
 
4.1 Generation of SSX4 knock-in SK-LC-17 cell line 
4.1.1 SSX4 knock-in vector 
The promoter architecture of SSX4 gene was taken into account while designing the SSX4 
knock-in (KI) vector. The SSX4 promoter was previously characterized (Gure AO, 
unpublished data) by luciferase reporter constructs that were generated by PCR amplification 
of genomic DNA with forward (A1, A2, etc.) and reverse (B) primers shown in Figure 4.1. 
Luciferase reporter experiments showed that the minimal promoter activity of SSX4 lay 
between primers A3.3 and A4. Interestingly, this promoter showed low but significant 
promoter activity in the reverse direction demonstrating bidirectional activity.     
 
 
Figure 4.1 Sequence of the SSX4 promoter-proximal region: Exons 1 and 2 (containing translation initiation 
code in red) are shown in yellow. Ornithine Aminotransferase Like (OATL) pseudogene which is disrupted by 
an L1 repeat is shown in light blue. Alu repeats at the 5’ end of the promoter are indicated. The primers that were 
used to generate promoter-reporter constructs are indicated above their respective sequences (boxed).  
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Since L1 repeats were localized upstream of A3 forward primer, the 5’ homology sequence of 
the KI vector started from the A3 primer and ended with B primer sequences in order to 
prevent integration of the KI vector into L1 repeat containing regions in the genome. 
Although the SSX 3’ homology sequences was amplified using SSX4 specific sequences, 
subsequent sequencing of this region after it was cloned into the KI vector revealed that it was 
derived from SSX7 which is highly homologous to SSX4 but not expressed in either testis or 
cancer cells. The KI vector contained two selection markers both of which were driven by 
their own promoters; phosphoglycerate kinase (PGK) promoter- driven hygromycin antibiotic 
gene provided positive selection whereas β-actin-driven diphteria toxin-A gene (DTA) 
provided negative selection. Following homologous recombination between the KI vector and 
the SSX4 gene mediated by SSX4 3’ and 5’ homology sequences, DTA toxin is expected to 
be cleaved off. Non-homologous recombination events, on the other hand, would not require 
DTA elimination and thus die due to the toxicity induced by DTA. The sequence of the KI 
vector showing its components is given in Appendix B.  
4.1.2 Screening of SSX4 KI clones for GFP expression by flow cytometry 
Integration of KI vector into SSX4 gene would lead to expression of EGFP from SSX4 
promoter. In order to check whether GFP could indeed be expressed from the SSX4 promoter, 
we transfected SK-LC-17 cells transiently with the KI vector lacking diphteria toxin (Step6) 
and performed flow cytometry analysis. As a positive control, we used transfected SK-LC-17 
cells with pHygEGFP plasmid which has the EGFP under the control of the strong CMV 
promoter (Figure 4.2). 
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Figure 4.2: Dot plot analysis of untransfected SK-LC-17 cells and the same cells transiently transfected 
with pHygEGFP and the Step6 construct. 20.000 cells were counted and gated for the analysis. The cutoff for 
GFP expression intensity was in reference to that obtained for the untransfected SK-LC-17 cells. The number 
and percentage of cells within each quadrant are shown in tables next to each dot plot. The upper right quadrant 
(UR) indicates GFP positive cells. 
 
 
As shown in Figure 4.3, the percentage of cells within the UR quadrant for untransfected cells 
were 0.05%, compared to 46.5% for pHygEGFP, and 16.59% for Step 6 KI vector transfected 
cells. These results showed that the SSX4 promoter as contained within the KI vector was 
functional upon transient transfection into SK-LC-17 cells. The Step 6 vector is 9840 bp 
compared to pHygEGFP (5793 bp), which possibly accounts for its lower transfection 
efficiency. In addition, GFP expression intensity of the pHygEGFP transfected cells was 
higher as relative to Step6 transfected cells since GFP was expressed from the strong CMV 
promoter.   
 
.   
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Following verification of GFP expression from SSX4 promoter, 7.5 x 106 SK-LC-17 cells 
were stably transfected with the KI construct and clone selection was performed by growing 
the cells in hygromycin at 50 mg/ml, corresponding to the concentration at which >90% of the 
parental cells are killed in a week. Although initially more than a hundred clones survived 
hygromycin selection, about 30 of them died subsequently, possibly reflecting clones that had 
DTA integrated into their genome which showed its effect later on in the drug selection 
process. Thus the insertion efficiency was about 1:105, which is very high. We screened 70 
stable clones for GFP expression by flow cytometry and chose 42 of them with GFP 
expression. We observed that only one clone (clone #70) could be classified as 100% GFP 
positive, while all others had partial positivity (Table 4.1 and Figure 4.6).   
4.1.3 Determination of KI insertion site of GFP expressing SSX4 KI vector 
transfected clones by nested PCR 
To determine correct insertion of the KI vector, we used forward primers homologous to 
genomic DNA sequences that would be expected to locate 640 to 500 bp 5’ to the forward end 
of the KI vector, combined with reverse primers homologous to EGFP sequence, not normally 
found in genomic DNA of the cells. A control plasmid was generated in order to test the 
amplification efficiency of these primers in nested PCR. This control plasmid contained the 
SSX4 promoter-proximal region (A1-B) that thus contained sites for the forward primers 
(shown in Figure 4.1) and the EGFP sequence. Therefore, it represented the final DNA 
sequence upon the correct insertion of KI vector into the SSX4 gene. Two independent nested 
PCR reactions were performed using two sets of primer pairs for each reaction. Figure 4.3 
shows the location of these primers within the control plasmid sequences. In the first run of 
reaction (40 cycles), we did not observe any amplification products either specific or non-
specific (data not shown). The 2nd run of reaction using the primary products yielded specific 
amplicons for 7 of the 42 stable clones (Figures 4.4 and 4.5). The products amplified by 
P4&M7 and A2.1&M4 primer pairs were gel-purified and sequenced with A2.1 and M4 
primers. 
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Figure 4.3.: Primers used in nested PCR in context of the SSX4 5’ region after correct KI vector insertion. 
The region between primers A3 and B is contained within the KI vector as SSX4 5’ homology sequence. 
Sequences shown in green are of EGFP and would not be expected to occur in the genomic DNA of 
untransfected cells. P4 and A2.1 are forward primers whereas M26, M4, and M7 are reverse primers. The primer 
pairs that were used in each nested PCR reaction was as follows: P4&M4 → A2.1&M26; P4&M7 → A2.1&M4.  
Sequences that were typically confirmed by sequencing analyses are highlighted in yellow. 
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Figure 4.4: 2nd run of nested PCR with A2.1&M26 primer pair: Stable KI clones are indicated by numbers. 
The fist run was carried out using the P4&M4 primer pair in Figure 4.3.  SK-LC-17 was used as a negative 
control while the control plasmid was used as a positive control. The expected amplicon is 1580 base pairs and 
was obtained from all clones shown. These products were gel-purified for sequencing.  
 
 
 
Figure 4.5: 2nd run of nested PCR with A2.1&M4 primer pair: Stable KI clones are indicated by numbers. 
The first run was carried out using P4&M7 primer pair in Figure 4.3. The amplicon was 1702 base pairs. The 
PCR for clone #14 was subsequently repeated and a band of similar intensity to the others was obtained. These 
products were gel purified and sequenced with the same PCR primer pair. 
 
 
4.1.4 Sequencing of the amplified products for individual stable clones 
Figure 4.3 shows the sequenced regions of the amplified products with A2.1 forward and M4 
reverse primers in yellow. According to the BLAST results given in Appendix C, the 
sequenced region with A2.1 forward primer aligned to the expected sequence in the SSX4 
promoter-proximal region at %99 identity, where the first exon of Ornithine Aminotransferase 
Like (OATL) pseudogene lies in the genomic DNA whereas it aligned to the genomic clones 
that contained other family members of SSX gene family at < %95 identity (Appendix C). 
Moreover, the sequenced region with M4 reverse primer aligned perfectly to the SSX4 
minimal promoter (Appendix C). This verified correct insertion of the KI vector into SSX4 
gene for clones #14, 21, 70, 77, 85 and 96 except clone #66.  
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4.1.5 Flow cytometry analysis of SSX4 KI clones that were verified by nested 
PCR 
We observed a heterogeneous GFP expression of SSX4 KI clones except Clone #70 in the 
initial screening by flow cytometry (Figure 4.6). The percentage of GFP expressing cells and 
their GFP expression intensity and the corresponding histogram plots are given in Table 4.1 
and Figure 4.6, respectively. 
 
Table 4.1: The percentage of GFP expressing cells and their GFP expression intensity 
 % GFP positive cells (M1) GFP expression intensity 
SK-LC-17 0.50 32.39 
Clone #14 36.74 28.53 
Clone #21 24.65 24.18 
Clone #70 99.51 251.38 
Clone #77 68.05 105.25 
Clone #85 23.82 53.36 
Clone #96 41.87 67.99 
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Figure 4.6: Histogram plot analysis of SSX4 KI clones: The percentage of GFP expressing cells (M1) and 
their GFP expression intensity are given in Table 4.1. 20.000 cells were counted and gated for the analysis. 
Cutoff for GFP expression intensity was based on that observed for untransfected SK-LC-17 cells. 
 
We performed a second flow cytometry analysis of SSX4 KI clones in order to see whether 
clones were stably expressing GFP (Table 4.2 and Figure 4.7).  
 
Table 4.2: The percentage of GFP expressing cells and their GFP expression intenstiy 
 % GFP positive cells (M1) GFP expression intensity 
SK-LC-17 0.62 28.07 
Clone #14 36.12 32.11 
Clone #21 1.30 29.52 
Clone #70 99.72 199.39 
Clone #77 66.33 98.21 
Clone #85 2.94 38.05 
Clone #96 52.43 61.24 
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Figure 4.7: Histogram plot analysis of SSX4 KI clones. The percentage of GFP expressing cells (M1) and 
their GFP expression intensity are given in Table 4.2. 20.000 cells were counted and gated for the analysis. 
Cutoff for GFP expression intensity was based on that observed for untransfected SK-LC-17 cells. 
 
 
Comparison of these flow cytometry analyses showed that clone #85 and #21 lost their GFP 
expression. We observed only minor differences in terms of percentage of GFP expressing 
cells and GFP expression intensity for clones #14, #70, #77 and #96. 
4.1.6 Quantitative real-time PCR data for SSX4 gene in KI clones 
There are 2 SSX4 genes (SSX4; SSX4B) located head to head orientation in the Xp11.23. 
Since they are nearly identical copies, we could not differentiate whether SSX4 KI construct 
integrated into one of them or both by sequencing results. Quantification of SSX4 expression 
in these clones by qPCR would possibly help us understand this. If KI construct integrated 
into both SSX4 and SSX4B, the clones would not express SSX4. If it integrated into one of 
them, the clones would have SSX4 expression reduced by %50. We compared SSX4 
transcript levels of clones with that of Clone #1 which gave no band in nested PCR (negative 
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control), and SK-LC-17. According to qPCR results, Clone 21 and 85 had reduced SSX4 
expression whereas others expressed SSX4 even at higher levels than SK-CL-17 (Figure 4.8). 
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Figure 4.8: Relative SSX4 expression in SSX4 KI clones. SSX4 expression was checked by qPCR using SSX4 
Taqman MGB probe in SSX4 KI clones. Relative expression was calculated using ΔΔCt method and SSX4 
expression in SK-LC-17 was taken as the reference. Colon cDNA was used as a negative control to show that 
SSX4 is not expressed in normal tissues.  
 
 
 
4.2 Meta-analysis of tumor and cell line microarray datasets 
4.2.1 Hierarchical clustering analysis of tumor and cell line microarray datasets 
showed coordinate CT-X gene expression 
We obtained raw data for 2 cell line datasets and 8 tumor datasets from GEO and Array 
Express (Table 3.8). 4 of tumor datasets were generated by using Affymetrix HG-U133A 
platforms and the rest were generated by using HG-U133Plus2 platforms. The raw data were 
normalized with GC-RMA algorithm using GeneSpring GX 9.0.6 software (Agilent 
Technologies). All the arrays within datasets were included in further analyses according to 
the quality control (QC) analysis of GeneSpring GX 9.0.6 (section 3.3.9.6.2, data not shown).  
Subsequent to normalization, we used seven CT-X gene families, NY-ESO-1, SSX, GAGE, 
MAGEA, MAGEB, MAGEC and SPANX, for the hierarchical clustering analysis of tumor 
and cell line datasets, individually (Table 3.9 and Table 3.10). The clustering analysis 
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demonstrated that the selected CT-X genes were coordinately expressed in all tumor and cell 
line datasets, and that the samples could be categorized into three distinct groups; CT-X 
positive group expressing more than one CT-X gene family, CT-X intermediate group 
expressing only one CT-X gene family  and  CT-X negative group showing no CT-X gene 
expression. Two representative cluster images, one for the GSE4824 dataset containing lung 
cancer cell lines and GSE10072 composed of lung tumor samples, are shown in Figures 4.9 
and 4.10, respectively.  
 
 
 
4.4     7.4      10.3 
Figure 4.9: Hierarchical clustering analysis of lung cancer cell lines (GSE4824 dataset). The normalized 
expression values of  44 probesets corresponding to the selected CT-X genes were used to establish the 
hierarchical clustering using GeneSpring GX 9.06. Average linkage method and Euclidean distance as a matrix 
measure were used. Color code below the heatmap shows the range of normalized expression values. The tree at 
the top of the heatmap represents samplewise clustering. The tree on the left of the heatmap represents genewise 
clustering. 
 
 59
 
 
4.5    7.8      11.1 
Figure 4.10: Hierarchical clustering analysis of lung adenocarcinoma tumors (GSE10072 dataset). The 
normalized expression values of  44 probesets corresponding to the selected CT-X genes were used to establish 
the hierarchical clustering using GeneSpring GX 9.06. Average linkage method and Euclidean distance as a 
matrix measure were used. Color code below the heatmap shows the range of normalized expression values. The 
tree at the top of the heatmap represents samplewise clustering.The tree on the left of the heatmap represents 
genewise clustering. 
 
Lung and HCC tumors expressed CT-X genes at a higher frequency than ovarian and breast 
tumors, verifying previous reports on CT-X gene expression patterns of different tumors 
(Hoffman O 2008; Simpson AJ, 2005). In addition, the expression frequency of CT gene 
families was variable in tumor datasets: SSX genes were less frequently expressed in breast, 
lung, and ovarian tumors with the exception of HCC, whereas MAGE-A and GAGE genes 
were more frequently expressed in all tumors. All the members of one gene family were not 
expressed simultaneously in a dataset. This was expected for SSX gene family. It was 
previously shown that SSX1, 2 and 4 are expressed at substantial levels whereas SSX3, 5 and 
6 are rarely expressed and SSX7, 8 and 9 expression are not detected among tumor tissues 
(Gure, Wei et al. 2002).  
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4.2.2 CT-X grouping of tumor and cell line datasets 
To compare CT-X positive and negative samples by RankProd analysis, described in the 
following section, we first identified these samples as described in detail in section 3.3.9.5.  
Grouping was performed separately for cell line and tumor datasets. Using the combined data 
for tumor and cell line datasets, we determined an average rank value as the cut-off above 
which a sample would be considered positive for expression. The average rank value was 
slightly different for the combined data of  cell line datasets and tumor datasets that were 
generated either by HG-U133A or HG-U133Plus2 arrays as shown in Table 4.3. In this way, 
we determined CT-X expression intensity for each array and generated three CT-X groups 
based on the clustering analysis for each dataset. The number of samples in CT-X positive, 
intermediate and negative groups are listed for cell line and tumor datasets in Tables 4.4, 4.5 
and 4.6, respectively.  
 
Table 4.3: The average rank value of 3.5 in the combined data for cell line datasets and tumor datasets 
(HG-U133A and HG-U133Plus2) 
  The average rank value 
Cell line datasets (HG-U133A) 10856th rank (%48.7) 
Tumor datasets (HG-U133A) 10001st rank (%44.9) 
Tumor datasets (HG-U133Plus2) 28581st rank (%52.3 
 
 
 
Table 4.4: The number of samples in CT-X positive, negative and intermediate groups for cancer cell line 
datasets 
GSE number 
# Samples in CT-X 
positive group 
# Samples in CT-X 
negative group 
# Samples in CT-X 
intermediate group 
GSE4824/LCCL*  20 28 22 
GSE5720/NCI-60 CLP** 24 25 11 
*LCCL: lung cancer cell lines; **CLP: cell line panel 
 
 
Table 4.5: The number of samples in CT-X positve, negative and intermediate groups for tumor datasets 
generated by HG-U133A arrays 
GSE number/Array Express 
ID 
# Samples in CT 
positive group 
# Samples in CT 
negative group 
# Samples in CT 
intermediate group 
E-TABM-36/HCC*  16 37 4 
GSE10072/LADC**  11 41 6 
E-GEOD-GSE7390/BT& 14 164 20 
GSE6008/OT&& 8 78 13 
*HCC: Hepatocellular carcinoma, **LADC: Lung adenocarcinoma, &Node-negative breast tumors, &&Ovarian 
tumors 
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Table 4.6: Number of samples in CT-X positive, negative and intermediate groups for tumor datasets 
generated by HG-U133Plus2 arrays 
GSE number 
# Samples in CT 
positive group 
# Samples in CT 
negative group 
# Samples in CT 
intermediate group 
GSE9843/HCC* 28 44 19 
GSE9891/OT&& 38 209(42***) 38 
GSE3141/LT** 33 52 26 
GSE5460/ BT& 5 97(48***) 25 
*HCC: Hepatocellular carcinoma, &&Ovarian tumors, **LT: Lung tumors,  &Breast tumors,  
*** The numbers of samples had to be reduced for meta-analysis due to memory limitations of the hardware 
utilized.  
 
4.2.3 Meta-analysis of tumor datasets 
The probesets with normalized expression values below the corresponding values of the mean 
rank value (Table 4.3) were filtered out from each array using an R script. Then  common 
probesets were combined in a data matrix with an R script to be used in meta-analysis 
(Appendix A). After data pre-processing on HG-U133A platform, 19,421 probesets out of 
22,283 probesets remained for the combined tumor data.  
 
RankProd was utilized to identify differentially expressed genes between CT-X positive and 
negative groups. Meta-analysis of tumor datasets resulted in the identification of 1875 
probesets that were up-regulated in the CT-X positive group compared to CT-X negative 
group, with a FC≥1.2; a P-value of <0.05 and 1881 down-regulated probesets satisfying the 
same criteria (Table 4.7). 
 
Table 4.7: The number of probesets that were identified in the meta-analysis of tumor datasets (HG-
U133A) with a FC≥1.2 and FC≥1.5 at 0.05 significance 
 FC≥1.2, P<0.05 FC≥1.5, P<0.05 
#probe sets down-regulated in CT-X positive group 1881 309 
#probe sets up-regulated in CT-X positive group 1875 336 
 
 
4.2.3.1 Validation of the rank-product method using tumor datasets generated using 
HG-U133Plus2 arrays 
In order to test the reliability of the rank-product method we performed a second meta-
analysis with RankProd using data from tumor samples generated using the HG-U133Plus2 
platform. The datasets selected for validation analysis were from the same tumor types as 
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those used for generating the HG-U133A based data, namely, HCC, primary lung, breast and 
ovarian tumors, shown in Table 3.8. 
 
To generate data from the HG-133Plus2 based datasets that could be comparable to that 
obtained from HG-U133A based datasets, we filtered in those probesets used for the initial 
meta-analysis with HG-U133A based data (corresponding to ~19,415 probesets) from HG-
U133Plus2 based tumor data by an R based script. After we combined normalized data from 
individual datasets, we ran the RankProd package. We compared the meta-analysis of the HG-
U133A and the filtered HG-U133Plus2 based data and identified 681 common probesets that 
were up-regulated in CT-X positive group compared to CT negative group, with a fold change 
(FC) ≥1.2 and an FDR (False Discovery Rate) or P-value of ≤0.05; and 824 common 
probesets that were down-regulated and satisfying the same criteria. Table 4.8 lists the 
number of probesets identified in each meta-analysis and the number of probesets common to 
both. 
 
Table 4.8: The number of probesets that were identified in the meta-analysis of  HG-U133A and HG-
U133Plus2 based data and the number of probesets that were common between them (FC≥1.2, P≤0.05). 
  
#down-regulated in 
CT-X positive 
#up-regulated in CT-
positive 
Meta-analysis of the HG-U133A based data 1881 1875 
Meta-analysis of the HG-U133Plus2 based data 1841 1807 
Common number of probesets 824 681 
 
 
4.2.3.2 DAVID functional annotation clustering analysis of common probesets between 
meta-analysis of HG-U133A and HG-U133Plus2 based data 
In order to understand the biological meaning of the output probeset lists, we performed 
DAVID functional annotation clustering analysis of common probesets that were down-
regulated as well as for those that were up-regulated, more than 1.2 fold (FC≥1.2, P≤0.05) in 
the CT-X positive group compared to the CT-X negative group. This analytic module of 
DAVID clusters functionally similar terms associated with the gene or probeset list into 
functional annotation groups and then ranks these groups by giving them enrichment scores 
(Huang da, Sherman et al. 2009). The enrichment score given to each functional annotation 
group is the geometric mean of all the P-values of each annotation term (GO term) in the 
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group. Since enrichment score 1.3 is equivalent to a P-value of 0.05, we focused on the 
annotation groups with scores ≥1.3.  
 
DAVID functional annotation clustering analysis identified 10 annotation clusters with a fold 
enrichment of  ≥1.3 using 688 DAVID IDs among 824 down-regulated common probesets 
with a FC ≥1.2 and a P-value of P≤0.05. The first three functional annotation groups with the 
highest enrichment score values are listed in Table 4.9. Percentage (%) indicates the ratio of 
DAVID IDs  that belong to the annotation term (e.g. “~response to wounding”) to total 
DAVID IDs.    
 
Table 4.9: The functional annotation groups for down-regulated common probesets (FC≥1.2, p≤0.05) in 
the CT-X positive group compared to the CT-X negative group 
Functional Group 1 / Enrichment score 4.91       
Term % P-value FDR* 
GO:0009611~response to wounding 7.27% 6.50E-09 1.24E-05 
GO:0009605~response to external stimulus 9.01% 5.42E-08 1.03E-04 
GO:0006954~inflammatory response 4.80% 1.49E-05 0.028333967 
GO:0006950~response to stress 11.34% 3.99E-05 0.075976292 
GO:0006952~defense response 6.40% 5.31E-04 1.006668669 
GO:0050896~response to stimulus 17.88% 0.031113311 45.25675988 
Functional Group 2 /Enrichment score 4.69       
Term       
GO:0050817~coagulation 2.62% 4.18E-06 0.007970879 
GO:0007596~blood coagulation 2.47% 1.54E-05 0.029440702 
GO:0050878~regulation of body fluid levels 2.76% 2.51E-05 0.047791569 
GO:0007599~hemostasis 2.47% 3.11E-05 0.059306511 
GO:0042060~wound healing 2.62% 7.01E-05 0.133501166 
Functional Group 3 / Enrichment score 3.23       
Term       
GO:0050727~regulation of inflammatory response 1.16% 1.68E-04 0.319095341 
GO:0031347~regulation of defense response 1.16% 1.68E-04 0.319095341 
GO:0050729~positive regulation of inflammatory response 0.73% 0.001225652 2.310702665 
GO:0031349~positive regulation of defense response 0.73% 0.001225652 2.310702665 
GO:0048583~regulation of response to stimulus 1.16% 0.001650018 3.098893738 
*FDR: False Discovery Rate 
 
 
 
DAVID functional annotation clustering analysis identified 21 annotation clusters with a fold 
enrichment of  ≥1.3 using 570 DAVID IDs among 681 up-regulated common probesets with a 
FC≥1.2 and a P-value of P≤0.05. The first three functional annotation groups with the highest 
enrichment score values are listed in Table 4.10. 
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Table 4.10: The functional annotation groups for up-regulated common probesets  (FC≥1.2, p≤0.05) in the 
CT-X positive group compared to the CT-X negative group 
Functional Group 1 / Enrichment score 25.94       
Term % P-Value FDR 
GO:0000278~mitotic cell cycle 12.28% 5.04E-33 9.60E-30 
GO:0022403~cell cycle phase 12.63% 5.56E-32 1.06E-28 
GO:0000279~M phase 11.23% 1.54E-31 2.94E-28 
GO:0007067~mitosis 9.82% 9.54E-30 1.82E-26 
GO:0022402~cell cycle process 17.89% 1.02E-29 1.94E-26 
GO:0007049~cell cycle 19.47% 1.27E-29 2.42E-26 
GO:0000087~M phase of mitotic cell cycle 9.82% 1.70E-29 3.24E-26 
GO:0051301~cell division 9.30% 9.42E-27 1.80E-23 
GO:0000074~regulation of progression through cell cycle 10.35% 2.00E-12 3.82E-09 
GO:0051726~regulation of cell cycle 10.35% 2.18E-12 4.15E-09 
Functional Group 2 / Enrichment score 8.73       
Term       
GO:0000070~mitotic sister chromatid segregation 2.63% 4.46E-12 8.49E-09 
GO:0000819~sister chromatid segregation 2.63% 8.02E-12 1.53E-08 
GO:0007059~chromosome segregation 3.33% 8.14E-12 1.55E-08 
GO:0030261~chromosome condensation 1.40% 4.52E-06 0.008616287 
GO:0007076~mitotic chromosome condensation 1.23% 1.72E-05 0.032750855 
Functional Group 3 / Enrichment score 7.04       
Term       
GO:0007017~microtubule-based process 7.19% 2.93E-19 5.58E-16 
GO:0007051~spindle organization and biogenesis 2.63% 9.32E-15 1.78E-11 
GO:0000226~microtubule cytoskeleton organization and biogenesis 3.86% 4.07E-13 7.76E-10 
GO:0007010~cytoskeleton organization and biogenesis 9.47% 1.16E-11 2.20E-08 
GO:0007018~microtubule-based movement 3.51% 1.18E-09 2.24E-06 
GO:0030705~cytoskeleton-dependent intracellular transport 3.68% 9.23E-09 1.76E-05 
GO:0046907~intracellular transport 8.25% 1.46E-04 0.277609046 
GO:0051649~establishment of cellular localization 9.65% 1.57E-04 0.299349739 
GO:0051641~cellular localization 9.65% 2.82E-04 0.536302863 
GO:0051234~establishment of localization 16.32% 0.558041728 99.99998262 
GO:0051179~localization 18.07% 0.751988594 100 
GO:0006810~transport 14.74% 0.784476042 100 
*FDR: False Discovery Rate 
 
 
We also performed DAVID functional annotation clustering analysis with the probeset lists 
generated either by the meta-analysis of HG-U133A or HG-U133Plus2 based data, and found 
identical functional annotation groups with the highest enrichment score values between these 
two analyses (data not shown). Similarly, the common down- and up-regulated probesets gave 
us the same functional annotation groups that are listed in Tables 4.9 and 4.10. This indicated 
the consistency of RankProd analysis which could generate almost identical biological output 
even when different set of tumor samples were utilized.  
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According to the DAVID functional annotation clustering analysis results, the probesets 
related to immune response and coagulation were downregulated whereas the probesets 
related to mitosis, cell cycle and cytoskeleton organization and biogenesis were upregulated in 
the CT-X positive group as compared to the CT-X negative group. It seems that tumors 
expressing CT-X genes have a higher proliferation rate and metastatic capacity (in regard to 
cytoskeleton organization and biogenesis) than tumors that are not expressing CT-X genes. 
4.2.4 Meta-analysis of cancer cell line datasets 
After data pre-processing on HG-U133A platform (explained in section 3.3.9.6.1), 18,411 
probe sets remained for the combined cell line data. RankProd was utilized to identify 
differentially expressed genes between CT-X positive and negative groups.  
 
Meta-analysis of cell line datasets resulted in the identification of 1211 probesets that were 
up-regulated in CT-X positive group compared to CT-X negative group, with a FC≥1.2; a P-
value of  ≤ 0.05 and 1539 down-regulated probesets satisfying the same criteria (Table 4.11).  
 
Table 4.11: The number of probesets that were identified in the meta-analysis of cell line datasets with a 
FC≥1.2 and FC≥1.5 at 0.05 significance. 
 FC≥1.2, P≤0.05 FC≥1.5, P≤0.05 
#probe sets down-regulated in CT-X positive group 1539 816 
#probe sets up-regulated in CT-X positive group 1211 615 
 
 
We compared the meta-analysis of cancer cell line datasets and tumor datasets both of which 
were generated by using HG-133A arrays and identified 227 common probesets that were up-
regulated in CT-X positive group compared to CT-X negative group, with a fold change (FC) 
≥1.2 and a P-value of ≤0.05; and 444 common probesets that were down-regulated and 
satisfying the same criteria. 
 
We utilized DAVID functional annotation clustering annalysis of probesets that were down-
regulated and up-regulated more than 1.5 fold change (FC≥1.5, P≤0.05) in CT-X positive 
group compared to CT-X negative group, respectively. This analysis identified 7 annotation 
clusters with a fold enrichment ≥1.3 using 501 DAVID IDs among 615 up-regulated 
probesets with a FC≥1.5 and a P-value of p≤0.05. The first four functional annotation groups 
with enrichment scores  ≥1.3 are listed in Table 4.12. Percentage (%) indicates the ratio of 
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DAVID IDs that belong to the annotation term (e.g. cellular localization ) to total DAVID 
IDs.  
 
Table 4.12: The functional annotation groups for up-regulated probesets (FC ≥ 1.5, p≤0.05) in the CT-X 
positive group compared to the CT-X negative group  
Functional Group 1 / Fold enrichment 3.26         
Term % P-Value FDR 
GO:0051641~cellular localization 11.60% 2.08E-06 0.003973984 
GO:0051649~establishment of cellular localization 11.20% 4.68E-06 0.008915578 
GO:0016043~cellular component organization and biogenesis 25.60% 1.91E-05 0.036356043 
GO:0046907~intracellular transport 9.20% 2.63E-05 0.050123855 
GO:0032940~secretion by cell 4.60% 3.26E-04 0.61937338 
GO:0051179~localization 25.40% 5.84E-04 1.107972291 
GO:0008104~protein localization 8.80% 7.29E-04 1.379625832 
GO:0045184~establishment of protein localization 8.20% 0.001475057 2.774665446 
GO:0033036~macromolecule localization 8.80% 0.00227037 4.240262173 
GO:0051234~establishment of localization 21.40% 0.004359533 7.991088354 
GO:0015031~protein transport 7.20% 0.007548161 13.44859852 
GO:0006886~intracellular protein transport 4.80% 0.011383711 19.6071726 
GO:0046903~secretion 4.60% 0.01263466 21.52429841 
GO:0006810~transport 20.00% 0.01295533 22.00871527 
Functional Group 2 / Fold enrichment 3.19       
Term       
GO:0006888~ER to Golgi vesicle-mediated transport 2.20% 5.13E-05 0.097786048 
GO:0048193~Golgi vesicle transport 2.60% 3.18E-04 0.605192487 
GO:0032940~secretion by cell 4.60% 3.26E-04 0.61937338 
GO:0045045~secretory pathway 3.80% 9.92E-04 1.873650133 
GO:0016192~vesicle-mediated transport 6.40% 0.001059073 1.999651131 
GO:0046903~secretion 4.60% 0.01263466 21.52429841 
Functional Group 3 / Fold enrichment 2.26       
Term       
GO:0046148~pigment biosynthetic process 1.40% 0.001101871 2.07965719 
GO:0006583~melanin biosynthetic process from tyrosine 0.80% 0.001202233 2.267028356 
GO:0006582~melanin metabolic process 0.80% 0.001202233 2.267028356 
GO:0042438~melanin biosynthetic process 0.80% 0.001202233 2.267028356 
GO:0042440~pigment metabolic process 1.40% 0.002176929 4.069161211 
GO:0019748~secondary metabolic process 1.40% 0.008135582 14.41993726 
GO:0009072~aromatic amino acid family metabolic process 1.00% 0.009161013 16.09085073 
GO:0006570~tyrosine metabolic process 0.80% 0.011028345 19.05451945 
GO:0006725~aromatic compound metabolic process 2.20% 0.01353118 22.87151411 
KEGG_PATHWAY_hsa00350:Tyrosine metabolism 0.60% 0.590723139 99.99873526 
Functional Group 4 / Fold enrichment 1.95       
Term       
GO:0007049~cell cycle 9.80% 0.001762793 3.307340064 
GO:0000279~M phase 4.20% 0.002046006 3.828940052 
GO:0007067~mitosis 3.60% 0.002251613 4.205938394 
GO:0000087~M phase of mitotic cell cycle 3.60% 0.00250899 4.675890718 
GO:0022403~cell cycle phase 4.80% 0.003433177 6.345445001 
GO:0022402~cell cycle process 8.00% 0.010295896 17.90406135 
GO:0000278~mitotic cell cycle 4.00% 0.019215595 30.91689662 
 67
GO:0051301~cell division 2.60% 0.097904121 85.9715428 
GO:0000074~regulation of progression through cell cycle 5.00% 0.159942087 96.39293745 
GO:0051726~regulation of cell cycle 5.00% 0.160815004 96.46371961 
*FDR: False Discovery Rate 
 
 
DAVID functional annotation clustering analysis found 4 annotation clusters with a fold 
enrichment ≥1.3 using 710 DAVID IDs among 816 down-regulated probesets with a FC ≥1.5 
and a P-value of p≤0.05. The first three functional annotation groups were listed in Table 
4.13. 
 
Table 4.13: The functional annotation groups for down-regulated probesets (FC ≥ 2.0, p≤0.05) in the CT-
X positive group compared to the CT-X negative group  
Functional Group 1 / Fold enrichment 6.53       
Term % P-Value FDR 
GO:0002376~immune system process 11.83% 3.19E-09 6.08E-06 
GO:0006955~immune response 8.87% 2.83E-07 5.39E-04 
GO:0050896~response to stimulus 21.69% 2.79E-05 0.053169586 
Functional Group 2 / Fold enrichment 4.93       
Term       
GO:0048519~negative regulation of biological process 13.94% 2.38E-07 4.55E-04 
GO:0048523~negative regulation of cellular process 13.10% 1.49E-06 0.002837092 
GO:0009892~negative regulation of metabolic process 5.07% 0.004607553 8.427016603 
Functional Group 3 / Fold enrichment 4.52       
Term       
GO:0012501~programmed cell death 10.28% 7.42E-07 0.00141389 
GO:0006915~apoptosis 10.14% 1.08E-06 0.002050884 
GO:0043067~regulation of programmed cell death 7.75% 2.13E-06 0.004065203 
GO:0030154~cell differentiation 18.31% 2.35E-06 0.004485707 
GO:0048869~cellular developmental process 18.31% 2.35E-06 0.004485707 
GO:0008219~cell death 10.42% 2.75E-06 0.005247704 
GO:0016265~death 10.42% 2.75E-06 0.005247704 
GO:0042981~regulation of apoptosis 7.61% 3.43E-06 0.006535566 
GO:0048468~cell development 13.52% 7.85E-06 0.014967071 
GO:0043065~positive regulation of apoptosis 4.51% 1.24E-05 0.023565591 
GO:0043068~positive regulation of programmed cell death 4.51% 1.47E-05 0.027949661 
GO:0006917~induction of apoptosis 3.66% 1.39E-04 0.264801062 
GO:0012502~induction of programmed cell death 3.66% 1.51E-04 0.287157479 
GO:0043069~negative regulation of programmed cell death 2.96% 0.023217395 36.09659327 
GO:0043066~negative regulation of apoptosis 2.82% 0.038411808 52.6050396 
GO:0006916~anti-apoptosis 2.11% 0.067378006 73.54439926 
*FDR: False Discovery Rate 
 
 
We observed nearly the same pattern for cancer cell lines as we observed for tumors with a 
few exceptions. Interestingly, the probesets that function to induce apoptosis were 
downregulated in the CT-X positive group as compared to the CT-X negative group. 
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4.2.5 Clustering analysis of probesets that were identified by meta-analysis of 
cell line datasets in GSE4824 lung cancer cell line dataset 
 
In meta-analysis, we simultaneously analyzed datasets from tumors and tumor cell lines 
originating from various tissues as reported in previous sections. We showed coordinate 
expression of CT-X genes in our datasets (Figures 4.9 and 4.10). By meta-analysis, we 
primarily aimed to find CT-X regulatory mechanisms that are common and drive CT-X gene 
expression in cancer, regardless of tissue origin. However, we also consider different cancer 
types might have unique mechanisms underlying CT-X gene expression. We, therefore, 
wanted to test if the probesets identified by meta-analysis could discriminate CT-X positive 
and negative samples when datasets were analysed individually. Therefore, we selected 25 
probesets (p<0.0001) with the highest fold change values from the up-regulated and down-
regulated probeset lists that were generated by the RankProd analysis of cell line datasets and 
then we performed a sample based clustering analysis with these probesets on the same 
samples used for the meta-analysis from one of the datasets (GSE4824). Indeed, hierarchical 
clustering analysis showed that these 25 selected probesets could not successfully classify 
lung cancer cell lines into the CT-X positive and negative groups although there was 
accumulation of samples of a given class in a particular cluster; this inability of discrimination 
might be due to variable expression pattern of probesets between samples (Figures 4.11 and 
4.12). Some of these probesets also might be unique in their expression to other dataset used 
(GSE5720) in meta-analysis.  
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4.6    8.2      11.9 
Figure 4.11: Hierarchical clustering analysis of CT-X positive and CT-X negative lung cancer cell lines 
(GSE4824) The normalized expression values of  25 probe sets (p<0.0001) up-regulated in CT-X positive lung 
cancer cell lines as relative to CT-X negative lung cancer cell lines were used to establish a sample based 
hierarchical clustering using GeneSpring GX 9.06. Average linkage method and Euclidean distance as a matrix 
measure were used. Color code below the heatmap shows the range of normalized expression values.The tree at 
the top of the heatmap represents samplewise clustering. Blue indicates CT-X positive cell lines wheras red 
indicates CT-X negative cell lines.  
 
 
 
 
4.6    8.2      11.9 
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Figure 4.12: Hierarchical clustering of CT-X positive and CT-X negative lung cancer cell lines (GSE4824). 
The normalized expression values of  25 probe sets (p<0.0001) down-regulated in CT-X positive group 
compared to CT-X negative group were used to establish a sample based hierarchical clustering using 
GeneSpring GX 9.06. Average linkage method and Euclidean distance as a matrix measure were used. Color 
code below the heatmap shows the range of normalized expression values. The tree at the top of the heatmap 
represents samplewise clustering. Blue indicates CT-X positive cell lines wheras red indicates CT-X negative 
cell lines.  
 
4.2.6 Class prediction analysis of GSE4824 lung cancer cell line dataset via BRB 
Array Tools 
 The fact that the probesets that were most significant in meta-analysis are not perfect 
identifiers of CT-X positive and negative samples could likely be due to dataset-specific 
differences of the fold change (FC) value of those probesets identified by the meta-analysis. 
This could be because of the underlying algorithm of the RankProd analysis (section 
3.3.9.6.2); as it first determines the expression difference (FC) of a given probeset by pair-
wise comparison within arrays in each dataset and calculates the rank product according to the 
rank of each FC value. Then, it combines the rank products from different datasets and 
determines the signifance of this rank product. Therefore, it is likely that an FC value of a 
probeset given in the end might be one that belongs to the most significant rank product and it 
might not reflect the actual fold change value which is expected to be more substantial. 
Moreover, the RankProd analysis relies on determination of an FC value without considering 
the correlation structure among probesets thus it is not sensitive to the variability around the 
FC values associated with each dataset. On the other hand, classification methods (class 
prediction) such as support vector machines take advantage of the relationships among the 
samples used in the analysis to extract the best discriminating combination of probesets 
maximizing the separation between groups, i.e., herein CT-X positive and negative samples. 
We, therefore, decided to perform class prediction analysis in the lung cancer cell line dataset, 
to reveal differences of gene expression that could clearly classify lung cancer cell line 
samples based on CT-X expression. We hoped that this type of analysis would reveal 
additional differences that could be validated by RT-PCR subsequently.  
 
The raw data of the GSE4824 dataset were normalized with GC-RMA algorithm using BRB 
Array Tools. Class prediction analysis was carried out at 0.001 significance using CT-X 
positive and CT-X negative lung cancer cell lines according to our previous classification 
(Table 4.4). All the predictors of the class prediction analysis including nearest centroid, 
compound covariate, support vector machines correctly discriminated CT-X positive and CT-
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X negative lung cancer cell lines giving %96 percent of classification on average (section 
3.3.0.7). Class prediction analysis resulted in the identification of 88 up-regulated and 48 
down-regulated probesets at 0.001 significance. Although excluding CT-X genes from the 
class prediction analysis reduced the percent of classification on average of  CT-X positive 
and negative lung cancer cell lines, almost the same probeset list with the same number of 
probesets was generated (data not shown). In the heatmap generated by clustering analysis 
with these probesets, CT-X negative (as shown by 0) and positive (as shown by 1) cell lines 
could be clearly differentiated. Interestingly, the probesets classified a subgroup of CT-X 
negative samples together with CT-X positive samples, but not the other way arround, 
possibly suggesting that mechanisms underlying CT-X gene expression might effect the cells 
in a two-tiered fashion, where some samples induce CT-X gene expression upon this 
mechanistic alteration, while others do not. 
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Figure 4.13: Hierarchical clustering of CT-X positive and CT-X negative lung cancer cell lines using the 
probesets generated by the class prediction analysis The mean-centered normalized expression values of 88 
up-regulated and 48 down-regulated probesets were used to establish a  hierarchical clustering using BRB Array 
Tools. Average linkage method and spearman rank correlation as a matrix measure were used. Red indicates 
upregulation wheras green indicates downregulation. At the top of the heatmap, CT-X positive cell lines are 
shown by 1 wheras CT-X negative cell lines are shown by 0. 
4.2.6.1 DAVID Functional annotation clustering analysis of probesets found by the 
class prediction analysis and selection of the probesets for validaton in lung 
cancer cell lines 
By using DAVID tools, we investigated the functions of individual probesets that were 
generated at 0.001 significance by class prediction analysis of lung cancer cell lines. We 
found that a subset of genes that were upregulated in the CT-X positive group as relative to 
the CT-X negative group, which are expressed in different cancer cells and associate with 
increased proliferation rate, metastasis and angiogenesis (Yang, Mani et al. 2004; Kasper, 
Vogel et al. 2005; Scaglia and Igal 2005; Muchemwa, Nakatsura et al. 2008; Scaglia and Igal 
2008; Shea, Wells et al. 2008). In addition, some of them confer drug resistance or sensitivity 
to cancer cells (Atienza, Roth et al. 2005; Kasper, Vogel et al. 2005; Zhang, Wang et al. 
2009). However, these genes were not enriched in the CT-X negative group.  
 
Of the 88 up-regulated and 48 down-regulated probe sets identified by the class-prediction 
analysis, 67 up-regulated and 30 down-regulated probesets were identical to that obtained by 
our meta-analysis We take this to further support the validity of the meta-analysis. We chose 
8 up-regulated probesets and 1 down-regulated probeset that behaved commonly in both 
meta-analysis and class prediction analysis to be validated in lung cancer cell lines. Table 
4.14 lists these probesets with fold changes and p-values given by meta-analysis and class 
pediction analysis and their associated biological process in normal tissues. 
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Table 4.14: The probesets selected for validation in lung cancer cell lines 
    
Class prediction 
analysis** Meta-analysis*   
Gene 
symbol Gene name 
Fold 
change P -value 
Fold 
change P- value Biological process 
SCD 
stearoyl-CoA desaturase (delta-9-
desaturase) 8.0472729 0.0002313 4.1718815 0 Fatty acid biosynthetic process 
RAD21 RAD21 homolog (S. pombe) 5.2286351 0.0005711 1.9766752 0 DNA repair 
HSPH1 heat shock 105kDa/110kDa protein 1 3.9502552 0.0004841 2.0466639 0
Protein metabolic process&response to 
unfolded protein 
HSP90B1 
heat shock protein 90kDa beta (Grp94), 
member 1 3.4590574 0.0001664 1.805706 0 RNA processing&RNA binding 
LAPTM4B 
lysosomal protein transmembrane 4 
beta 2.5006464 0.0008625 1.9290123 0 Transport / Localization 
NFYC nuclear transcription factor Y, gamma 2.2005275 0.0009699 1.601794 0.0001 Regulation of transcription 
SSRP1 structure specific recognition protein 1 2.1555008 0.0005962 1.4148274 0.0041
Transcription&DNA 
replication&DNA repair 
TWIST1 twist homolog 1 (Drosophila) 2.1365362 0.0009206 2.1834061 0 Transcription 
LIMK2 LIM domain kinase 2 
-
3.0896689 0.0005682 -2.0033 0
Protein modification process (protein 
kinase activity 
*Meta-analysis of 2 cancer cell line datasets (section 4.2.4) 
**Class prediction analysis of GSE4824 lung cancer cell line dataset 
 
 
4.3 Expression analysis of four CT-X genes in lung, colon, breast and HCC 
cancer cell lines to determine CT-X positive and negative cell lines 
Validation of the expression of the above described genes identified commonly by the meta-
analyis and class prediction analysis requires that we test tissues or cell lines that have been 
thoroughly caracterized with regard to their CT-X expression patterns. We, therefore, 
quantified the relative expression of four CT-X genes; namely SSX4A/SSX4B, 
CTAG1A/CTAG1B (NY-ESO-1), MAGEA3 and multiple GAGE genes using specific 
Taqman MGB (FAM labelled) probes by qPCR. We used ∆∆Ct values of SK-LC-17 samples 
as the reference. cDNA from normal colon tissue that is known not to express any of the CT-
X genes was used as a negative control. 
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Figure 4.14: Relative expression of SSX4A/SSX4B, CTAG1A/CTAG1B (NY-ESO-1), MAGEA3 and 
multiple GAGE genes in lung cancer cell lines. Expression of CT-X genes was checked by qPCR using 
specific Taqman MGB probes in lung cancer cell lines. Relative expression was calculated using ΔΔCt method 
and CT-X expression in SK-LC-17 was taken as the reference. Colon cDNA was used as a negative control to 
show that CT-X genes are not expressed in normal tissues. 
 
 
Figure 4.15: Relative expression of SSX4A/SSX4B, CTAG1A/CTAG1B (NY-ESO-1), MAGEA3 and 
multiple GAGE genes in colon cancer cell lines. Expression of CT-X genes was checked by qPCR using 
specific Taqman MGB probes in breast cancer cell lines. Relative expression was calculated using ΔΔCt method 
and CT-X expression in SK-LC-17 was taken as the reference. Colon cDNA was used as a negative control to 
show that CT-X genes are not expressed in normal tissues. 
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Figure 4.16: Relative expression of SSX4A/SSX4B, CTAG1A/CTAG1B (NY-ESO-1), MAGEA3 and 
multiple GAGE genes in breast cancer cell lines. Expression of CT-X genes was checked by qPCR using 
specific Taqman MGB probes in colon cancer cell lines. Relative expression was calculated using ΔΔCt method 
and CT-X expression in SK-LC-17 was taken as the reference. Colon cDNA was used as a negative control to 
show that CT-X genes are not expressed in normal tissues. 
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Figure 4.17: Relative expression of SSX4A/SSX4B, CTAG1A/CTAG1B (NY-ESO-1), MAGEA3 and 
multiple GAGE genes in HCC cell lines. Expression of CT-X genes was checked by qPCR using specific 
Taqman MGB probes in HCC cell lines. Relative expression was calculated using ΔΔCt method and CT-X 
expression in SK-LC-17 was taken as the reference. Colon cDNA was used as a negative control to show that 
CT-X genes are not expressed in normal tissues. 
 
 
Current evidence indicates that lung cancer and HCC express CT-X genes at high levels 
whereas breast expresses CT-X genes at moderate levels and colon expresses them at low 
levels (Hofmann, Caballero et al. 2008). According to our results, CT-X genes were expressed 
at different frequencies within cell lines of lung, breast, colon cancers and HCC. Lung cancer 
cell lines expressed CT-X genes at the highest level when compared to the cell lines of other 
tissues. We found that GAGE, in addition to MAGEA3, was the most frequently expressed 
CT-X genes in all cancer types tested.      
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5 DISCUSSION & FUTURE PERSPECTIVES 
 
In this study, we aimed to develop two approaches by which the mechanisms underlying the 
regulation of CT-X gene expression in cancer could be identified. CT-X genes are unique in 
that their expression is specific to tumors in adults and is correlated with tumor progression. 
They are expressed in a coordinate manner in tumors, supporting a common mechanism for 
their activation. The key event in the activation of CT-X genes in testis and during 
tumorigenesis is promoter-specific demethylation. However, the exact mechanisms targeting 
DNA hypomethylation to CT-X promoters remain to be described. Elucidating the 
mechanisms responsible for the reactivation of CT-X genes during tumorigenesis will not 
only contribute to the understanding of their role in tumorigenesis but also will bring on with 
novel therapeutic targets and prognostic indicators. 
 
5.1 Generation of an SSX4 knock-in cell line 
We used an SSX4 KI targeting vector in order to generate an SSX4 KI cell line with a GFP 
reporter gene that is expressed from SSX4 promoter. We first tested expression of GFP from 
SSX4 promoter cloned into the KI vector by transient transfection of SK-LC-17 cells with the 
KI vector lacking β-actin DTA (referred to as “Step 6”).  Flow cytometry analysis of the 
Step6 transfected SK-LC-17 cells showed that the SSX4 promoter as contained within the KI 
vector was functional and expressing GFP. Afterwards, we went on with stable transfection of 
SK-LC-17 cells with the KI vector and obtained 70 stable clones. Among 70 stable clones, 
clone #70 could be identified as 100% GFP positive and the rest were either GFP negative 
and showed partial GFP expression. Among the clones (41 clones) with heterogeneous GFP 
expression, we chose the ones containing a high percentage of GFP expressing cells. In order 
to determine correct insertion of the KI vector, we screened the clones by nested PCR using 
the forward primers that are homologous to the SSX4 5’ sequence in the promoter-proximal 
region corresponding to the genomic DNA of the cell, combined with the reverse primers 
homologous to EGFP sequence. We could observe neither an amplified product nor a non-
specific product in the first run of nested PCR. The 2nd run of PCR reaction using the primary 
products yielded specific amplicons for 7 of the 42 stable clones. Then, 6 of 7 clones (#14, 21, 
70, 77, 85 and 96) were sequence-verified.  
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We observed a heterogeneous GFP expression for SSX4 KI clones with correctly inserted KI 
vector except Clone #70 in the initial screening by flow cytometry. We first thought that this 
partial GFP expression could result from the fact that the KI vector might be inserted into 
another SSX gene in the SSX gene family. It was highly probable that the KI construct might 
be integrated into SSX7 since the 3’ SSX4 homology sequence was derived from SSX7 which 
is highly homologous to SSX4 but not expressed in either testis or cancer cells. Then, the 
clones first might have GFP expression due the activity of inserted SSX4 promoter and they 
might have lost GFP expression by time. However, in consequent experiments we obtained 
stable clones with correctly inserted KI vector which had also heterogeneous GFP expression. 
This challenged our previous idea. We repeated the flow cytometry analyses with these clones 
in order to see whether these clones were stably expressing GFP. We observed that clone #85 
and #21 lost their GFP expression and only minor differences were seen for clones #14, #70, 
#77 and #96 in terms of percentage of GFP expressing cells and GFP expression intensity. In 
both flow cytometry analyses, we used parental SK-LC-17 cells as the negative control and 
determined the cutoff for GFP expression intensity based on that observed for these cells. As 
it is noticed in Tables 4.1 and 4.2, the background fluorescence (M1) of SK-LC-17 cells 
differed between two flow cytometry analyses and these minor differences in terms of GFP 
expressing cells and GFP expression intensity might result from this. Even though #85 and 
#21 were correct clones, we were surprised that they lost their GFP expression. The 
sequencing of the amplified products with the M4 reverse primer only yielded 152 bp 
sequence information corresponding to the minimal SSX4 promoter. If there occurred any 
mutation upstream of this obtained sequence during homologous recombination that would 
result in the repression of GFP in these clones, we would not be able to see that. Therefore, 
we would have to obtain more sequence information on the clones which currently seem to 
have correctly integrated KI vector.   
 
We quantified SSX4 gene expression in these clones by qPCR in order to differentiate 
whether SSX4 KI construct integrated into one of the SSX4 genes (SSX4; SSX4B) or both of 
them, which are identical copies of the same gene located head-to-head orientation in the 
Xp11.23. We thought that if the KI construct integrated into one of them, the clones would 
have SSX4 expression reduced by %50. According to qPCR results, Clone #21 and #85 had 
reduced SSX4 expression relative to SK-LC-17 whereas others expressed SSX4 even at 
higher levels than SK-CL-17. Since these clones were generated by single-cell cloning, the 
individual clones might have varying SSX4 expression due to the heterogeneity of cell lines. 
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However, since clones were still expressing SSX4, we could say that the KI construct 
integrated into one of the SSX4 genes. Interestingly, the clones (#85 and #21) which lost their 
GFP expression also expressed SSX4 at lower levels as compared to other clones. This led us 
to think that these clones somehow might lose the expression of one of the SSX4 genes. It 
should be clarified why and how these clones lost expression of one of the SSX4 genes.  
 
Since clone #70 was classified as 100% GFP positive, we would go on with this clone. We 
want to transfect clone #70 with a CT-X negative cDNA library and select the clones with 
repressed GFP expression by flow cytometry. Sequencing of the genomic DNA with the 
primers, which are designed to obtain the integrated cDNA, would result in identification of 
the gene that causes repression of SSX4 promoter. In this strategy, our aim is to repress 
SSX4; thereby theoretically we should obtain some clones with methylated SSX4.  However, 
this would not be so easy considering the fact that cancer cells might lose the factors that 
target DNMTs to the promoters of CT-X genes (Figure 1.1) and if this was the case SSX4 
would not be repressed in these clones due to the absence of these factors. On the other hand, 
we could identify cDNAs that might cause SSX4 repression by other mechanisms that 
indirectly cause DNA methylation of CT-X genes. 
5.2 Meta-analysis of cell line and tumor datasets 
Based on the fact that CT-X gene expression occurs coordinately in cancer cells (Gure, Chua 
et al. 2005; Simpson, Caballero et al. 2005), we utilized a meta-analysis approach to identify 
differentially expressed genes between CT-X expressing (CT-X positive) and non-expressing 
(CT-X negative) cancer cells. We developed a methodology, which we made use of R based 
written functions, in order to classify tumors and tumor cell lines into CT-X positive and 
negative groups according to the expression pattern of seven CT-X gene families. We 
observed coordinate CT-X gene expression pattern which was clustered in all cell line and 
tumor datasets.  
 
We chose to use the rank product method as a meta-analysis approach since it was shown to 
be more powerful as compared to other meta-analysis methods based on a t-statistics (Hong 
and Breitling 2008). We validated the reliability and consistency of RankProd analysis by 
using a different set of tumor datasets generated by HG-U133Plus2 arrays. Our strategy was 
to employ the same probesets with which RankProd analysis was performed for tumor 
datasets generated by HG-U133A arrays. This validation resulted in the identification of 
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almost similar biological outcome of CT-X positive and negative tumors for both analyses 
revealed by DAVID functional annotation clustering analysis. We found that CT-X positive 
tumors have higher proliferative and metastatic capacity indicating worse prognosis. We and 
others have already shown that CT-X gene expression is associated with advanced disease and 
other variables that indicate worse prognosis in different types of tumors (Gure AO,2005; 
Condomines M , 2007; Velazquez EF, 2007). In addition, CT-X positive tumors appear to 
have repressed immune response. In the literature, there are a number publications indicating 
that T-cell responses against CT-X genes were in general low or they were not sustained, 
thereby following postvaccination tumor relapsed again (Marchand, van Baren et al. 1999; 
Jager, Gnjatic et al. 2000; Zendman, Ruiter et al. 2003). Therefore, our findings were in 
parallel to the current evidence on CT-X genes. 
 
CT-X genes are expressed in proliferating germ cells in testis, which have the capacity to self-
renew thereby resembling adult stem cells. Interestingly, NY-ESO-1, SSX, MAGEA3, 
NRAGE were found to be expressed in human mesenchymal stem cells of the bone marrow 
and down-regulated after differentiating into osteocyte and adipocyte (Cronwright, Le Blanc 
et al. 2005). In addition, it was shown by immunohistochemical analysis that CT-X genes 
including NY-ESO-1 and MAGEA3 are expressed heterogeneously in tumor tissues meaning 
that all the cells in the tumor population are not expresssing CT-X genes (Scanlan, Gure et al. 
2002). All these findings suggest that CT-X gene expression might be a stem cell marker, be 
it in normal or tumor tissues. According to our meta-analysis, CT-X positive tumors seem to 
be dividing more as compared to CT-X negative tumors associated to self-renewal, and 
proliferative capacity of cancer stem cells that maintains the tumor cell mass. Thus, it is 
probable that CT-X positivity may confer tumor cells with a proliferative capacity and stem 
cell like phenotype.   
 
Moreover, in human mesenchymal stem cells SSX was shown to be localized in the 
cytoplasm and co-stained with matrix metalloproteinase 2 (MMP2) and vimentin 
(Cronwright, Le Blanc et al. 2005). Further investigation revealed that the migration of a 
melanoma cell line (DFW), which expresses SSX, MMP2, and vimentin, decreases when SSX 
is down-regulated. In addition, E-cadherin expression increases, mimicking a mesenchymal 
epithelial transition. These results suggest that SSX might have a functional role in normal 
stem cell migration and having a potentially similar function in cancer cell metastases 
(Cronwright, Le Blanc et al. 2005). These findings were also in aggrement with our meta-
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analysis of tumors as CT-X positive tumors overexpress genes that are associated with 
metastasis and angionenesis. In the light of these findings, our approach could infer the 
functional connection of CT-X gene expression with cancer and stem cell biology and the 
specific functions of CT-X genes. This would be further clarified by functional experiments.  
 
Although RankProd could generate consistent and reliable data, it might result in 
identification of tissue-specific gene expression pattern when analyzing tumors originating 
from different tissues. In addition, it does not take into account the covariance structure of the 
probeset expression leading to identification of probesets as significant solely based on their 
fold change value. This could not be very informative or might be false-positive regarding the 
mechanisms underlying CT-X gene expression in tumors since many of the CT-X genes are 
coordinately expressed; in fact many probesets in the whole genome might exhibit coordinate 
expression patterns. We partially verified this in lung cancer cell line dataset by clustering 
analysis using the probesets generated by meta-analysis and observed that the probesets that 
were most significant in meta-analysis could not discriminate CT-X positive and negative 
samples (section 4.2.5). We therefore performed class prediction analysis in lung cancer cell 
line dataset to identify the probesets with more substantial gene expression differences 
between CT-X positive and negative samples (section 4.2.6). We thought that from this type 
of analysis we can easily select the probesets that could be validated by RT-PCR 
subsequently. We chose this dataset since we want to perform validation experiments in lung 
cancer cell lines with known CT-X expression profiles. Although class prediction analysis 
correctly classified CT-X positive and negative lung cancer cell lines, there appeared to be a 
subgroup of CT-X negative cell lines that were classified together with those exhibiting CT-X 
positivity suggesting that the mechanisms underlying CT-X gene expression in this subgroup 
might be activated leading to a similar gene expression profile of CT-X positive group. It is 
also possible that the subgroup might express additional markers (other CT-X genes) not 
considered in the given study leading to its discrimination from other CT-X negative cell 
lines. This should be verified by additional analyses considering other CT-X genes. A similar 
class prediction analysis would be performed for the other cancer cell line dataset (GSE5720). 
If a subgroup similar to the one in lung cancer cell line dataset was generated, the RankProd 
analysis would be re-performed after excluding these subgroups from cancer cell line datasets. 
 
Lastly, we obtained parallel results between meta-analysis and class prediction analysis. As 
we expected, the probesets identified by class prediction analysis have higher fold changes 
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that the probesets identified by meta-analysis. We chose 8 up-regulated and 1 down-regulated 
genes common to both analyses. The functions of these genes are briefly given below. 
Interestingly, RAD21, HSP90B1 and LAPTM4B were shown to confer drug resistance in 
different tumors. This could be associated with CT-X gene expression and we would verify 
this by testing the effect of chemotherapeutic drugs in CT-X expressing lung cancer cell lines. 
In contrast, one gene, SSRP1, seemed to confer drug sensitivity and this could also be 
checked in anti-cancer therapies in lung cancer. Overexpression of TWIST1 and LIMK2 is 
implicated in metastasis. Interestingly, we found overexpression of TWIST1 whereas 
downregulation of LIMK2 in our class prediction analysis. NFYC is a transcription factor that 
induces Gadd45a expression which indirectly causes DNA demethylation. This seems to be 
relevant to CT-X regulation considering that CT-X genes are activated by promoter-specific 
DNA demethylation. Therefore, the functional role of NFYC in relation to epigenetic 
deregulation of CT-X genes should also be confirmed. Lastly, SCD and HSP105 which are 
expressed in different cell lines should also be verified in CT-X positive cell lines in order to 
confirm the proliferative consequences.  
 
We will validate these genes in lung cancer cells for which we quantified the expression of 
four CT-X genes, namely NY-ESO-1, MAGEA3, GAGE and SSX4, by probe-based qPCR 
and classified them as CT-X expressing and non-expressing cell lines. In the long term, if we 
would find correlation between their expression and CT-X positivity, further functional 
analyses would be performed in order to explore their functional relationship to CT-X genes.   
5.2.1 Up-regulated genes in CT-X positive lung cancer cell lines 
SCD: Stearoyl-CoA desaturase is an iron-containing enzyme that catalyzes a rate-limiting 
step in the synthesis of unsaturated fatty acids. By globally regulating lipid metabolism, 
stearoyl-CoA desaturase activity modulates cell proliferation and survival. Simian virus 40-
transformed human lung fibroblasts bearing a knockdown of human stearoyl-CoA desaturase 
exhibited a dramatic decrease in proliferation rate and abolition of anchorage-independent 
growth (Scaglia and Igal 2005). Remarkably, the reduction of SCD1 expression in lung cancer 
cells significantly delayed the formation of tumors and reduced the growth rate of tumor 
xenografts in mice (Scaglia and Igal 2008).  
 
RAD21: The protein encoded by this gene is highly similar to the gene product of 
Schizosaccharomyces pombe rad21, a gene involved in the repair of DNA double-strand 
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breaks, as well as in chromatid cohesion during mitosis. RAD21 is a novel target for 
developing cancer therapeutics that can potentially enhance the antitumor activity of 
chemotherapeutic agents acting via induction of DNA damage. RAD21 was overexpressed in 
several human breast cancer cell lines when compared to normal breast tissue. RAD21 
depletion by siRNA in breast cancer cell lines MCF-7 and T-47D decreased proliferation and 
increased apoptosis in these cells. Moreover, MCF-7 cell sensitivity to two DNA-damaging 
chemotherapeutic agents, etoposide and bleomycin, was increased after inhibition of RAD21 
expression (Atienza, Roth et al. 2005). 
 
HSPH1 (HSPH105): Heat shock proteins (HSP) support the folding and function of many 
proteins, and are important components of the ER stress response. Heat shock protein 105 
(hsp105) was overexpressed in human colon and pancreatic adenocarcinoma. In addition 
thyroid, esophageal, breast and bladder carcinoma and islet cell tumor, gastric malignant 
lymphoma, pheochromocytoma, and seminoma overexpressed hsp105. On the other hand, 
hsp105 was evidently overexpressed only in the testis among human adult normal tissues (Kai 
M, 2003) The expression of HSP105 was related to the invasiveness of the lesions. High 
expression of HSP105 is associated with malignant melanoma especially advanced and 
metastatic lesions (Muchemwa, Nakatsura et al. 2008). 
 
HSP90B1 (GRP94): HSP90 proteins normally associate with other co-chaperones and play 
important roles in folding newly synthesized proteins or stabilizing and refolding denatured 
proteins after stress . The upregulation of GRP78 and GRP94 can significantly confer the 
chemoresistance to VP-16 in human lung cancer cell line SK-MES-1 (Zhang, Wang et al. 
2009). 
 
LAPTM4B: LAPTM4b was upregulated in solid tumors of lung 88% (23/26) and in colon 
carcinoma 67% (18/27) patients. In addition an overexpression of LAPTM4b in the majority 
of carcinomas of the uterus (30/44), breast (27/53) and ovary (11/16). A proposed role for 
LAPTM4b during disease progression of malignant cells and its putative dual functional 
involvement in tumour cell proliferation as well as in multidrug-resistance may represent 
LAPTM4b as a target suitable for development of novel therapeutic agents (Kasper, Vogel et 
al. 2005). 
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NFYC: NFYC gene encodes one subunit of a trimeric complex forming a highly conserved 
transcription factor that binds with high specificity to CCAAT motifs in the promoters of a 
variety of genes. and both the Oct-1 and NF-Y concertedly participate in TSA-induced 
activation of the gadd45 promoter. (Hirose, Sowa et al. 2003). Gadd45a (growth arrest and 
DNA-damage-inducible protein 45 alpha), a nuclear protein involved in maintenance of 
genomic stability, DNA repair and suppression of cell growth was shown to promote repair-
mediate DNA demethylation (Barreto, Schafer et al. 2007) 
 
SSRP1: The protein encoded by this gene is a subunit of a heterodimer that, along with 
SUPT16H, forms chromatin transcriptional elongation factor FACT. FACT interacts 
specifically with histones H2A/H2B to effect nucleosome disassembly and transcription 
elongation. FACT and cisplatin-damaged DNA may be crucial to the anticancer mechanism 
of cisplatin. This encoded protein contains a high mobility group box which most likely 
constitutes the structure recognition element for cisplatin-modified DNA (Landais, Lee et al. 
2006). 
 
TWIST1: TWIST1 is a basic helix-loop-helix (bHLH) transcription factor. Twist is a master 
regulator of morphogenesis and plays an essential role in tumor metastasis. Twist contributes 
to metastasis by promoting an epithelial-mesenchymal transition (EMT) in breast cancer 
(Yang, Mani et al. 2004). TWIST expression was detected in the large majority of human 
glioma-derived cell lines and human gliomas examined. Levels of TWIST mRNA were 
associated with the highest grade gliomas. Overexpression of TWIST protein in a human 
glioma cell line significantly enhanced tumor cell invasion, a hallmark of high-grade gliomas 
(Elias, Tozer et al. 2005). 
 
5.2.2 Down-regulated genes in CT-X positive lung cancer cell lines 
LIMK2: There are approximately 40 known eukaryotic LIM proteins containing the LIM 
domains. LIM domains are highly conserved cysteine-rich structures containing 2 zinc 
fingers. Although zinc fingers usually function by binding to DNA or RNA, the LIM motif 
probably mediates protein-protein interactions. The LIM kinases have been proposed to play 
an important role in tumour-cell invasion and metastasis. Increased expression of LIMK2 
leads to metastatic phenotype in cancer cells (Shea, Wells et al. 2008). 
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7 APPENDICES 
 
7.1 APPENDIX A: THE “GROUPING”, “PRE-PROCESSING” AND 
“RANKPROD” SCRIPTS USED IN R 
7.1.1 The “grouping” script 
#this function reads ct-x gene names and their family names from 
u133agroups_genenames.txt. 
u133a<-read.table("~/duygu/u133agroups_genenames.txt", sep="\t", header=T) 
u133a<-as.matrix(u133a) 
 
#this function gets the names of the datasets. 
files<-try(system("ls ~/duygu/HG-U133AData_Allsamples_New/",intern=T)) 
 
#from names this function reads data. 
readgivenfilelist<-function(x,skip) { 
for (i in 1:length(x)) { 
y=read.table(x[i],header=T, skip=skip, sep="\t") 
rownames(y)=y[,1] 
assign(x[i],y[,-1], envir=as.environment(pos=1)) 
} 
} 
readgivenfilelist(files,4) 
 
#this function combines all read data in one matrix. 
zdata<-function(x) { 
z=get(ls(pos=1)[x[1]], envir=as.environment(pos=1)) 
data=as.matrix(z) 
for (i in 2:length(x) ) { 
y=as.matrix(get(ls(pos=1)[x[i]], envir=as.environment(pos=1))) 
data<-cbind(data,y) 
} 
return(data) 
} 
#zalldata<-zdata(c(2,3,5:13)) 
 
#this function gives an output such that rows are the unique genes and columns are the 
columns of the selected data and values are the mean values of each ct-x gene for each 
experiment. 
zctdata<-function(x,y) { 
#x;data 
#y;u133aCTgenes 
#j is the number of unique ct gene families 
#the mean of probesets belonging to one gene. 
j=length(genes<-unique(sub('\\s+$', '', y[,2], perl = TRUE))) 
print(j) 
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for (i in 1:length(x)) { 
        z=as.matrix(get(ls(pos=1)[x[i]], envir=as.environment(pos=1))) 
        data=matrix(ncol=ncol(z),nrow=j) 
        di=1 
                for (k in 1:j) { 
                        probes<-sub('\\s+$', '', y[,1], perl = TRUE)[which(sub('\\s+$', '', y[,2], perl = 
TRUE)==genes[k])] 
                        if (length(probes)>1) { 
                        lp=length(probes) 
                        pindex=vector(length=lp) 
                        for(l in 1:lp) { 
                        pindex[l]=which(rownames(z)==probes[l]) 
                        } 
                        v=t(apply(z[pindex,],2,mean)) 
                        colnames(v)=NULL 
                        rownames(v)=NULL                         
                        } 
                        else { 
                        v=t(z[which(rownames(z)==probes),]) 
                        colnames(v)=NULL 
                        rownames(v)=NULL 
                        } 
 data[k,]<-v 
 print(genes[k]) 
 print(length(rownames(data))) 
} 
colnames(data)<-colnames(z) 
rownames(data)<-as.vector(genes) 
        assign(paste("zct_",ls(pos=1)[x[i]],sep=""),data,envir=as.environment(pos=1)) 
} 
} 
#zctdata(c(1,2,4:12),u133a) 
 
#this function calculates the mean normalized expression values of probesets belonging to 
each ct-x gene family. 
zctdataf<-function(x,y) { 
j=length(family<-unique(sub('\\s+$', '', y[,3], perl = TRUE))) 
print(j) 
for (i in 1:length(x)) { 
        z=as.matrix(get(ls(pos=1)[x[i]], envir=as.environment(pos=1))) 
        data=matrix(ncol=ncol(z),nrow=j) 
        di=1 
                for (k in 1:j) { 
                        genes<-sub('\\s+$', '', y[,2], perl = TRUE)[which(sub('\\s+$', '', y[,3], perl = 
TRUE)==family[k])] 
                        if (length(genes)>1) { 
                        lp=length(genes) 
                        pindex=vector(length=lp) 
                        for(l in 1:lp) { 
                        pindex[l]=which(rownames(z)==genes[l]) 
 95
                        } 
                        v=t(apply(z[pindex,],2,mean)) 
                        colnames(v)=NULL 
                        rownames(v)=NULL 
                        } 
                        else { 
                        v=t(z[which(rownames(z)==genes),]) 
                        colnames(v)=NULL 
                        rownames(v)=NULL 
                        } 
 data[k,]<-v 
 } 
rownames(data)<-as.vector(family) 
colnames(data)<-colnames(z) 
        assign(paste("z",ls(pos=1)[x[i]],sep=""),data,envir=as.environment(pos=1)) 
} 
} 
#zctdataf(c(17:27),u133a) 
 
#this single script calculates the mean rank value as the cutoff.  
mean(apply(zalldata,2,function(x){sum(x<3.5)+1})) 
 
 
 
#this function assigns a number (“0” and “1”) for each ct-x gene family.  
groupmeans2zeroonep<-function(x,y) { 
for (i in 1:length(x)) { 
z=as.matrix(get(ls(pos=1)[x[i]], envir=as.environment(pos=1))) 
newmatrix<-matrix(nrow=dim(z)[1],ncol=dim(z)[2]) 
colnames(newmatrix)=colnames(z) 
rownames(newmatrix)=rownames(z) 
org=as.matrix(get(ls(pos=1)[y[i]], envir=as.environment(pos=1))) 
for (j in 1:ncol(z)) { 
cutoff<-sort(org[,j])[the mean rank value] 
subbso<-which(z[,j]>=cutoff) 
subbsu<-which(z[,j]<cutoff) 
newmatrix[subbso,j]<-1 
newmatrix[subbsu,j]<-0 
} 
assign(paste("z",ls(pos=1)[x[i]],"01", sep=""), newmatrix, envir=as.environment(pos=1)) 
} 
} 
#groupmeans2zeroonep(c(30:40),c(1,2,5:13)) 
 
#this function calculates the sum values of 0 and 1 for each ct-x gene family 
sumofones<-function(x) { 
for (i in 1:length(x)) { 
z=as.matrix(get(ls(pos=1)[x[i]], envir=as.environment(pos=1))) 
newvector<-vector(length=dim(z)[2]) 
names(newvector)=colnames(z) 
 96
newvector<-apply(z,2,sum,na.rm=T) 
assign(paste("z",ls(pos=1)[x[i]],"sum", sep=""), newvector, envir=as.environment(pos=1)) 
} 
} 
#sumofones(c(43:53)) 
 
#this function classifies each sample according to the sum values of ct-x gene families.  
giveclass<-function(x) { 
for (i in 1:length(x)) { 
z=get(ls(pos=1)[x[i]], envir=as.environment(pos=1)) 
print(names(z)) 
newvector<-vector(length=length(z)) 
subct<-which(z>1) 
subnonct<-which(z==0) 
subinter<-which(z==1) 
newvector[subct]<-1 
newvector[subnonct]<-0 
newvector[subinter]<--1 
names(newvector)=names(z) 
assign(paste("z",ls(pos=1)[x[i]],"class", sep=""), newvector, envir=as.environment(pos=1)) 
}} 
#giveclass(c(55:65)) 
 
 
#this function writes the classification of samples into .txt file. 
writeclass<-function(x,filename) { 
for (i in 1:length(x)) { 
z=get(ls(pos=1)[x[i]], envir=as.environment(pos=1)) 
write.table(paste("#",ls(pos=1)[x[i]],sep=""),filename,sep="\t",quote=F,append=T,eol="\n",co
l.names=F,row.names=F) 
write.table(z,filename,sep="\t",quote=F,append=T,eol="\n") 
}} 
writeclass(c(67:77),"groups.txt") 
 
 
for (i in 1:length(x)) { 
z=ls(pos=1)[x[i]] 
 
7.1.2  “Pre-processing” and “RankProd” scripts 
#from names this function reads data. 
readgivenfilelist<-function(x,skip) { 
for (i in 1:length(x)) { 
y=read.table(x[i],header=T, skip=skip, sep="\t") 
rownames(y)=y[,1] 
assign(x[i],y[,-1], envir=as.environment(pos=1)) 
} 
} 
readgivenfilelist(files,4) 
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#this function combines all read data in one matrix. 
zdata<-function(x) { 
z=get(ls(pos=1)[x[1]], envir=as.environment(pos=1)) 
data=as.matrix(z) 
for (i in 2:length(x) ) { 
y=as.matrix(get(ls(pos=1)[x[i]], envir=as.environment(pos=1))) 
data<-cbind(data,y) 
} 
return(data) 
} 
#zalldata<-zdata(c(2,3,5:13)) 
 
#this function filters out probesets with normalized expression values above the cutoff (y) in 
combined array data called x. 
filterunder<-function (x,y) { 
z=vector(length=dim(x)[1]) 
z2=vector(length=dim(x)[2]) 
for (j in 1:dim(x)[2]) { 
z2[j]<-sort(x[,j])[y] 
} 
for (i in 1:dim(x)[1]) { 
if (any(x[i,]>z2)) { 
z[i]=T 
} 
else { 
z[i]=F 
} 
} 
return(z) 
} 
 
#combine the common probesets after data filtering. 
zdata<-function(x) { 
z=get(ls(pos=1)[x[1]], envir=as.environment(pos=1)) 
data=as.matrix(z) 
for (i in 2:length(x) ) { 
y=as.matrix(get(ls(pos=1)[x[i]], envir=as.environment(pos=1))) 
data<-cbind(data,y) 
} 
return(data) 
} 
 
#After data-processing, RP analysis was run with the following scripts using data[sub]. 
library(RankProd) 
#the number of ct-x positive (1) and ct-x negative (0) samples in data[sub] is indicated by 
data.cl in order.  
data.cl<-c(rep(0,52),rep(1,33),rep(0,48),rep(1,5),rep(0,44),rep(1,28),rep(0,42),rep(1,38)) 
#the origin of each data in data[sub] is indicated by data.origin. 
data.origin<-c(rep(1,85),rep(2,53),rep(3,72),rep(4,80)) 
#RP analysis was run 
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RP.adv.out <- RPadvance (data[sub,], data.cl, data.origin, num.perm = 100, logged = TRUE, 
gene.names = rownames(data[sub,]), rand = 123) 
#generates RP plot (PFP vs the number of identified probesets. 
plotRP(RP.adv.out,cutoff=0.05) 
jpeg("tumor133a.jpeg") 
#generates the output probeset lists, p≤0.05. 
table=topGene(RP.adv.out, cutoff = 0.05, method = "pfp", logged = TRUE, logbase=2, 
gene.names = rownames(data[sub,])) 
up=table$Table1 
down=table$Table2 
write.csv(down,"tumor133adown.csv") 
write.csv(up,"tumor133aup.csv") 
 
#this function gets the probesets used in meta-analyis of hg-u133a based data from hg-
u133plus2 arrays. 
forplus2<-rownames(data)[sub] 
fdpia<-function(probelist,rows) { 
subs=vector() 
for (i in 1:length(probelist)) { 
subs=c(which(probelist[i]==rows),subs) 
 } 
return(subs) 
} 
#RP was run.  
RP.adv.out <- RPadvance (data[rev(p2rows),], data.cl, data.origin, num.perm = 100, logged = 
TRUE, gene.names = rownames(data[rev(p2rows),]), rand = 123) 
table=topGene(RP.adv.out, cutoff = 0.05, method = "pfp", logged = TRUE, logbase=2, 
gene.names = rownames(data[rev(p2rows),])) 
up=table$Table1 
down=table$Table2 
write.csv(down,"pdown.csv") 
write.csv(up,"pup.csv") 
 
7.2 APPENDIX B: THE SEQUENCE OF THE SSX4 KNOCK-IN 
VECTOR 
 
Sequences confirmed by sequencing analysis are shown in yellow. Transcription start and 
stop codons of EGFP and HYG are highlighted in red. Sequencing primers for EGFP are 
shown in brackets. The restriction enzymes used in the construction of the KI vector are in red 
letters and underlined. The following are how the other sequences are shown: β-actin DTA; 
SSX4 5’ = SSX4 A3-B; EGFP; SV40 PolyA site; PGK-HYG (Hygromycin); SSX4 3’ = 
SSX7 3’; β-lac ; f1 ori 
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GCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAGGAATTCGAGCTCGGTACCCCCTAGTAACCGAGACATTGAATGGGGCAGTGTCCACA
AGGGCGGAGGCTATTCCTGTACATCTGGGCCTACGGAGCCAGCACCCATCGCCAAAACTCTTCATCCTCTTCCTCAATCTCGCTTTCTCTCTCG
CTTTTTTTTTTTTTCTTCTTCTTTTTTTTTTTTTTTTTCAAAAGGAGGGGAGAGGGGGTAAAAAAATGCTGCACTGTGCGGCGAGGCCGGTGAG
TGAGCGACGCGGAGCCAATCAGCGCCCGCCGTTCCGAAAGTTGCCTTTTATGGCTCGAGTGGCCGCTGTGGCGTCCTATAAAACCCGGCGGCGC
AACGCGCAGCCACTGTCGAGTCGCGTCCACCCGCGAGCACAGCTTCTTTGCAGCTCCTTCGTTGCCGGTCCACACCCGCCACCAGGTAAGCAGG
GACGCCGGGCCCAGCGGGCCTTCGCTCTCTCGTGGCTAGTACCTCACTGCAGGGTCCTGAGGATCACTCAGAACGGACACCATGGGCGGGTGGA
GGGTGGTGCCGGGCCGCGGAGCGGACACTGGCACAGCCAACTTTACGCCTAGCGTGTAGACTCTTTGCAGCCACATTCCCGCGGTGTAGACACT
CGTGGGCCCGCTCCCGCTCGGTGCGTGGGGCTTGGGGACACACTAGGGTCGCGGTGTGGGCATTTGATGAGCCGGTGCGGCTTGCGGGTGTTAA
AAGCCGTATTAGGTCCATCTTGAGAGTACACAGTATTGGGAACCAGACGCTACGATCACGCCTCAATGGCCTCTGGGTCTTTGTCCAAACCGGT
TTGCCTATTCGGCTTGCCGGGCGGGCGGGCGGGCGGGCGGGCGCGGCAGGGCCGGCTCGGCCGGGTGGGGGCTGGGATGCCACTGCGCGTGCGC
TCTCTATCACTGGGCATCGAGGCGCGTGTGCGCTAGGGAGGGAGCTCTTCCTCTCCCCCTCTTCCTAGTTAGCTGCGCGTGCGTATTGAGGCTG
GGAGCGCGGCTGCCCGGGGTTGGGCGAGGGCGGGGCCGTTGTCCGGAAGGGGCGGGGTCACAGTGGCACGGGCGCCTTGTTTGCGCTTCCTGCT
GGGTGTGGTCGCCTCCCGCGCGCGCACAAGCCGCCCGTCGGCGCAGTGTAGGCGGAGCTTGCGCCCGTTTGGGGAGGGGGCGGAGGTCTGGCTT
CCTGCCCTAGGTCCGCCTCCGGGCCAGCGTTTGCCTTTTATGGTAATAATGCGGCCGGTCTGCGCTTCCTTTGTCCCCTGAGCTTGGGCGCGCG
CCCCCTGGCGGCTCGAGCCCGCGGCTTGCCGGAAGTGGGCAGGGCGGCAGCGGCTGCTCTTGGCGGCCCCGAGGTGACTATAGCCTTCTTTTGT
GTCTTGATAGTTCGCCATGGATCCTGATGATGTTGTTGATTCTTCTAAATCTTTTGTGATGGAAAACTTTTCTTCGTACCACGGGACTAAACCT
GGTTATGTAGATTCCATTCAAAAAGGTATACAAAAGCCAAAATCTGGTACACAAGGAAATTATGACGATGATTGGAAAGGGTTTTATAGTACCG
ACAATAAATACGACGCTGCGGGATACTCTGTAGATAATGAAAACCCGCTCTCTGGAAAAGCTGGAGGCGTGGTCAAAGTGACGTATCCAGGACT
GACGAAGGTTCTCGCACTAAAAGTGGATAATGCCGAAACTATTAAGAAAGAGTTAGGTTTAAGTCTCACTGAACCGTTGATGGAGCAAGTCGGA
ACGGAAGAGTTTATCAAAAGGTTCGGTGATGGTGCTTCGCGTGTAGTGCTCAGCCTTCCCTTCGCTGAGGGGAGTTCTAGCGTTGAATATATTA
ATAACTGGGAACAGGCGAAAGCGTTAAGCGTAGAACTTGAGATTAATTTTGAAACCCGTGGAAAACGTGGCCAAGATGCGATGTATGAGTATAT
GGCTCAAGCCTGTGCAGGAAATCGTGTCAGGCGATCTCTTTGTGAAGGAACCTTACTTCTGTGGTGTGACATAATTGGACAAACTACCTACAGA
GATTTAAAGCTATAAGGTAAATATAAAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAATTGTTTGTGTATTTTAGATTCCAACCTAT
GGAACTGATGAATGGGAGCAGTGGTGGAATGCAGATCTGCAAGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCGAGCTCTTACGC
GTGCTAGCCCGGGCTCGAGAGAGGTTGGAGGGCCTTGGACTGTTTTTTTAGTTCCAACAGATGTAGAAGCCACTGAAGAATGAACTCCACGACT
AAGTACAGCAAACCTCCGCAAATGTGCTAGTTTGGAAAACATTGTGTCTTTCAAATAGAAAAATCACAGATCGACTATTTTTTCTTCCCACGGT
TCAGACTAGAATCCAGATGTTTAACCCAAGATCCAGGGACGGTCTTCAGAGAGTTCAAAATCTCCTGATGGCGCCTGAGGACCACCCACTTTGT
CGCACAAAGTGTGGCTGGAGGAGGCGACAACATTCTGCAATGTCACTGCCCAAGGATGATGGACCAATCAGGGCAGTTAGTGAACTCCATCTGG
CCAATTAGAAGTCAGAACAGTAGGCGGAACAAGGGAAGCTGATGTGGCGTCTGTCAGTCCAGGCTCTAGGGACAGAACCTTCCCAAGGCGGGGG
GGAGGGGAGACTCTGATTTTCCCGCCGAAAGCGTCCCCTTGGATTGGCTACTTTAAATTCAGAGTACGCACACGCCGATTTGCCCTTTTGATTC
TTCCACAATCAGGGTAAGCATGCGCTGATTTTCTCTTTCCATTCTTCCTACCCCTCCCCTCCGCCGTGGTGCACTTCTTATCTAATTTTAATAA
TGTATTTATGTGAGGCAGGTCGCCATCTCAAATTCTTCCTGTCAGTTTCTAACTTTTTCAGGTATGGGATTTTTCCTAGGAGCTCTGTAGTAAC
TTAAAAAATCTGGGCTGGGCGTGGTGGCTCACGCTTGTAATCCCAGCACTTTGGAGGCCCACAGGTGGTGGATCGCTTGAACCCGGGAGGCGGA
GGTTGCAGTGAGCCACGATCGCGCCACTGCAACACAGCCTGGGCAACAGAGCGAGACCCTGTCTCAAAAAAAAAAAAAAAAAAAAAAAACTCCT
GGGCTCAAGCGATCCTCTCGCCTCGGCCCCGGGACTACAGGCGTGCACCACCCCGCCCAGAGCACCAAAGGTCCTGAGGCTGGAAAGACTCAGG
CTGTTTCTCTCGCAGGTGAGACTGCTCCCAGTGCAAGCTTATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAG
CTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCA
CCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCA
GCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAG
GTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGT
ACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGG
CAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCC
GCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGT
ACAAGTAATCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGA
AAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTC
ATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTAAAATCGATAAGGATCGCGATCG
ATGAATTCACGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAGGGGGGATGTGCTGCAAGGCGATTAA
GTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGGGCCAGTGAATTCTACCGGGTAGGGGAGGCGCTTTTCCCAAG
GCAGTCTGGAGCATGCGCTTTAGCAGCCCCGCTGGCACTTGGCGCTACACAAGTGGCCTCTGGCCTCGCACACATTCCACATCCACCGGTAGCG
CCAACCGGCTCCGTTCTTTGGTGGCCCCTTCGCGCCACCTTCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCCCGCAGCTCGCGTCGTGC
AGGACGTGACAAATGGAAGTAGCACGTCTCACTAGTCTCGTGCAGATGGACAGCACCGCTGAGCAATGGAAGCGGGTAGGCCTTTGGGGCAGCG
GCCAATAGCAGCTTTGCTCCTTCGCTTTCTGGGCTCAGAGGCTGGGAAGGGGTGGGTCCGGGGGCGGGCTCAGGGGCGGGCTCAGGGGCGGGGC
GGGCGCGAAGGTCCTCCGGAGCCCGGCATTCTGCACGCTTCAAAAGCGCACGTCTGCCGCGCTGTTCTCCTCTTCCTCATCTCCGGGCCTTTCG
ACCGATCCAGCCGCCACCATGAAAAAGCCTGAACTCACCGCGACGTCTGTCGAGAAGTTTCTGATCGAAAAGTTCGACAGCGTCTCCGACCTGA
TGCAGCTCTCGGAGGGCGAAGAATCTCGTGCTTTCAGCTTCGATGTAGGAGGGCGTGGATATGTCCTGCGGGTAAATAGCTGCGCCGATGGTTT
CTACAAAGATCGTTATGTTTATCGGCACTTTGCATCGGCCGCGCTCCCGATTCCGGAAGTGCTTGACATTGGGGAATTCAGCGAGAGCCTGACC
TATTGCATCTCCCGCCGTGCACAGGGTGTCACGTTGCAAGACCTGCCTGAAACCGAACTGCCCGCTGTTCTGCAGCCGGTCGCGGAGGCCATGG
ATGCGATCGCTGCGGCCGATCTTAGCCAGACGAGCGGGTTCGGCCCATTCGGACCGCAAGGAATCGGTCAATACACTACATGGCGTGATTTCAT
ATGCGCGATTGCTGATCCCCATGTGTATCACTGGCAAACTGTGATGGACGACACCGTCAGTGCGTCCGTCGCGCAGGCTCTCGATGAGCTGATG
CTTTGGGCCGAGGACTGCCCCGAAGTCCGGCACCTCGTGCACGCGGATTTCGGCTCCAACAATGTCCTGACGGACAATGGCCGCATAACAGCGG
TCATTGACTGGAGCGAGGCGATGTTCGGGGATTCCCAATACGAGGTCGCCAACATCTTCTTCTGGAGGCCGTGGTTGGCTTGTATGGAGCAGCA
GACGCGCTACTTCGAGCGGAGGCATCCGGAGCTTGCAGGATCGCCGCGGCTCCGGGCGTATATGCTCCGCATTGGTCTTGACCAACTCTATCAG
AGCTTGGTTGACGGCAATTTCGATGATGCAGCTTGGGCGCAGGGTCGATGCGACGCAATCGTCCGATCCGGAGCCGGGACTGTCGGGCGTACAC
AAATCGCCCGCAGAAGCGCGGCCGTCTGGACCGATGGCTGTGTAGAAGTACTCGCCGATAGTGGAAACCGACGCCCCAGCACTCGTCCGAGGGC
AAAGGAATAGTCGAGAAATTGATGATCTATTAAACAATAAAGATGTCCACTAAAATGGAAGTTTTTCCTGTCATACTTTGTTAAGAAGGGTGAG
AACAGAGTACCTACATTTTGAATGGAAGGATTGGAGCTACGGGGGTGGGGGTGGGGTGGGATTAGATAAATGCCTGCTCTTTACTGAAGGCTCT
TTACTATTGCTTTATGATAATGTTTCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCGTCGACAGATCTGCACGTTTCTCTCCCTTAGGCTTCTGTTCTGATGAGTCCAA
GTGTCTCTGTGGCATCCCGGCACCCCCACACCGTCCCTACCTTCCTTCTCTCGGCTTGTATCTTTCTTTCTTTCTTTTTTTTTGAGTCTGAGTC
TCAGTCTGTCACCTAGGCTAGTTTGCAGTAGTGCAGTCATAGCTCACTGCAGCCTTGAACTCCTGGCCTCAAGCAATACTCCAGCCTCAGCCTC
CCAAAGCACTGGTACTACAGATATGAGCCACCGTGACAGGTCAAAGCTTGTCTCTTAAGGAATAAACATTTTGCTTCTTTCTAGGCTTCAAGGC
CACCCTCCCACCTTTCATGCATAATACAGGGGCCACAGACCTCCAGGGGAATGATTTTGATAATGACCGTAACCAAGGGAATCAGGGTGAGTAG
ACGGGAAGGGGCTGGAAAGGGTCTCCTCAAGCCCAGCTGCTTTTCAGCTCAGCTACTTGGGAAAGATCCTCAGGCATTTGTTCCCTCATACACA
TCAGGGCTGAGTGAAAAAAAAAAAAATTGCATGCAGAAAGTTAACTACAGAGGCCATTCATATAAAATTTTAAAACACGAAAAACAAGAATATA
TATTTTTATAGATAATAAGTAAATGGTAAATGTATACAAACATGAATGTGAATAAAAAGCCATCAAATTGAGGTGACTGGCTGTAAGTGGAGGA
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GGGAGGGCGGGCAGGGATTGCTGAGTGCTGCACAGACAGCTTCAGCTGTGACTTGTTGATAGTGTGTTTTGTTTGTTTTTGTTTTTGAGATGGA
GTTTCACTCTTCTCGGCCAGGGTAGAGTGCAATAAGGCAATCTCAGCTCACTCCAACTTTCACCTCCTGGGTTCAAGTGATTCTCCTGCCTCAG
CCTCCGGAGTAGCTGGGGTTACGGGTGCCCGCCCCCACACCCAGCTCATTTTTTATTTTTGGTAGAGACGGGGTTTTACCATGTTGACCAGGCT
GGTCTCAAACTTCCTGACCTCAGGTGATCCACCTGCCTCAGCCTCCCAAAGTGCTGGGATTACAAGTGTGAGCTACCATGCCCGGCCTGTTTGT
AGTTTTTCTAATATTGTGAATAAATAAATCAAACCTAGCATAGCTGTGGGGTAATGTTGAGATCCGACTGGACTCAATATTATTCCTCATACTT
TTCTGTGTGTTTGAAATATTTCTTTTTTAGATGACATGTTGTTCTTCCTAAGCACCATTAATGAATCAAAGGACTGCTAAAAAAATGTTACAAG
AGAAAAAAAGAAGAAAGAAAATGTTACAACTGTAGATTCGCCAAAAACTTCCAGAGTTTGTCTCATTAACAGCATGTAGGTATTGGATAGGTAT
CTTAGGAGTGAGGATGATGAACACATTATGTAATAAAGATCGCTGTTTCTCTGTATTTTATCAGAGCCAAATAGTCTTTTCATTCCCAAAGAAC
CCTGATTCTCCGTGATGAGCTTGGAAGAGAGTTTGAAAGAGTGATCCCTCATCCAACACACAGAGAGAGCTTTCCCACTTGCCAGAGAGCAGAG
ATAACATAGGGTGAAAAAAAGACAGGTTCTTCGGTAGAGATCTTTGTACGTTTTGGGAATATAAAGGGGTCACATATGTGTTTCCTTGCTCTTC
TGCTCTGACAACACAATTATAAGACAAGGTCAGAACGTCCAAACTGTCTCCAATAGACCTATTACTCCCCAACTAAAAAGGCCAGATTCTAAAA
TCTCCCACGATCACTGTAAGAGATCTGAAAATCCAGTGCTTGGGTGTCTGCCAAGATTTTGACATTAAAGGACTGTCTTTATACTGAAAATATC
TCAGAGCCACTGGACTAAATCATCCATGGTTCATCACACATTTAACAGCTTAATTCACATACCATAAGATTCACCCATTTGAAGTGTGCAATGA
TTTTCAGTTGTTGCACATCTTGAGTGGATACAGTTCAGATTCCTAACCAATCAATTTAATTATTTGGAAAAAAATAAAAGATATGTAAAGGAAT
AAGATGAGACTGTGATGGGGTTTAGTCCCCATTTGATAAACCATGAGATGGAAAATTCTGAATTGATGCCACAGATAAATGAATCAACCATGAC
TAAACATAATTCAGAAGCAAAACTGAAATAACTCCTCAACAATGAGTGGACTCATAACACTCTGCTGCAGAATACCCTGATGCTACAGAAGTCT
CTAGAGTTTGGAAATCTTTACCAACAAAGAAAAATTCTGATATATTCTCTTTCAGTTGAACGTCCTCAGATGACTTTTTGCAGGCTCCAGAGAA
TCTTCCCGAAGGTGAGTGTCTCTCAGATCTAAAGGACCAGAGAACCTTTGTCCCTCCATGGATGCAAACACTGGTAAGAGTGGGAGAATATAAA
AAATGCCCTCACTGCCTCCTTCTCCCCATGTCTATCACAACACCTGATGTAGCACCAACAGCTTAATAATACTAACAGTTGTGATCCTTAATAC
ATCTTTTGTTTTCATAGTGATGCCAGATACTATTTTAAGCAGTTCACATGGATTAATGTATTTAATCCTTAAGAAGACCTGTATGACTTTGTTT
CTATTATTATCTCCAAATAATAATGAGTCACACACTTCGGTTGTCGTCCATATAAAAGCCATGTGACTTGGCACAAGTCTTCTAAGTTCTCTGA
GCTCCAGATTCCTGGTCCATGAAATGGAAGTAAAGAATCGTAGTTATCAGCAACATAATAATAAAATGAGGCTATTGGGGTATAGATATGTTAA
ATAATTTTCCTGGGGCACAGTGGCAGTGGTAGTCTAATCCAGAGCTCCAAGCCATTTAAAGCTCATTCACGTTTGCATTTGTTTATGAAGTTCA
GATGTTGCTCACTAGGGCTTCACCCCATAGGGCCTGCTGGTGCTTCCATTGAGACACCCATTCTCGCAATAGGAAAGACCAGCTGGCCTCTGCT
CTGTTACTGGGACCACTTGCATGGCTTAGGAATCGTTTTGACTGTTGGCCCCTCCCTACTGTGAGCTCCTTGATGGTCGACCGATGCCCTTGAG
AGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTCGTAGGA
CAGGTGCCGGCAGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCG
GTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGT
TGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAG
ATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGA
AGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTC
AGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAG
GATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGC
GCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCA
AGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTA
AGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAG
TAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCG
TCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATC
AGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCT
AGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCAT
TCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAG
AAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACT
GGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATA
GCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACC
CACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGA
ATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACA
TATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGCGCCCTGTAGCGGCGCATTAAG
CGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCC
ACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTG
ATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTT
GTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAG
CTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTGCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGC
GATCGGTGCGGGCCTCTTCGCTATTACGCCAGCCCAAGCTACCATGATAAGTAAGTAATATTAAGGTACGGGAGGTACTTGGA 
 
7.3 APPENDIX C: SEQUENCING RESULTS OF SSX4 KI CLONES 
 
BLAST analysis of the sequenced region with M4 reverse primer: 
 
>ref|NG_005575.1|  Homo sapiens synovial sarcoma, X breakpoint 4/synovial sarcoma,  
X breakpoint 4B region (SSX4/SSX4B@) on chromosome X, Length=29447 
 
Score =  246 bits (133),  Expect = 3e-63 
Identities = 133/133 (100%), Gaps = 0/133 (0%) 
Strand=Plus/Plus 
 
Query  1    CTCCTGGGCTCAAGCGATCCTCTCGCCTCGGCCCCGGGACTACAGGCGTGCACCACCCCG  60 
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            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  786  CTCCTGGGCTCAAGCGATCCTCTCGCCTCGGCCCCGGGACTACAGGCGTGCACCACCCCG  845 
 
Query  61   CCCAGAGCACCAAAGGTCCTGAGGCTGGAAAGACTCAGGCTGTTTCTCTCGCAGGTGAGA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  846  CCCAGAGCACCAAAGGTCCTGAGGCTGGAAAGACTCAGGCTGTTTCTCTCGCAGGTGAGA  905 
 
Query  121  CTGCTCCCAGTGC  133 
            ||||||||||||| 
Sbjct  906  CTGCTCCCAGTGC  918 
 
 
Score =  246 bits (133),  Expect = 3e-63 
Identities = 133/133 (100%), Gaps = 0/133 (0%) 
Strand=Plus/Minus 
 
Query  1      CTCCTGGGCTCAAGCGATCCTCTCGCCTCGGCCCCGGGACTACAGGCGTGCACCACCCCG  60 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  28373  CTCCTGGGCTCAAGCGATCCTCTCGCCTCGGCCCCGGGACTACAGGCGTGCACCACCCCG  28314 
 
Query  61     CCCAGAGCACCAAAGGTCCTGAGGCTGGAAAGACTCAGGCTGTTTCTCTCGCAGGTGAGA  120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  28313  CCCAGAGCACCAAAGGTCCTGAGGCTGGAAAGACTCAGGCTGTTTCTCTCGCAGGTGAGA  28254 
 
Query  121    CTGCTCCCAGTGC  133 
              ||||||||||||| 
Sbjct  28253  CTGCTCCCAGTGC  28241 
 
 
BLAST analysis of the sequenced region with A2.1 forward  primer: 
 
>ref|NG_005851.1|  Homo sapiens ornithine aminotransferase pseudogene (LOC791095)  
on chromosome X, Length=3843 
 
GENE ID: 791095 LOC791095 | ornithine aminotransferase pseudogene 
 
Score =  464 bits (251),  Expect = 2e-128 
Identities = 254/255 (99%), Gaps = 1/255 (0%) 
Strand=Plus/Minus 
 
The Sbjct sequence belonged to SSX4 gene which showed 99% identity to the sequenced region.  
 
Query  1    CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACC-TGGAA  59 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  713  CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACCATGGAA  654 
 
Query  60   TACTATGCAGCCATAAAAATTGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATTG  119 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  653  TACTATGCAGCCATAAAAATTGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATTG  594 
 
Query  120  GAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGAATATTCTCA  179 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  593  GAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGAATATTCTCA  534 
 
Query  180  CTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAACATCACACTC  239 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
 102
Sbjct  533  CTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAACATCACACTC  474 
 
Query  240  TGGGGACTGTTGTGG  254 
            ||||||||||||||| 
Sbjct  473  TGGGGACTGTTGTGG  459 
 
 
>gb|AF196972.1|  Homo sapiens chromosome X multiple clones map p11.23, complete  
Sequence, Length=122568 
 
Score =  464 bits (251),  Expect = 2e-128 
Identities = 254/255 (99%), Gaps = 1/255 (0%) 
Strand=Plus/Minus 
 
The Sbjct sequence belonged to SSX4 gene which showed 99% identity to the sequenced region.  
 
Query  1     CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACC-TGGAA  59 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  7308  CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACCATGGAA  7249 
 
Query  60    TACTATGCAGCCATAAAAATTGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATTG  119 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7248  TACTATGCAGCCATAAAAATTGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATTG  7189 
 
Query  120   GAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGAATATTCTCA  179 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7188  GAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGAATATTCTCA  7129 
 
Query  180   CTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAACATCACACTC  239 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7128  CTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAACATCACACTC  7069 
 
Query  240   TGGGGACTGTTGTGG  254 
             ||||||||||||||| 
Sbjct  7068  TGGGGACTGTTGTGG  7054 
 
 
Score =  339 bits (183),  Expect = 1e-90 
Identities = 229/251 (91%), Gaps = 3/251 (1%) 
Strand=Plus/Plus 
 
The Sbjct sequence belonged to SSX7 pseudogene which showed 91% identity to the sequenced 
region. 
 
Query  1      CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACC-TGGAA  59 
              |||||||||||| |||||||||||||||||||||||||||||||||| |||||| ||||| 
Sbjct  32271  CCCAAATGTCCATCAATGATAGACTGGATTAAGAAAATGTGGCACATCTACACCATGGAA  32330 
 
Query  60     TACTATGCAGCCATAA-AAATTGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATT  118 
              |||||||||||||||| |||  |||||||||||||||||||||||||||||||||||  | 
Sbjct  32331  TACTATGCAGCCATAAGAAA-GGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAGCT  32389 
 
Query  119    GGAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGAATATTCTC  178 
              ||||| ||||||||| || ||||||||||||| ||| |||||||||||||  |||||||| 
Sbjct  32390  GGAAACCATCATTCTGAGCAAACTATCGCAAGGACAGAAAACCAAACACCTCATATTCTC  32449 
 
Query  179    ACTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAACATCACACT  238 
              |||||||||||||||||||||||||||| ||| ||||||||||  ||||||||||||||  
Sbjct  32450  ACTCATAGGTGGGAATTGAACAATGAGAACACTTGGACACAGGGTGGGGAACATCACACA  32509 
 103
 
Query  239    CTGGGGACTGT  249 
              |||| | |||| 
Sbjct  32510  CTGGTGCCTGT  32520 
 
 
>emb|AL606490.14|  Human DNA sequence from clone RP11-344N17 on chromosome X Contains  
the 3'end of the SSX1 gene for synovial sarcoma X breakpoint 1, a synovial sarcoma X 
breakpoint pseudogene, four ornithine aminotransferase (gyrate atrophy)(OAT) pseudogenes, the 
SSX9 gene for synovial sarcoma X breakpoint 9, a synovial sarcoma X breakpoint 4 pseudogene 
(psiSSX4), the SSX3 gene for synovial sarcoma X breakpoint 3, a novel gene, the SSX4 gene for 
synovial sarcoma X breakpoint 4 and the 3' end of a novel gene similar to synovial sarcoma X 
breakpoint 4, complete sequence, Length=141676 
 
Score =  459 bits (248),  Expect = 7e-127 
Identities = 253/255 (99%), Gaps = 1/255 (0%) 
Strand=Plus/Plus 
 
The Sbjct sequence belonged to SSX4 gene which showed 100% identity to the sequenced region. 
 
Query  1       CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACC-TGGAA  59 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  116636  CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACCATGGAA  116695 
 
Query  60      TACTATGCAGCCATAAAAATTGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATTG  119 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  116696  TACTATGCAGCCATAAAAATTGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATTG  116755 
 
 
 
Query  120     GAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGAATATTCTCA  179 
               |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  116756  GAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGCATATTCTCA  116815 
 
Query  180     CTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAACATCACACTC  239 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  116816  CTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAACATCACACTC  116875 
 
Query  240     TGGGGACTGTTGTGG  254 
               ||||||||||||||| 
Sbjct  116876  TGGGGACTGTTGTGG  116890 
 
 
Score =  392 bits (212),  Expect = 7e-107 
Identities = 241/255 (94%), Gaps = 1/255 (0%) 
Strand=Plus/Plus 
 
The Sbjct sequence belonged to SSX3 which showed 94% identity to the sequenced region. 
 
Query  1      CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACC-TGGAA  59 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  77615  CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACCATGGAA  77674 
 
Query  60     TACTATGCAGCCATAAAAATTGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATTG  119 
              ||||||||||||||||||| ||||||||||||||||||||||||||||||||||||  || 
Sbjct  77675  TACTATGCAGCCATAAAAAATGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAGCTG  77734 
 
 
 
 104
Query  120    GAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGAATATTCTCA  179 
              |||| |||||||||||| |||||||| |||| |||||||||||||||||| || |||||| 
Sbjct  77735  GAAACCATCATTCTCAGCAAACTATCCCAAGGACAAAAAACCAAACACCGCATGTTCTCA  77794 
 
Query  180    CTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAACATCACACTC  239 
              ||||||||||||||||||||||||||| |||||||||||||||||||||||||||||| | 
Sbjct  77795  CTCATAGGTGGGAATTGAACAATGAGAACACATGGACACAGGAAGGGGAACATCACACAC  77854 
 
Query  240    TGGGGACTGTTGTGG  254 
               |||| ||||||||| 
Sbjct  77855  CGGGGCCTGTTGTGG  77869 
 
 
 Score =  375 bits (203),  Expect = 7e-102 
 Identities = 238/255 (93%), Gaps = 1/255 (0%) 
 Strand=Plus/Minus 
 
The Sbjct sequence belonged to the AL606490.14 genomic clone not to SSX4 showing 93% identity 
to the sequenced region. 
 
Query  1       CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATATACACC-TGGAA  59 
               |||||||||||||||||||||||||||||||||||||||||||||||| ||||| ||||| 
Sbjct  130847  CCCAAATGTCCAACAATGATAGACTGGATTAAGAAAATGTGGCACATAGACACCATGGAA  130788 
 
Query  60      TACTATGCAGCCATAAAAATTGATGAGTTCATGTCCTTTGTAGGGACATGGATGAAATTG  119 
               ||||||| ||||||||||| ||||||| ||||||||||||||||||||||||||| | || 
Sbjct  130787  TACTATGTAGCCATAAAAAATGATGAGCTCATGTCCTTTGTAGGGACATGGATGACACTG  130728 
 
Query  120     GAAATCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGAATATTCTCA  179 
               |||| |||||||||||| ||||||| ||||| |||||||||||||||||| || |||||| 
Sbjct  130727  GAAACCATCATTCTCAGCAAACTATTGCAAGGACAAAAAACCAAACACCGCATGTTCTCA  130668 
 
Query  180     CTCATAGGTGGGAATTGAACAATGAGATCACATGGACACAGGAAGGGGAACATCACACTC  239 
               ||||||||||||| ||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct  130667  CTCATAGGTGGGACTTGAACAATGAGAACACATGGACACAGGAAGGGGAACATCACACTC  130608 
 
Query  240     TGGGGACTGTTGTGG  254 
                |||| ||||||||| 
Sbjct  130607  CGGGGCCTGTTGTGG  130593 
 
 
 
 
 
 
